| # | Thr. | #G | #C | GO BP | GO CC | GO MF | KEGG | miRNA | CHR |
| 1 | 4/2 | 12 | 5 | xenobiotic metabolic process (1.0e-04/1.8e-02/ 3/ 13) | glucuronosyltransferase activity (1.1e-04/1.4e-02/ 3/12) | Pentose and glucuronate interconversions (1.7e-04/2.4e-02/ 3/13) | |||
| 2 | 4/2 | 30 | 6 | response to external stimulus (6.6e-04/1.4e+00/ 9/ 370) | extracellular space (3.4e-06/8.1e-01/ 9/246) | cytokine activity (1.1e-02/2.5e-01/ 4/73) | Cytokine-cytokine receptor interaction (9.6e-03/5.4e-01/ 5/122) | ||
| 3 | 4/2 | 25 | 8 | response to external stimulus (3.6e-02/1.1e+00/ 6/ 370) | extracellular space (1.3e-03/6.5e-01/ 6/246) | ||||
| 4 | 4/2 | 42 | 8 | multicellular organismal process (1.3e-02/7.2e+00/ 17/1648) | extracellular region (3.8e-02/3.4e+00/ 10/700) | ||||
| 5 | 4/2 | 25 | 8 | cell leading edge (1.2e-02/1.5e-01/ 3/47) | glycosaminoglycan binding (4.6e-02/1.7e-01/ 3/58) | ||||
| 6 | 4/2 | 5 | 6 | ||||||
| 7 | 4/2 | 23 | 7 | Golgi vesicle transport (5.0e-02/2.0e-01/ 3/ 74) | ATP-dependent RNA helicase activity (4.9e-02/4.1e-02/ 2/15) | ||||
| 8 | 4/2 | 10 | 3 | ||||||
| 9 | 4/2 | 4 | 3 | detection of hormone stimulus (3.3e-02/5.5e-04/ 1/ 1) | toxin transporter activity (3.9e-02/5.2e-04/ 1/1) | ||||
| 10 | 4/2 | 10 | 3 | ||||||
| 11 | 4/2 | 17 | 3 | regulation of insulin secretion (1.6e-02/2.2e-02/ 2/ 10) | membrane fraction (1.6e-02/7.3e-01/ 5/362) | ||||
| 12 | 4/2 | 27 | 6 | immune response (7.3e-03/7.7e-01/ 6/ 295) | integral to membrane (4.5e-02/5.4e+00/ 12/2022) | ||||
| 13 | 4/2 | 11 | 5 | ||||||
| 14 | 4/2 | 4 | 6 | facial nerve development (3.3e-02/5.5e-04/ 1/ 1) | |||||
| 15 | 4/2 | 31 | 3 | regulation of monooxygenase activity (2.8e-02/3.2e-02/ 2/ 8) | extracellular region (3.9e-04/2.4e+00/ 11/700) | ||||
| 16 | 4/2 | 19 | 5 | translational elongation (5.1e-08/1.8e-01/ 7/ 93) | cytosolic ribosome (7.2e-09/1.5e-01/ 7/71) | structural constituent of ribosome (3.9e-05/2.4e-01/ 6/123) | Ribosome (4.0e-04/2.6e-01/ 5/70) | ||
| 17 | 4/2 | 7 | 7 | nervous system development (1.2e-02/3.4e-01/ 4/ 411) | |||||
| 18 | 4/2 | 31 | 6 | cell adhesion (6.1e-03/1.4e+00/ 8/ 376) | extracellular region (2.1e-04/2.6e+00/ 12/700) | Wnt signaling pathway (2.6e-03/4.0e-01/ 5/110) | |||
| 19 | 4/2 | 4 | 4 | regulation of isoprenoid metabolic process (3.3e-02/5.5e-04/ 1/ 1) | collagen type XV (1.4e-02/5.0e-04/ 1/1) | ||||
| 20 | 4/2 | 14 | 4 | ||||||
| 21 | 4/2 | 7 | 5 | negative regulation of vascular endothelial growth factor receptor signaling pathway (4.4e-02/8.2e-04/ 1/ 1) | |||||
| 22 | 4/2 | 10 | 4 | neurological system process (3.9e-02/4.5e-01/ 4/ 328) | syntrophin complex (3.1e-02/1.3e-03/ 1/1) | ||||
| 23 | 4/2 | 33 | 4 | ||||||
| 24 | 4/2 | 11 | 4 | regulation of B cell differentiation (1.8e-03/6.2e-03/ 2/ 5) | anchored to membrane (2.6e-02/4.9e-02/ 2/39) | ||||
| 25 | 4/2 | 11 | 5 | syntrophin complex (3.1e-02/1.3e-03/ 1/1) | phosphatase activity (3.9e-02/1.7e-01/ 3/145) | ||||
| 26 | 4/2 | 5 | 8 | benzoate metabolic process (3.9e-02/6.9e-04/ 1/ 1) | kynureninase activity (4.6e-02/6.5e-04/ 1/1) | ||||
| 27 | 4/2 | 13 | 4 | ||||||
| 28 | 4/2 | 6 | 3 | positive regulation of T-helper 1 type immune response (3.9e-02/6.9e-04/ 1/ 1) | |||||
| 29 | 4/1.8 | 5 | 7 | ||||||
| 30 | 4/1.8 | 10 | 5 | response to wounding (5.5e-04/2.8e-01/ 5/ 231) | extracellular region part (1.2e-03/4.4e-01/ 5/387) | G-protein-coupled receptor binding (7.8e-04/3.1e-02/ 3/30) | |||
| 31 | 4/1.8 | 17 | 5 | anion transport (2.3e-02/1.4e-01/ 3/ 59) | plasma membrane (3.1e-02/3.1e+00/ 9/1443) | anion transmembrane transporter activity (2.5e-02/1.3e-01/ 3/63) | |||
| 32 | 4/1.8 | 17 | 9 | translational elongation (3.7e-11/2.0e-01/ 9/ 93) | ribosome (7.2e-10/3.2e-01/ 9/151) | structural constituent of ribosome (3.1e-06/2.5e-01/ 7/123) | Ribosome (4.8e-06/2.3e-01/ 6/70) | ||
| 33 | 4/1.8 | 6 | 7 | ||||||
| 34 | 4/1.8 | 14 | 6 | ||||||
| 35 | 4/1.8 | 6 | 7 | ||||||
| 36 | 4/1.8 | 27 | 9 | vesicle coating (4.5e-02/4.5e-02/ 2/ 13) | membrane part (4.2e-02/8.3e+00/ 16/2426) | ||||
| 37 | 4/1.8 | 7 | 6 | cellular developmental process (1.4e-02/4.5e-01/ 4/ 824) | |||||
| 38 | 4/1.8 | 8 | 5 | negative regulation of keratinocyte differentiation (4.8e-02/9.6e-04/ 1/ 1) | |||||
| 39 | 4/1.8 | 5 | 9 | Tetrachloroethene degradation (4.3e-02/7.3e-04/ 1/1) | |||||
| 40 | 4/1.8 | 13 | 6 | positive regulation of epithelial cell proliferation (1.9e-02/2.5e-02/ 2/ 15) | |||||
| 41 | 4/1.8 | 5 | 7 | ||||||
| 42 | 4/1.8 | 6 | 8 | cellular sodium ion homeostasis (2.7e-02/4.1e-04/ 1/ 1) | |||||
| 43 | 4/1.8 | 15 | 6 | myosin complex (2.2e-02/4.4e-02/ 2/25) | |||||
| 44 | 4/1.8 | 5 | 9 | alpha-N-acetylneuraminate alpha-2,8-sialyltransferase activity (3.9e-02/5.2e-04/ 1/1) | |||||
| 45 | 4/1.8 | 5 | 10 | cellular copper ion homeostasis (4.8e-02/9.6e-04/ 1/ 7) | cadmium ion binding (7.9e-04/3.1e-03/ 2/6) | 16 (1.0e-02/ 0.2200/ 4/416) | |||
| 46 | 4/1.6 | 33 | 12 | multicellular organismal process (3.6e-03/5.4e+00/ 15/1648) | neuron projection (4.7e-02/2.6e-01/ 3/66) | ||||
| 47 | 4/1.6 | 6 | 10 | ||||||
| 48 | 4/1.6 | 7 | 11 | conditioned taste aversion (4.4e-02/8.2e-04/ 1/ 1) | nicotinic acetylcholine-gated receptor-channel complex (4.9e-02/2.3e-03/ 1/3) | ||||
| 49 | 4/1.6 | 4 | 13 | positive regulation of fibrinolysis (2.7e-02/4.1e-04/ 1/ 1) | |||||
| 50 | 4/1.6 | 6 | 11 | 10-formyltetrahydrofolate metabolic process (3.3e-02/5.5e-04/ 1/ 1) | collagen type XI (3.1e-02/1.3e-03/ 1/2) | ||||
| 51 | 4/1.6 | 8 | 7 | ||||||
| 52 | 4/1.6 | 6 | 11 | ||||||
| 53 | 4/1.6 | 9 | 12 | ||||||
| 54 | 4/1.6 | 12 | 5 | ||||||
| 55 | 4/1.6 | 49 | 11 | bone mineralization (8.3e-03/8.9e-02/ 3/ 18) | extracellular region (4.1e-02/4.1e+00/ 11/700) | transmembrane receptor activity (2.4e-02/1.7e+00/ 8/334) | |||
| 56 | 4/1.6 | 5 | 10 | ||||||
| 57 | 4/1.6 | 4 | 12 | vitamin metabolic process (1.1e-02/1.9e-02/ 2/ 46) | thiamin diphosphokinase activity (3.9e-02/5.2e-04/ 1/1) | ||||
| 58 | 4/1.6 | 9 | 8 | positive regulation of epithelial cell proliferation (1.0e-02/1.6e-02/ 2/ 15) | extracellular region (1.4e-02/7.9e-01/ 5/700) | ||||
| 59 | 4/1.6 | 40 | 13 | collagen metabolic process (7.4e-03/8.4e-02/ 3/ 22) | sarcomere (6.0e-03/1.1e-01/ 3/25) | ||||
| 60 | 4/1.6 | 9 | 7 | terminal button (4.9e-02/2.3e-03/ 1/2) | |||||
| 61 | 4/1.4 | 24 | 13 | response to external stimulus (7.2e-03/1.1e+00/ 7/ 370) | extracellular space (9.7e-04/6.2e-01/ 6/246) | ||||
| 62 | 4/1.4 | 4 | 14 | brush border membrane (4.5e-02/2.0e-03/ 1/4) | |||||
| 63 | 4/1.4 | 4 | 19 | drug transport (3.3e-02/5.5e-04/ 1/ 1) | drug:hydrogen antiporter activity (3.9e-02/5.2e-04/ 1/1) | ||||
| 64 | 4/1.4 | 24 | 15 | behavior (7.3e-05/5.0e-01/ 7/ 166) | extracellular space (4.3e-07/6.5e-01/ 9/246) | cytokine activity (5.0e-03/1.9e-01/ 4/73) | Cytokine-cytokine receptor interaction (4.0e-03/4.5e-01/ 5/122) | ||
| 65 | 4/1.4 | 25 | 17 | glycosaminoglycan binding (4.9e-02/1.8e-01/ 3/58) | miR-320/320abcd (0.03572/ 1.4470/ 9/377) | ||||
| 66 | 4/1.4 | 9 | 17 | digestion (2.8e-04/2.6e-02/ 3/ 27) | calcium ion binding (1.6e-03/3.6e-01/ 5/402) | Neuroactive ligand-receptor interaction (3.3e-02/1.8e-01/ 3/83) | |||
| 67 | 4/1.4 | 6 | 18 | low-density lipoprotein receptor catabolic process (4.4e-02/8.2e-04/ 1/ 1) | toxin receptor binding (4.6e-02/6.5e-04/ 1/1) | ||||
| 68 | 4/1.4 | 6 | 15 | ||||||
| 69 | 4/1.4 | 5 | 16 | growth hormone secretion (4.4e-02/8.2e-04/ 1/ 3) | proteinaceous extracellular matrix (1.1e-02/3.9e-02/ 2/156) | extracellular matrix structural constituent conferring tensile strength (3.9e-02/5.2e-04/ 1/2) | |||
| 70 | 4/1.4 | 5 | 12 | ||||||
| 71 | 4/1.2 | 14 | 24 | DNA replication (1.1e-11/3.2e-01/ 10/ 181) | nucleoplasm (8.0e-08/9.3e-01/ 10/570) | DNA primase activity (1.5e-03/4.7e-03/ 2/3) | Cell cycle (9.2e-04/3.2e-01/ 5/98) | ||
| 72 | 4/1.2 | 4 | 19 | positive regulation of interleukin-6 biosynthetic process (2.7e-02/4.1e-04/ 1/ 3) | |||||
| 73 | 4/1.2 | 6 | 21 | regulation of axon diameter (3.9e-02/6.9e-04/ 1/ 1) | neurofilament (4.9e-02/2.3e-03/ 1/3) | ||||
| 74 | 4/1.2 | 24 | 16 | extracellular region (2.0e-04/1.9e+00/ 10/700) | |||||
| 75 | 4/1.2 | 7 | 21 | glutamine catabolic process (4.8e-02/9.6e-04/ 1/ 1) | extracellular region part (5.7e-03/3.4e-01/ 4/387) | ||||
| 76 | 4/1.2 | 4 | 26 | microtubule (4.5e-02/7.5e-02/ 2/148) | C-4 methylsterol oxidase activity (3.2e-02/3.9e-04/ 1/1) | ||||
| 77 | 4/1.2 | 8 | 26 | nuclear division (1.1e-05/1.4e-01/ 5/ 174) | spindle (2.2e-05/7.1e-02/ 4/80) | ||||
| 78 | 4/1.2 | 4 | 18 | putrescine metabolic process (3.3e-02/5.5e-04/ 1/ 1) | agmatinase activity (3.9e-02/5.2e-04/ 1/1) | ||||
| 79 | 4/1.2 | 4 | 27 | ||||||
| 80 | 4/1.2 | 12 | 18 | ||||||
| 81 | 4/1.2 | 6 | 22 | nutrient reservoir activity (3.9e-02/5.2e-04/ 1/1) | |||||
| 82 | 4/1.2 | 4 | 24 | cerebellar granular layer development (3.3e-02/5.5e-04/ 1/ 1) | |||||
| 83 | 4/1.2 | 5 | 22 | growth hormone receptor complex (1.7e-02/6.3e-04/ 1/1) | |||||
| 84 | 4/1.2 | 6 | 26 | leukocyte chemotaxis (2.4e-05/1.2e-02/ 3/ 17) | extracellular region part (2.8e-03/2.9e-01/ 4/387) | cytokine activity (2.9e-03/5.7e-02/ 3/73) | Cytokine-cytokine receptor interaction (2.4e-02/1.8e-01/ 3/122) | ||
| 85 | 4/1 | 24 | 18 | extracellular region (5.6e-03/1.8e+00/ 8/700) | |||||
| 86 | 4/1 | 4 | 33 | ||||||
| 87 | 4/1 | 9 | 34 | nuclear division (3.8e-07/1.7e-01/ 6/ 174) | chromosome, centromeric region (1.7e-05/6.4e-02/ 4/63) | ||||
| 88 | 4/1 | 4 | 21 | dentate gyrus development (4.4e-02/8.2e-04/ 1/ 2) | Tetrachloroethene degradation (4.3e-02/7.3e-04/ 1/1) | ||||
| 89 | 4/1 | 4 | 30 | brain-derived neurotrophic factor receptor signaling pathway (2.7e-02/4.1e-04/ 1/ 1) | terminal button (2.6e-02/1.0e-03/ 1/2) | brain-derived neurotrophic factor binding (3.9e-02/5.2e-04/ 1/1) | |||
| 90 | 4/1 | 24 | 23 | behavior (1.3e-03/5.2e-01/ 6/ 166) | extracellular space (1.2e-05/6.8e-01/ 8/246) | Jak-STAT signaling pathway (2.1e-02/3.6e-01/ 4/88) | |||
| 91 | 4/1 | 5 | 32 | positive regulation of fibrinolysis (3.3e-02/5.5e-04/ 1/ 1) | collagen type XI (2.6e-02/1.0e-03/ 1/2) | gamma-aminobutyric acid:sodium symporter activity (3.9e-02/5.2e-04/ 1/1) | |||
| 92 | 4/1 | 18 | 20 | translational elongation (7.4e-11/2.2e-01/ 9/ 93) | ribosome (1.4e-09/3.4e-01/ 9/151) | structural constituent of ribosome (4.5e-06/2.7e-01/ 7/123) | Ribosome (2.3e-05/2.8e-01/ 6/70) | ||
| 93 | 4/1 | 4 | 33 | extrinsic to organelle membrane (1.4e-02/5.0e-04/ 1/1) | |||||
| 94 | 4/1 | 4 | 31 | alpha-N-acetylneuraminate alpha-2,8-sialyltransferase activity (3.9e-02/5.2e-04/ 1/1) | |||||
| 95 | 3.8/2 | 60 | 9 | multicellular organismal process (3.2e-04/1.1e+01/ 26/1648) | extracellular region (1.5e-04/4.9e+00/ 17/700) | ||||
| 96 | 3.8/2 | 13 | 5 | ||||||
| 97 | 3.8/2 | 9 | 6 | glycoside metabolic process (4.8e-02/9.6e-04/ 1/ 1) | extracellular region (1.4e-02/7.9e-01/ 5/700) | ||||
| 98 | 3.8/2 | 23 | 6 | extracellular region (9.2e-04/1.8e+00/ 9/700) | Complement and coagulation cascades (1.3e-02/1.1e-01/ 3/34) | ||||
| 99 | 3.8/2 | 9 | 4 | ||||||
| 100 | 3.8/2 | 11 | 7 | defense response (1.5e-02/3.2e-01/ 4/ 263) | extracellular region (3.7e-02/9.7e-01/ 5/700) | ||||
| 101 | 3.8/2 | 25 | 3 | brush border (1.5e-02/3.4e-02/ 2/13) | |||||
| 102 | 3.8/2 | 10 | 3 | ||||||
| 103 | 3.8/2 | 5 | 6 | regulation of axon diameter (3.9e-02/6.9e-04/ 1/ 1) | neurofilament (4.3e-02/1.9e-03/ 1/3) | ||||
| 104 | 3.8/2 | 24 | 4 | anion transport (4.3e-02/1.9e-01/ 3/ 59) | anion transmembrane transporter activity (4.4e-02/1.7e-01/ 3/63) | ||||
| 105 | 3.8/2 | 6 | 5 | cartilage development (1.1e-02/1.8e-02/ 2/ 26) | |||||
| 106 | 3.8/2 | 5 | 7 | antibacterial humoral response (2.0e-02/2.7e-04/ 1/ 1) | phagocytic vesicle membrane (1.7e-02/6.3e-04/ 1/1) | ||||
| 107 | 3.8/2 | 13 | 8 | response to virus (3.5e-04/1.0e-01/ 4/ 67) | |||||
| 108 | 3.8/2 | 9 | 6 | intrinsic to internal side of plasma membrane (1.7e-02/6.3e-04/ 1/1) | |||||
| 109 | 3.8/2 | 23 | 3 | ||||||
| 110 | 3.8/2 | 5 | 4 | growth hormone receptor complex (1.7e-02/6.3e-04/ 1/1) | |||||
| 111 | 3.8/2 | 9 | 4 | histone phosphorylation (4.8e-02/9.6e-04/ 1/ 1) | |||||
| 112 | 3.8/2 | 7 | 3 | endoplasmic reticulum lumen (1.1e-02/3.0e-02/ 2/48) | |||||
| 113 | 3.8/1.8 | 12 | 7 | cellular aldehyde metabolic process (1.3e-02/1.9e-02/ 2/ 14) | integral to synaptic vesicle membrane (3.3e-02/1.4e-03/ 1/1) | aldo-keto reductase activity (1.1e-02/1.4e-02/ 2/11) | Bile acid biosynthesis (4.4e-02/4.4e-02/ 2/17) | ||
| 114 | 3.8/1.8 | 6 | 8 | phosphoglycerate kinase activity (3.2e-02/3.9e-04/ 1/1) | |||||
| 115 | 3.8/1.8 | 6 | 8 | negative regulation of vascular endothelial growth factor receptor signaling pathway (4.4e-02/8.2e-04/ 1/ 1) | |||||
| 116 | 3.8/1.8 | 8 | 7 | female pregnancy (4.4e-02/4.5e-02/ 2/ 47) | |||||
| 117 | 3.8/1.8 | 37 | 10 | membrane organization (3.8e-02/1.1e+00/ 6/ 235) | cell leading edge (2.8e-02/2.1e-01/ 3/47) | glycosaminoglycan binding (1.4e-02/2.6e-01/ 4/58) | |||
| 118 | 3.8/1.8 | 14 | 8 | neurological system process (8.7e-04/5.4e-01/ 6/ 328) | photoreceptor inner segment (3.8e-02/1.6e-03/ 1/1) | amine binding (2.0e-02/2.1e-02/ 2/15) | |||
| 119 | 3.8/1.8 | 17 | 5 | positive regulation of epithelial cell proliferation (3.0e-02/3.3e-02/ 2/ 15) | extracellular region (1.1e-02/1.5e+00/ 7/700) | ||||
| 120 | 3.8/1.8 | 13 | 11 | intermediate filament bundle assembly (6.4e-04/3.7e-03/ 2/ 3) | neurofilament (2.2e-04/3.8e-03/ 2/3) | ||||
| 121 | 3.8/1.8 | 19 | 4 | blood coagulation (1.2e-02/1.0e-01/ 3/ 50) | signal transducer activity (1.5e-02/1.8e+00/ 8/798) | Complement and coagulation cascades (1.6e-02/1.2e-01/ 3/34) | |||
| 122 | 3.8/1.8 | 9 | 8 | ||||||
| 123 | 3.8/1.8 | 49 | 12 | anatomical structure development (5.7e-05/6.3e+00/ 20/1233) | extracellular region (9.3e-03/3.9e+00/ 12/700) | ||||
| 124 | 3.8/1.8 | 7 | 8 | benzoate metabolic process (4.4e-02/8.2e-04/ 1/ 1) | |||||
| 125 | 3.8/1.8 | 9 | 6 | integral to plasma membrane (3.1e-02/5.5e-01/ 4/549) | |||||
| 126 | 3.8/1.8 | 13 | 7 | ||||||
| 127 | 3.8/1.8 | 21 | 4 | defense response (1.9e-02/6.1e-01/ 5/ 263) | signal transducer activity (4.4e-02/1.7e+00/ 7/798) | ||||
| 128 | 3.8/1.8 | 35 | 10 | membrane organization (5.9e-03/1.0e+00/ 7/ 235) | oncostatin-M receptor complex (7.1e-04/8.1e-03/ 2/2) | oncostatin-M receptor activity (7.4e-03/1.3e-02/ 2/3) | |||
| 129 | 3.8/1.8 | 13 | 7 | enzyme linked receptor protein signaling pathway (2.7e-02/3.8e-01/ 4/ 232) | Focal adhesion (1.2e-02/3.4e-01/ 4/153) | ||||
| 130 | 3.8/1.8 | 9 | 5 | Fc receptor complex (2.6e-02/1.0e-03/ 1/1) | heme binding (4.8e-02/4.1e-02/ 2/45) | ||||
| 131 | 3.8/1.8 | 22 | 5 | anion transport (3.9e-02/1.8e-01/ 3/ 59) | anion transmembrane transporter activity (4.4e-02/1.7e-01/ 3/63) | ||||
| 132 | 3.8/1.8 | 4 | 12 | T cell proliferation during immune response (3.3e-02/5.5e-04/ 1/ 1) | apolipoprotein E receptor activity (3.9e-02/5.2e-04/ 1/1) | ||||
| 133 | 3.8/1.6 | 6 | 10 | ||||||
| 134 | 3.8/1.6 | 16 | 7 | anion transport (2.0e-02/1.3e-01/ 3/ 59) | anion transmembrane transporter activity (2.2e-02/1.2e-01/ 3/63) | ||||
| 135 | 3.8/1.6 | 7 | 9 | phosphoglycerate kinase activity (4.6e-02/6.5e-04/ 1/1) | |||||
| 136 | 3.8/1.6 | 11 | 12 | cartilage development (2.8e-02/3.2e-02/ 2/ 26) | extracellular space (3.5e-02/2.5e-01/ 3/246) | ||||
| 137 | 3.8/1.6 | 56 | 13 | multicellular organismal process (3.8e-04/9.7e+00/ 24/1648) | sarcomere (1.4e-02/1.6e-01/ 3/25) | ||||
| 138 | 3.8/1.6 | 17 | 12 | intermediate filament bundle assembly (1.1e-03/4.9e-03/ 2/ 3) | neurofilament (4.2e-04/5.3e-03/ 2/3) | cytokine activity (2.1e-02/1.2e-01/ 3/73) | |||
| 139 | 3.8/1.6 | 6 | 11 | negative regulation of vascular endothelial growth factor receptor signaling pathway (4.4e-02/8.2e-04/ 1/ 1) | |||||
| 140 | 3.8/1.6 | 7 | 6 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II (3.6e-03/9.0e-03/ 2/ 11) | MHC class II protein complex (6.3e-04/6.2e-03/ 2/7) | Systemic lupus erythematosus (1.3e-02/1.2e-01/ 3/55) | |||
| 141 | 3.8/1.6 | 7 | 14 | ||||||
| 142 | 3.8/1.6 | 7 | 12 | response to lipid hydroperoxide (4.4e-02/8.2e-04/ 1/ 1) | platelet dense granule lumen (2.0e-02/7.6e-04/ 1/1) | ||||
| 143 | 3.8/1.6 | 9 | 11 | ||||||
| 144 | 3.8/1.4 | 8 | 15 | alpha-N-acetylneuraminate alpha-2,8-sialyltransferase activity (4.6e-02/6.5e-04/ 1/1) | |||||
| 145 | 3.8/1.4 | 6 | 18 | ||||||
| 146 | 3.8/1.4 | 8 | 21 | cell morphogenesis (1.0e-02/3.0e-01/ 4/ 317) | |||||
| 147 | 3.8/1.4 | 36 | 17 | Golgi vesicle transport (2.7e-02/3.5e-01/ 4/ 74) | cell leading edge (2.6e-02/2.0e-01/ 3/47) | ||||
| 148 | 3.8/1.4 | 8 | 11 | regulation of aldosterone metabolic process (4.4e-02/8.2e-04/ 1/ 1) | growth hormone receptor complex (2.6e-02/1.0e-03/ 1/1) | ||||
| 149 | 3.8/1.4 | 5 | 17 | NADPH oxidase complex (3.1e-02/1.3e-03/ 1/2) | |||||
| 150 | 3.8/1.4 | 8 | 13 | ||||||
| 151 | 3.8/1.4 | 7 | 11 | putrescine metabolic process (4.4e-02/8.2e-04/ 1/ 1) | voltage-gated sodium channel complex (4.9e-02/2.3e-03/ 1/3) | ||||
| 152 | 3.8/1.4 | 5 | 21 | cell morphogenesis (4.2e-02/2.2e-01/ 3/ 317) | |||||
| 153 | 3.8/1.4 | 5 | 16 | brain-derived neurotrophic factor receptor signaling pathway (3.9e-02/6.9e-04/ 1/ 1) | terminal button (3.1e-02/1.3e-03/ 1/2) | amylase activity (4.6e-02/6.5e-04/ 1/1) | |||
| 154 | 3.8/1.4 | 15 | 14 | immune response (5.0e-02/4.9e-01/ 4/ 295) | extracellular region (3.7e-02/9.7e-01/ 5/700) | ||||
| 155 | 3.8/1.4 | 7 | 16 | rhythmic process (3.8e-02/4.0e-02/ 2/ 49) | signal transducer activity (3.9e-02/5.2e-01/ 4/798) | Circadian rhythm (5.7e-05/1.8e-02/ 3/12) | |||
| 156 | 3.8/1.4 | 4 | 22 | lymphangiogenesis (3.3e-02/5.5e-04/ 1/ 1) | |||||
| 157 | 3.8/1.4 | 17 | 16 | ||||||
| 158 | 3.8/1.4 | 6 | 16 | glycoside metabolic process (3.9e-02/6.9e-04/ 1/ 1) | fibrinogen complex (4.5e-02/2.0e-03/ 1/4) | beta-glucosidase activity (4.6e-02/6.5e-04/ 1/1) | |||
| 159 | 3.8/1.4 | 6 | 18 | collagen type VII (1.4e-02/5.0e-04/ 1/1) | |||||
| 160 | 3.8/1.2 | 4 | 30 | microtubule (4.5e-02/7.5e-02/ 2/148) | |||||
| 161 | 3.8/1.2 | 6 | 27 | fascia adherens (3.1e-02/1.3e-03/ 1/2) | |||||
| 162 | 3.8/1.2 | 27 | 15 | multicellular organismal development (2.0e-05/4.6e+00/ 17/1284) | extracellular space (3.3e-05/7.8e-01/ 8/246) | cytokine activity (7.9e-04/2.4e-01/ 5/73) | Jak-STAT signaling pathway (2.6e-04/4.2e-01/ 6/88) | ||
| 163 | 3.8/1.2 | 5 | 24 | positive regulation of immunoglobulin production (3.9e-02/6.9e-04/ 1/ 1) | beta-glucosidase activity (3.9e-02/5.2e-04/ 1/1) | ||||
| 164 | 3.8/1.2 | 15 | 13 | prostanoid metabolic process (9.7e-03/1.6e-02/ 2/ 9) | integral to synaptic vesicle membrane (4.1e-02/1.8e-03/ 1/1) | aldo-keto reductase activity (2.2e-04/1.8e-02/ 3/11) | Metabolism of xenobiotics by cytochrome P450 (2.0e-02/1.4e-01/ 3/37) | ||
| 165 | 3.8/1.2 | 10 | 20 | extracellular matrix organization (4.8e-02/4.7e-02/ 2/ 43) | extracellular matrix part (3.2e-02/5.7e-02/ 2/64) | ||||
| 166 | 3.8/1.2 | 7 | 21 | glycoside metabolic process (3.9e-02/6.9e-04/ 1/ 1) | collagen type XI (3.1e-02/1.3e-03/ 1/2) | beta-glucosidase activity (4.6e-02/6.5e-04/ 1/1) | |||
| 167 | 3.8/1.2 | 6 | 29 | cell morphogenesis (5.3e-03/2.6e-01/ 4/ 317) | |||||
| 168 | 3.8/1.2 | 5 | 23 | collagen type XI (2.0e-02/7.6e-04/ 1/2) | |||||
| 169 | 3.8/1.2 | 23 | 23 | DNA replication (5.7e-12/5.2e-01/ 12/ 181) | nucleoplasm (2.0e-09/1.6e+00/ 14/570) | DNA primase activity (3.4e-03/7.8e-03/ 2/3) | Cell cycle (2.7e-04/4.3e-01/ 6/98) | ||
| 170 | 3.8/1.2 | 7 | 18 | benzoate metabolic process (3.9e-02/6.9e-04/ 1/ 1) | |||||
| 171 | 3.8/1.2 | 4 | 17 | type III intermediate filament (1.4e-02/5.0e-04/ 1/1) | neurexin binding (3.9e-02/5.2e-04/ 1/1) | ||||
| 172 | 3.8/1.2 | 6 | 28 | positive regulation of protein export from nucleus (3.3e-02/5.5e-04/ 1/ 2) | |||||
| 173 | 3.8/1 | 21 | 34 | cell cycle phase (1.5e-15/7.5e-01/ 15/ 287) | microtubule cytoskeleton (6.7e-12/8.1e-01/ 13/322) | microtubule motor activity (1.0e-05/8.1e-02/ 5/37) | Cell cycle (1.5e-02/1.4e-01/ 3/98) | ||
| 174 | 3.8/1 | 32 | 18 | behavior (2.5e-02/6.4e-01/ 5/ 166) | extracellular region (1.3e-05/2.5e+00/ 13/700) | ||||
| 175 | 3.8/1 | 7 | 33 | keratinocyte activation (4.4e-02/8.2e-04/ 1/ 1) | |||||
| 176 | 3.8/1 | 10 | 34 | ||||||
| 177 | 3.8/1 | 11 | 40 | proteolysis (2.5e-02/7.4e-01/ 5/ 603) | proteasome core complex (5.2e-03/1.9e-02/ 2/17) | threonine-type endopeptidase activity (2.2e-02/2.3e-02/ 2/18) | |||
| 178 | 3.8/1 | 9 | 37 | humoral immune response (7.9e-04/3.7e-02/ 3/ 30) | extracellular region (5.2e-04/7.1e-01/ 6/700) | Complement and coagulation cascades (4.9e-02/5.0e-02/ 2/34) | |||
| 179 | 3.8/1 | 6 | 29 | 16 (2.4e-02/ 0.2640/ 4/416) | |||||
| 180 | 3.8/1 | 5 | 33 | ||||||
| 181 | 3.8/1 | 6 | 30 | regulation of liquid surface tension (3.9e-02/6.9e-04/ 1/ 1) | |||||
| 182 | 3.8/1 | 8 | 37 | cell morphogenesis (1.7e-02/3.5e-01/ 4/ 317) | |||||
| 183 | 3.6/2 | 53 | 6 | regulation of peptidyl-serine phosphorylation (2.1e-04/2.7e-02/ 3/ 4) | extracellular space (1.3e-06/1.5e+00/ 12/246) | growth factor activity (3.9e-05/5.6e-01/ 8/94) | Cytokine-cytokine receptor interaction (1.8e-03/1.2e+00/ 8/122) | ||
| 184 | 3.6/2 | 77 | 7 | multicellular organismal process (8.2e-06/1.4e+01/ 34/1648) | extracellular region (4.1e-07/6.4e+00/ 24/700) | ||||
| 185 | 3.6/2 | 48 | 7 | membrane organization (1.9e-02/1.3e+00/ 7/ 235) | oncostatin-M receptor complex (1.3e-03/1.1e-02/ 2/2) | oncostatin-M receptor activity (1.1e-02/1.7e-02/ 2/3) | |||
| 186 | 3.6/2 | 10 | 9 | synaptic vesicle transport (1.6e-02/2.2e-02/ 2/ 18) | |||||
| 187 | 3.6/2 | 13 | 4 | growth hormone receptor complex (3.6e-02/1.5e-03/ 1/1) | |||||
| 188 | 3.6/2 | 33 | 5 | response to stimulus (2.8e-02/5.0e+00/ 13/1350) | integral to plasma membrane (2.0e-03/1.9e+00/ 9/549) | receptor activity (3.5e-02/1.9e+00/ 8/533) | |||
| 189 | 3.6/2 | 22 | 4 | multicellular organismal process (7.8e-03/4.1e+00/ 12/1648) | endocytic vesicle (3.0e-02/5.3e-02/ 2/21) | ||||
| 190 | 3.6/2 | 28 | 4 | ||||||
| 191 | 3.6/2 | 25 | 6 | placenta development (4.8e-02/4.7e-02/ 2/ 18) | B cell receptor signaling pathway (1.9e-02/1.4e-01/ 3/47) | ||||
| 192 | 3.6/2 | 27 | 5 | cell adhesion (4.5e-02/1.2e+00/ 6/ 376) | extracellular region (4.2e-03/2.1e+00/ 9/700) | ||||
| 193 | 3.6/2 | 8 | 8 | ||||||
| 194 | 3.6/2 | 12 | 5 | integral to membrane (3.3e-02/2.8e+00/ 8/2022) | |||||
| 195 | 3.6/2 | 18 | 9 | extracellular space (2.4e-02/4.7e-01/ 4/246) | |||||
| 196 | 3.6/2 | 45 | 3 | regulation of monooxygenase activity (3.6e-02/3.8e-02/ 2/ 8) | extracellular region (7.4e-04/3.4e+00/ 13/700) | ||||
| 197 | 3.6/2 | 24 | 5 | ||||||
| 198 | 3.6/2 | 34 | 4 | integral to membrane (2.9e-02/8.4e+00/ 17/2022) | |||||
| 199 | 3.6/2 | 10 | 4 | G-protein coupled receptor protein signaling pathway (7.0e-03/2.6e-01/ 4/ 237) | extracellular space (4.8e-02/2.8e-01/ 3/246) | ||||
| 200 | 3.6/2 | 24 | 5 | induction (1.3e-02/2.0e-02/ 2/ 8) | extracellular region (1.4e-03/1.9e+00/ 9/700) | ||||
| 201 | 3.6/2 | 60 | 3 | DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator (2.4e-02/3.0e-02/ 2/ 5) | MAP-kinase scaffold activity (5.9e-03/1.3e-02/ 2/2) | Maturity onset diabetes of the young (3.5e-02/3.9e-02/ 2/5) | |||
| 202 | 3.6/2 | 48 | 5 | cell adhesion (1.1e-03/2.2e+00/ 11/ 376) | extracellular region (1.8e-06/4.1e+00/ 18/700) | promoter binding (3.4e-02/3.2e-02/ 2/6) | Wnt signaling pathway (5.0e-02/8.1e-01/ 5/110) | ||
| 203 | 3.6/2 | 9 | 7 | regulation of axon diameter (3.3e-02/5.5e-04/ 1/ 1) | |||||
| 204 | 3.6/1.8 | 6 | 3 | detection of hormone stimulus (4.4e-02/8.2e-04/ 1/ 1) | |||||
| 205 | 3.6/1.8 | 79 | 12 | anatomical structure development (2.2e-06/1.1e+01/ 31/1233) | extracellular region (5.6e-04/6.4e+00/ 19/700) | extracellular matrix structural constituent (4.0e-02/3.8e-01/ 4/42) | |||
| 206 | 3.6/1.8 | 13 | 5 | growth hormone receptor complex (3.6e-02/1.5e-03/ 1/1) | |||||
| 207 | 3.6/1.8 | 10 | 9 | ||||||
| 208 | 3.6/1.8 | 8 | 9 | angiogenesis (1.3e-02/1.1e-01/ 3/ 104) | collagen type XV (2.6e-02/1.0e-03/ 1/1) | ||||
| 209 | 3.6/1.8 | 35 | 9 | plasma membrane (1.1e-03/5.1e+00/ 15/1443) | transmembrane receptor activity (1.6e-02/1.2e+00/ 7/334) | ||||
| 210 | 3.6/1.8 | 19 | 5 | ||||||
| 211 | 3.6/1.8 | 17 | 10 | G-protein coupled receptor protein signaling pathway (4.4e-02/4.5e-01/ 4/ 237) | extracellular space (5.3e-06/4.3e-01/ 7/246) | cytokine activity (1.9e-03/1.4e-01/ 4/73) | |||
| 212 | 3.6/1.8 | 21 | 8 | activation of plasma proteins during acute inflammatory response (1.4e-03/4.4e-02/ 3/ 17) | |||||
| 213 | 3.6/1.8 | 10 | 7 | growth hormone receptor complex (2.8e-02/1.1e-03/ 1/1) | |||||
| 214 | 3.6/1.8 | 9 | 5 | cartilage development (1.5e-02/2.1e-02/ 2/ 26) | |||||
| 215 | 3.6/1.8 | 30 | 6 | plasma membrane (2.8e-02/4.2e+00/ 11/1443) | extracellular matrix structural constituent (2.6e-02/1.3e-01/ 3/42) | ||||
| 216 | 3.6/1.8 | 62 | 10 | post-Golgi vesicle-mediated transport (1.0e-02/9.8e-02/ 3/ 14) | cytoplasmic vesicle (7.8e-04/2.4e+00/ 11/323) | oncostatin-M receptor activity (1.7e-02/2.2e-02/ 2/3) | miR-320/320abcd (0.04930/ 3.7490/14/377) | ||
| 217 | 3.6/1.8 | 11 | 8 | extracellular region (2.4e-02/8.8e-01/ 5/700) | |||||
| 218 | 3.6/1.8 | 8 | 8 | N-formyl peptide receptor activity (4.6e-02/6.5e-04/ 1/1) | |||||
| 219 | 3.6/1.8 | 15 | 6 | phagocytic vesicle membrane (3.8e-02/1.6e-03/ 1/1) | |||||
| 220 | 3.6/1.6 | 17 | 11 | multicellular organismal process (2.9e-02/2.9e+00/ 9/1648) | extracellular space (1.9e-02/4.3e-01/ 4/246) | structural constituent of muscle (3.6e-02/3.3e-02/ 2/18) | |||
| 221 | 3.6/1.6 | 12 | 11 | myelination (2.1e-02/2.6e-02/ 2/ 17) | internode region of axon (3.3e-02/1.4e-03/ 1/1) | ||||
| 222 | 3.6/1.6 | 14 | 11 | proteinaceous extracellular matrix (1.6e-02/1.8e-01/ 3/156) | |||||
| 223 | 3.6/1.6 | 13 | 13 | DNA replication (5.3e-08/3.2e-01/ 8/ 181) | nucleoplasm (3.9e-05/9.3e-01/ 8/570) | DNA primase activity (1.3e-03/4.3e-03/ 2/3) | Cell cycle (2.8e-02/1.8e-01/ 3/98) | ||
| 224 | 3.6/1.6 | 8 | 14 | glycoside metabolic process (4.8e-02/9.6e-04/ 1/ 1) | brush border (2.0e-03/1.1e-02/ 2/13) | ||||
| 225 | 3.6/1.6 | 8 | 11 | negative regulation of vascular endothelial growth factor receptor signaling pathway (4.8e-02/9.6e-04/ 1/ 1) | |||||
| 226 | 3.6/1.6 | 15 | 8 | ||||||
| 227 | 3.6/1.6 | 12 | 16 | chromatin silencing (1.2e-02/1.8e-02/ 2/ 12) | |||||
| 228 | 3.6/1.6 | 10 | 10 | regulation of axon diameter (3.3e-02/5.5e-04/ 1/ 1) | |||||
| 229 | 3.6/1.6 | 17 | 10 | myosin complex (8.1e-04/5.4e-02/ 3/25) | |||||
| 230 | 3.6/1.6 | 9 | 13 | ||||||
| 231 | 3.6/1.6 | 42 | 14 | behavior (3.4e-05/8.9e-01/ 9/ 166) | extracellular space (1.3e-06/1.2e+00/ 11/246) | cytokine activity (2.9e-05/3.5e-01/ 7/73) | Cytokine-cytokine receptor interaction (4.4e-04/7.2e-01/ 7/122) | ||
| 232 | 3.6/1.6 | 8 | 17 | ||||||
| 233 | 3.6/1.6 | 13 | 14 | ||||||
| 234 | 3.6/1.6 | 16 | 11 | cell soma (3.7e-02/6.1e-02/ 2/37) | MAP-kinase scaffold activity (7.1e-04/3.4e-03/ 2/2) | ||||
| 235 | 3.6/1.6 | 13 | 11 | collagen type XI (4.5e-02/2.0e-03/ 1/2) | |||||
| 236 | 3.6/1.6 | 17 | 11 | extracellular region part (7.9e-03/6.3e-01/ 5/387) | |||||
| 237 | 3.6/1.6 | 9 | 13 | ||||||
| 238 | 3.6/1.6 | 13 | 11 | ||||||
| 239 | 3.6/1.6 | 11 | 8 | cellular developmental process (4.2e-02/9.0e-01/ 5/ 824) | growth hormone receptor complex (3.1e-02/1.3e-03/ 1/1) | ||||
| 240 | 3.6/1.4 | 11 | 12 | ||||||
| 241 | 3.6/1.4 | 18 | 19 | nuclear division (2.6e-12/3.8e-01/ 11/ 174) | spindle (2.4e-10/1.7e-01/ 8/80) | microtubule motor activity (2.1e-04/7.2e-02/ 4/37) | |||
| 242 | 3.6/1.4 | 32 | 17 | DNA replication (3.1e-19/7.4e-01/ 18/ 181) | nucleoplasm (5.3e-09/2.2e+00/ 16/570) | DNA-directed DNA polymerase activity (4.8e-03/6.3e-02/ 3/18) | Cell cycle (6.8e-05/5.4e-01/ 7/98) | ||
| 243 | 3.6/1.4 | 6 | 20 | fatty acid alpha-oxidation (4.4e-02/8.2e-04/ 1/ 1) | |||||
| 244 | 3.6/1.4 | 8 | 15 | brain-derived neurotrophic factor receptor signaling pathway (4.4e-02/8.2e-04/ 1/ 1) | terminal button (4.5e-02/2.0e-03/ 1/2) | ||||
| 245 | 3.6/1.4 | 7 | 12 | type IV hypersensitivity (4.4e-02/8.2e-04/ 1/ 1) | axonemal dynein complex (3.6e-02/1.5e-03/ 1/2) | ||||
| 246 | 3.6/1.4 | 12 | 15 | collagen type XI (4.5e-02/2.0e-03/ 1/2) | |||||
| 247 | 3.6/1.4 | 10 | 11 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II (7.4e-03/1.4e-02/ 2/ 11) | MHC class II protein complex (1.3e-03/8.8e-03/ 2/7) | chloride channel activity (3.2e-02/3.0e-02/ 2/29) | Systemic lupus erythematosus (2.0e-02/1.4e-01/ 3/55) | ||
| 248 | 3.6/1.4 | 17 | 15 | vascular process in circulatory system (4.6e-02/4.5e-02/ 2/ 30) | photoreceptor inner segment (4.1e-02/1.8e-03/ 1/1) | ||||
| 249 | 3.6/1.4 | 12 | 14 | neuropeptide signaling pathway (2.7e-02/3.2e-02/ 2/ 33) | 16 (4.2e-02/ 0.5280/ 5/416) | ||||
| 250 | 3.6/1.4 | 8 | 12 | positive regulation of cell activation (3.3e-02/3.7e-02/ 2/ 45) | external side of plasma membrane (1.8e-02/4.0e-02/ 2/45) | ||||
| 251 | 3.6/1.4 | 6 | 17 | basal protein localization (2.7e-02/4.1e-04/ 1/ 1) | hemidesmosome (3.1e-02/1.3e-03/ 1/2) | ErbB-2 class receptor binding (3.9e-02/5.2e-04/ 1/1) | |||
| 252 | 3.6/1.4 | 12 | 20 | ||||||
| 253 | 3.6/1.4 | 10 | 16 | integral to plasma membrane (4.8e-02/6.2e-01/ 4/549) | B cell receptor signaling pathway (5.1e-03/8.6e-02/ 3/47) | ||||
| 254 | 3.6/1.4 | 31 | 15 | DNA replication (2.0e-16/6.9e-01/ 16/ 181) | nucleoplasm (2.0e-10/2.2e+00/ 17/570) | DNA-dependent ATPase activity (1.6e-03/1.3e-01/ 4/39) | DNA replication (2.5e-06/1.8e-01/ 6/33) | ||
| 255 | 3.6/1.2 | 51 | 19 | post-Golgi vesicle-mediated transport (8.0e-03/8.8e-02/ 3/ 14) | oncostatin-M receptor complex (1.5e-03/1.2e-02/ 2/2) | oncostatin-M receptor activity (1.2e-02/1.8e-02/ 2/3) | miR-320/320abcd (0.04869/ 3.1570/13/377) | ||
| 256 | 3.6/1.2 | 9 | 19 | ||||||
| 257 | 3.6/1.2 | 7 | 17 | oxytocin receptor activity (4.6e-02/6.5e-04/ 1/1) | |||||
| 258 | 3.6/1.2 | 6 | 21 | necrotic cell death (3.9e-02/6.9e-04/ 1/ 1) | |||||
| 259 | 3.6/1.2 | 11 | 29 | cell morphogenesis (3.6e-02/4.3e-01/ 4/ 317) | |||||
| 260 | 3.6/1.2 | 7 | 18 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II (3.6e-03/9.0e-03/ 2/ 11) | MHC class II protein complex (6.3e-04/6.2e-03/ 2/7) | chloride channel activity (2.0e-02/2.3e-02/ 2/29) | Systemic lupus erythematosus (1.3e-02/1.2e-01/ 3/55) | ||
| 261 | 3.6/1.2 | 12 | 23 | ||||||
| 262 | 3.6/1.2 | 8 | 19 | ||||||
| 263 | 3.6/1.2 | 10 | 18 | ||||||
| 264 | 3.6/1.2 | 6 | 23 | ||||||
| 265 | 3.6/1.2 | 37 | 21 | cell cycle phase (3.6e-22/1.3e+00/ 23/ 287) | chromosomal part (5.6e-16/9.0e-01/ 17/198) | microtubule motor activity (9.5e-05/1.4e-01/ 5/37) | DNA replication (1.2e-02/1.1e-01/ 3/33) | ||
| 266 | 3.6/1.2 | 13 | 22 | transmembrane receptor activity (4.3e-02/4.3e-01/ 4/334) | |||||
| 267 | 3.6/1.2 | 5 | 21 | ||||||
| 268 | 3.6/1.2 | 10 | 23 | brush border (2.6e-03/1.3e-02/ 2/13) | |||||
| 269 | 3.6/1 | 8 | 31 | ||||||
| 270 | 3.6/1 | 42 | 23 | multicellular organismal development (1.3e-05/6.9e+00/ 22/1284) | extracellular space (1.2e-08/1.2e+00/ 13/246) | cytokine activity (2.5e-06/3.6e-01/ 8/73) | Cytokine-cytokine receptor interaction (2.3e-05/9.4e-01/ 9/122) | miR-17-5p/20/93.mr/106/519.d (0.04869/ 4.3477/15/639) | |
| 271 | 3.6/1 | 7 | 31 | keratinocyte activation (4.8e-02/9.6e-04/ 1/ 1) | |||||
| 272 | 3.6/1 | 8 | 25 | ||||||
| 273 | 3.6/1 | 54 | 34 | nuclear division (9.5e-45/1.2e+00/ 36/ 174) | microtubule cytoskeleton (3.7e-19/2.1e+00/ 25/322) | microtubule motor activity (7.4e-09/2.3e-01/ 9/37) | Cell cycle (1.1e-05/4.3e-01/ 7/98) | ||
| 274 | 3.6/1 | 11 | 33 | ||||||
| 275 | 3.6/1 | 7 | 34 | positive regulation of nitric oxide biosynthetic process (3.6e-03/9.0e-03/ 2/ 11) | membrane raft (1.7e-02/3.9e-02/ 2/44) | ||||
| 276 | 3.6/1 | 9 | 38 | positive regulation of fibrinolysis (4.8e-02/9.6e-04/ 1/ 1) | extracellular region (3.9e-02/6.2e-01/ 4/700) | ||||
| 277 | 3.6/1 | 16 | 30 | ||||||
| 278 | 3.6/1 | 8 | 38 | ||||||
| 279 | 3.4/2 | 11 | 9 | angiogenesis (1.1e-03/1.4e-01/ 4/ 104) | collagen type XV (3.3e-02/1.4e-03/ 1/1) | ||||
| 280 | 3.4/2 | 53 | 5 | ||||||
| 281 | 3.4/2 | 32 | 3 | regulation of organ growth (2.4e-02/2.9e-02/ 2/ 10) | |||||
| 282 | 3.4/2 | 23 | 7 | embryonic eye morphogenesis (1.6e-02/2.2e-02/ 2/ 8) | aldo-keto reductase activity (2.8e-02/2.7e-02/ 2/11) | ||||
| 283 | 3.4/2 | 41 | 3 | Rap GTPase activator activity (6.4e-03/1.2e-02/ 2/3) | |||||
| 284 | 3.4/2 | 41 | 5 | chondroitin sulfate proteoglycan biosynthetic process (3.6e-02/3.8e-02/ 2/ 8) | extracellular region (2.4e-03/3.4e+00/ 12/700) | protein complex binding (4.2e-02/3.9e-01/ 4/86) | |||
| 285 | 3.4/2 | 22 | 5 | positive regulation of proteolysis (1.9e-02/2.4e-02/ 2/ 11) | |||||
| 286 | 3.4/2 | 23 | 4 | positive regulation of peptidyl-tyrosine phosphorylation (1.4e-03/4.4e-02/ 3/ 18) | |||||
| 287 | 3.4/2 | 8 | 5 | sterol biosynthetic process (7.8e-04/3.7e-02/ 3/ 34) | monooxygenase activity (3.9e-02/3.5e-02/ 2/34) | Biosynthesis of steroids (1.4e-03/5.1e-02/ 3/23) | |||
| 288 | 3.4/2 | 13 | 7 | ||||||
| 289 | 3.4/2 | 42 | 4 | inflammatory response (2.5e-02/6.3e-01/ 5/ 153) | bile acid transmembrane transporter activity (6.7e-03/1.2e-02/ 2/3) | ||||
| 290 | 3.4/2 | 20 | 5 | cilium (5.5e-03/1.1e-01/ 3/46) | Rab GTPase binding (3.3e-02/3.0e-02/ 2/13) | ||||
| 291 | 3.4/2 | 17 | 5 | Golgi membrane (3.1e-03/4.9e-01/ 5/243) | |||||
| 292 | 3.4/2 | 82 | 9 | Golgi vesicle transport (7.5e-03/7.2e-01/ 6/ 74) | cytoplasmic vesicle (2.0e-03/3.1e+00/ 12/323) | oncostatin-M receptor activity (2.6e-02/2.9e-02/ 2/3) | miR-320/320abcd (0.00711/ 4.9986/19/377) | ||
| 293 | 3.4/2 | 36 | 3 | multicellular organismal process (3.4e-02/6.6e+00/ 15/1648) | actomyosin (2.0e-03/1.2e-02/ 2/3) | Complement and coagulation cascades (4.8e-02/2.0e-01/ 3/34) | |||
| 294 | 3.4/2 | 15 | 5 | complement activation, alternative pathway (4.4e-03/1.0e-02/ 2/ 5) | extracellular region part (1.8e-03/7.3e-01/ 6/387) | endopeptidase inhibitor activity (1.5e-02/1.1e-01/ 3/58) | |||
| 295 | 3.4/2 | 28 | 3 | ||||||
| 296 | 3.4/2 | 72 | 7 | acute inflammatory response (1.7e-02/3.0e-01/ 4/ 37) | cytoplasmic vesicle (2.4e-03/2.7e+00/ 11/323) | oncostatin-M receptor activity (2.1e-02/2.6e-02/ 2/3) | |||
| 297 | 3.4/2 | 45 | 3 | regulation of cytokine biosynthetic process (2.3e-02/1.4e-01/ 3/ 31) | brush border (1.3e-03/6.4e-02/ 3/13) | ||||
| 298 | 3.4/2 | 21 | 5 | innate immune response (2.5e-03/1.7e-01/ 4/ 65) | extracellular region (3.9e-03/1.7e+00/ 8/700) | ||||
| 299 | 3.4/2 | 29 | 4 | positive regulation of tyrosine phosphorylation of Stat3 protein (1.6e-02/2.2e-02/ 2/ 7) | |||||
| 300 | 3.4/1.8 | 29 | 7 | neurotransmitter transport (1.3e-02/1.1e-01/ 3/ 36) | brush border (2.1e-02/4.3e-02/ 2/13) | ||||
| 301 | 3.4/1.8 | 25 | 6 | regulation of multicellular organismal process (2.5e-03/9.2e-01/ 7/ 320) | |||||
| 302 | 3.4/1.8 | 14 | 12 | ||||||
| 303 | 3.4/1.8 | 25 | 10 | intermediate filament bundle assembly (2.7e-03/8.2e-03/ 2/ 3) | neurofilament (9.5e-04/8.3e-03/ 2/3) | ||||
| 304 | 3.4/1.8 | 13 | 4 | ||||||
| 305 | 3.4/1.8 | 27 | 5 | organic anion transport (2.2e-02/2.7e-02/ 2/ 8) | extracellular region (1.1e-03/2.2e+00/ 10/700) | ||||
| 306 | 3.4/1.8 | 30 | 8 | translational elongation (4.6e-09/3.2e-01/ 9/ 93) | ribosome (9.0e-08/5.1e-01/ 9/151) | structural constituent of ribosome (3.8e-05/3.8e-01/ 7/123) | Ribosome (2.3e-05/2.8e-01/ 6/70) | ||
| 307 | 3.4/1.8 | 17 | 9 | ||||||
| 308 | 3.4/1.8 | 49 | 8 | defense response (3.5e-02/1.5e+00/ 7/ 263) | extracellular region (9.3e-03/3.9e+00/ 12/700) | transmembrane receptor activity (3.9e-02/1.9e+00/ 8/334) | |||
| 309 | 3.4/1.8 | 18 | 8 | ||||||
| 310 | 3.4/1.8 | 12 | 7 | ||||||
| 311 | 3.4/1.8 | 24 | 4 | ||||||
| 312 | 3.4/1.8 | 33 | 5 | neurotransmitter transport (1.8e-02/1.2e-01/ 3/ 36) | brush border (5.7e-04/4.8e-02/ 3/13) | ||||
| 313 | 3.4/1.8 | 71 | 10 | vesicle-mediated transport (1.3e-02/3.0e+00/ 11/ 358) | cytoplasmic vesicle (2.4e-03/2.7e+00/ 11/323) | oncostatin-M receptor activity (2.0e-02/2.5e-02/ 2/3) | miR-320/320abcd (0.02123/ 4.2094/16/377) | ||
| 314 | 3.4/1.8 | 33 | 4 | translational elongation (3.5e-06/3.1e-01/ 7/ 93) | cytosolic part (2.1e-07/3.8e-01/ 8/108) | structural constituent of ribosome (8.4e-04/4.3e-01/ 6/123) | Ribosome (2.1e-03/3.6e-01/ 5/70) | ||
| 315 | 3.4/1.6 | 72 | 12 | response to external stimulus (5.8e-07/3.3e+00/ 18/ 370) | extracellular region (2.5e-09/5.9e+00/ 26/700) | growth factor activity (2.9e-05/7.4e-01/ 9/94) | Cytokine-cytokine receptor interaction (7.5e-04/1.4e+00/ 9/122) | ||
| 316 | 3.4/1.6 | 16 | 8 | peptide secretion (2.4e-02/2.9e-02/ 2/ 19) | brush border (4.6e-03/1.8e-02/ 2/13) | ||||
| 317 | 3.4/1.6 | 64 | 10 | organ development (6.7e-06/6.0e+00/ 22/ 743) | extracellular space (2.5e-09/1.9e+00/ 16/246) | receptor binding (5.5e-07/3.0e+00/ 18/408) | Cytokine-cytokine receptor interaction (1.7e-04/1.5e+00/10/122) | ||
| 318 | 3.4/1.6 | 9 | 12 | cartilage development (2.4e-02/2.9e-02/ 2/ 26) | extracellular space (3.5e-02/2.5e-01/ 3/246) | ||||
| 319 | 3.4/1.6 | 18 | 9 | brush border (9.0e-03/2.6e-02/ 2/13) | |||||
| 320 | 3.4/1.6 | 37 | 12 | amino acid biosynthetic process (1.1e-03/1.3e-01/ 4/ 30) | cell surface (6.7e-03/5.6e-01/ 5/130) | pyridoxal phosphate binding (2.3e-02/1.2e-01/ 3/31) | |||
| 321 | 3.4/1.6 | 9 | 11 | cartilage development (1.9e-02/2.5e-02/ 2/ 26) | extracellular space (3.5e-02/2.5e-01/ 3/246) | ||||
| 322 | 3.4/1.6 | 24 | 11 | extracellular space (1.1e-04/6.5e-01/ 7/246) | cytokine activity (4.2e-03/1.8e-01/ 4/73) | ||||
| 323 | 3.4/1.6 | 32 | 8 | extracellular region (4.0e-03/2.6e+00/ 10/700) | |||||
| 324 | 3.4/1.6 | 26 | 7 | cognition (3.2e-02/6.9e-01/ 5/ 210) | |||||
| 325 | 3.4/1.6 | 11 | 9 | ||||||
| 326 | 3.4/1.6 | 54 | 9 | plasma membrane (3.7e-03/8.0e+00/ 19/1443) | transmembrane receptor activity (1.1e-02/1.9e+00/ 9/334) | Cyanoamino acid metabolism (3.5e-02/3.9e-02/ 2/5) | |||
| 327 | 3.4/1.6 | 13 | 9 | cell recognition (3.8e-02/3.9e-02/ 2/ 24) | |||||
| 328 | 3.4/1.6 | 12 | 14 | ||||||
| 329 | 3.4/1.6 | 33 | 7 | activation of plasma proteins during acute inflammatory response (5.0e-03/7.2e-02/ 3/ 17) | |||||
| 330 | 3.4/1.6 | 10 | 11 | axonemal dynein complex (4.9e-02/2.3e-03/ 1/2) | |||||
| 331 | 3.4/1.6 | 14 | 10 | platelet dense granule lumen (4.1e-02/1.8e-03/ 1/1) | |||||
| 332 | 3.4/1.6 | 16 | 8 | cellular aldehyde metabolic process (1.7e-02/2.3e-02/ 2/ 14) | aldo-keto reductase activity (1.6e-02/1.8e-02/ 2/11) | Bile acid biosynthesis (2.5e-02/3.1e-02/ 2/17) | |||
| 333 | 3.4/1.6 | 9 | 17 | ||||||
| 334 | 3.4/1.6 | 26 | 9 | cell cycle phase (4.0e-06/9.8e-01/ 10/ 287) | chromosomal part (3.0e-08/6.5e-01/ 10/198) | DNA primase activity (3.9e-03/8.5e-03/ 2/3) | DNA replication (8.7e-04/1.3e-01/ 4/33) | ||
| 335 | 3.4/1.6 | 14 | 14 | brush border (4.6e-03/1.8e-02/ 2/13) | scavenger receptor activity (1.4e-02/1.7e-02/ 2/12) | ||||
| 336 | 3.4/1.6 | 11 | 12 | collagen type XI (4.9e-02/2.3e-03/ 1/2) | |||||
| 337 | 3.4/1.6 | 10 | 11 | kynurenine metabolic process (4.8e-02/9.6e-04/ 1/ 1) | |||||
| 338 | 3.4/1.6 | 61 | 4 | transcription termination (2.9e-02/3.4e-02/ 2/ 5) | extracellular region (1.4e-03/4.7e+00/ 15/700) | ||||
| 339 | 3.4/1.6 | 11 | 12 | brush border (3.2e-03/1.5e-02/ 2/13) | |||||
| 340 | 3.4/1.6 | 29 | 13 | cell-cell signaling (2.7e-03/9.1e-01/ 7/ 267) | extracellular space (1.4e-07/7.8e-01/ 10/246) | cytokine activity (6.0e-05/2.5e-01/ 6/73) | |||
| 341 | 3.4/1.6 | 37 | 11 | DNA replication (1.4e-17/8.7e-01/ 18/ 181) | chromosomal part (4.0e-13/9.0e-01/ 15/198) | DNA-directed DNA polymerase activity (2.2e-04/7.2e-02/ 4/18) | DNA replication (9.8e-10/1.9e-01/ 8/33) | ||
| 342 | 3.4/1.4 | 17 | 16 | brush border (7.1e-03/2.3e-02/ 2/13) | |||||
| 343 | 3.4/1.4 | 14 | 15 | brush border (5.4e-03/2.0e-02/ 2/13) | |||||
| 344 | 3.4/1.4 | 14 | 11 | synaptic vesicle transport (2.2e-02/2.7e-02/ 2/ 18) | |||||
| 345 | 3.4/1.4 | 31 | 16 | ||||||
| 346 | 3.4/1.4 | 56 | 15 | cell cycle phase (1.6e-27/1.9e+00/ 30/ 287) | chromosome (2.1e-18/1.7e+00/ 23/248) | microtubule motor activity (3.6e-05/2.2e-01/ 6/37) | DNA replication (3.4e-03/1.9e-01/ 4/33) | ||
| 347 | 3.4/1.4 | 22 | 17 | brush border (1.2e-02/3.1e-02/ 2/13) | |||||
| 348 | 3.4/1.4 | 18 | 19 | ||||||
| 349 | 3.4/1.4 | 13 | 22 | cell morphogenesis (4.7e-02/4.8e-01/ 4/ 317) | |||||
| 350 | 3.4/1.4 | 14 | 14 | synaptic vesicle transport (2.2e-02/2.7e-02/ 2/ 18) | |||||
| 351 | 3.4/1.4 | 26 | 20 | chromatin silencing (3.6e-02/3.8e-02/ 2/ 12) | Chronic myeloid leukemia (8.3e-03/2.6e-01/ 4/65) | ||||
| 352 | 3.4/1.4 | 9 | 14 | ||||||
| 353 | 3.4/1.4 | 8 | 12 | type IV hypersensitivity (4.8e-02/9.6e-04/ 1/ 1) | |||||
| 354 | 3.4/1.4 | 18 | 13 | peptide secretion (3.5e-02/3.6e-02/ 2/ 19) | MAP-kinase scaffold activity (9.0e-04/3.9e-03/ 2/2) | ||||
| 355 | 3.4/1.4 | 12 | 14 | ||||||
| 356 | 3.4/1.4 | 21 | 17 | humoral immune response (1.1e-04/7.0e-02/ 4/ 30) | extracellular space (1.3e-03/6.5e-01/ 6/246) | cytokine activity (3.4e-02/1.5e-01/ 3/73) | Y (4.5e-04/ 0.0689/ 4/ 31) | ||
| 357 | 3.4/1.4 | 16 | 18 | Glycine, serine and threonine metabolism (4.5e-02/4.6e-02/ 2/25) | |||||
| 358 | 3.4/1.4 | 7 | 16 | cartilage development (1.1e-02/1.8e-02/ 2/ 26) | |||||
| 359 | 3.4/1.4 | 13 | 21 | cell morphogenesis (5.9e-03/4.8e-01/ 5/ 317) | |||||
| 360 | 3.4/1.4 | 15 | 13 | eye photoreceptor cell differentiation (4.4e-03/1.0e-02/ 2/ 5) | cell projection part (4.9e-02/7.2e-02/ 2/38) | ||||
| 361 | 3.4/1.4 | 10 | 14 | generation of neurons (4.8e-02/2.1e-01/ 3/ 171) | |||||
| 362 | 3.4/1.4 | 27 | 16 | ||||||
| 363 | 3.4/1.2 | 13 | 19 | dephosphorylation (3.5e-02/1.7e-01/ 3/ 97) | |||||
| 364 | 3.4/1.2 | 52 | 17 | positive regulation of transcription from RNA polymerase II promoter (9.3e-06/9.9e-01/ 10/ 145) | extracellular space (1.7e-07/1.5e+00/ 13/246) | cytokine activity (1.0e-04/4.4e-01/ 7/73) | Cytokine-cytokine receptor interaction (1.8e-03/1.2e+00/ 8/122) | ||
| 365 | 3.4/1.2 | 20 | 25 | cell morphogenesis (3.6e-02/7.4e-01/ 5/ 317) | |||||
| 366 | 3.4/1.2 | 78 | 23 | cell cycle phase (3.1e-49/2.8e+00/ 49/ 287) | chromosome (1.2e-29/2.3e+00/ 35/248) | microtubule motor activity (6.2e-08/3.1e-01/ 9/37) | Cell cycle (1.9e-07/7.5e-01/10/98) | ||
| 367 | 3.4/1.2 | 12 | 22 | ||||||
| 368 | 3.4/1.2 | 14 | 19 | antigen processing and presentation of peptide antigen via MHC class I (2.8e-08/3.3e-02/ 5/ 17) | MHC class I protein complex (2.8e-09/2.6e-02/ 5/15) | MHC class I receptor activity (1.1e-08/1.6e-02/ 5/9) | Allograft rejection (2.8e-07/6.2e-02/ 5/21) | 6 (2.1e-02/ 0.7434/ 6/502) | |
| 369 | 3.4/1.2 | 21 | 25 | cell morphogenesis (4.4e-02/7.8e-01/ 5/ 317) | |||||
| 370 | 3.4/1.2 | 10 | 23 | ||||||
| 371 | 3.4/1.2 | 11 | 26 | ||||||
| 372 | 3.4/1.2 | 12 | 22 | collagen type XI (4.9e-02/2.3e-03/ 1/2) | |||||
| 373 | 3.4/1.2 | 23 | 29 | ||||||
| 374 | 3.4/1.2 | 13 | 21 | ||||||
| 375 | 3.4/1.2 | 10 | 21 | ||||||
| 376 | 3.4/1 | 22 | 40 | ||||||
| 377 | 3.4/1 | 44 | 26 | amino acid biosynthetic process (7.7e-05/1.6e-01/ 5/ 30) | pyridoxal phosphate binding (1.4e-04/1.5e-01/ 5/31) | Glycine, serine and threonine metabolism (2.0e-03/1.7e-01/ 4/25) | |||
| 378 | 3.4/1 | 11 | 28 | ||||||
| 379 | 3.4/1 | 16 | 29 | ||||||
| 380 | 3.4/1 | 80 | 37 | nuclear division (1.2e-53/1.8e+00/ 46/ 174) | microtubule cytoskeleton (1.5e-22/3.0e+00/ 32/322) | microtubule motor activity (2.4e-10/3.2e-01/ 11/37) | Cell cycle (7.7e-09/7.5e-01/11/98) | ||
| 381 | 3.4/1 | 18 | 35 | ||||||
| 382 | 3.4/1 | 14 | 28 | ||||||
| 383 | 3.4/1 | 14 | 29 | ||||||
| 384 | 3.2/2 | 52 | 4 | cell-cell signaling (2.9e-03/1.6e+00/ 9/ 267) | extracellular region (9.9e-05/4.2e+00/ 16/700) | hormone activity (3.6e-02/1.5e-01/ 3/29) | |||
| 385 | 3.2/2 | 136 | 8 | multicellular organismal process (1.7e-07/2.5e+01/ 54/1648) | extracellular region (1.0e-07/1.1e+01/ 34/700) | extracellular matrix structural constituent (5.3e-03/6.3e-01/ 6/42) | Cell junctions (2.2e-02/9.5e-01/ 6/59) | ||
| 386 | 3.2/2 | 45 | 3 | translational elongation (1.7e-05/3.8e-01/ 7/ 93) | cytosolic part (1.6e-06/4.9e-01/ 8/108) | structural constituent of ribosome (2.6e-03/5.4e-01/ 6/123) | Ribosome (5.1e-03/4.4e-01/ 5/70) | ||
| 387 | 3.2/2 | 104 | 7 | Golgi vesicle transport (3.1e-03/8.8e-01/ 7/ 74) | cytoplasmic vesicle (6.9e-05/3.9e+00/ 16/323) | oncostatin-M receptor activity (3.4e-02/3.6e-02/ 2/3) | miR-320/320abcd (0.00035/ 6.1825/24/377) | ||
| 388 | 3.2/2 | 18 | 3 | embryonic pattern specification (4.1e-02/4.1e-02/ 2/ 23) | |||||
| 389 | 3.2/2 | 8 | 7 | type IV hypersensitivity (4.8e-02/9.6e-04/ 1/ 1) | axonemal dynein complex (4.1e-02/1.8e-03/ 1/2) | ||||
| 390 | 3.2/2 | 26 | 6 | ||||||
| 391 | 3.2/2 | 82 | 3 | metal ion transport (7.1e-03/1.4e+00/ 8/ 177) | ion transmembrane transporter activity (2.0e-02/2.6e+00/ 10/299) | MAPK signaling pathway (4.5e-02/1.6e+00/ 7/186) | |||
| 392 | 3.2/2 | 26 | 4 | ||||||
| 393 | 3.2/2 | 8 | 6 | type IV hypersensitivity (4.4e-02/8.2e-04/ 1/ 1) | uropod (4.9e-02/2.3e-03/ 1/3) | ||||
| 394 | 3.2/2 | 26 | 4 | sterol biosynthetic process (1.6e-05/1.1e-01/ 5/ 34) | Biosynthesis of steroids (2.6e-05/1.3e-01/ 5/23) | ||||
| 395 | 3.2/2 | 20 | 5 | protein maturation via proteolysis (2.0e-02/2.5e-02/ 2/ 13) | carbohydrate binding (1.4e-02/2.7e-01/ 4/132) | ||||
| 396 | 3.2/2 | 42 | 5 | xenobiotic metabolic process (2.7e-03/5.7e-02/ 3/ 13) | fibril (1.3e-02/3.3e-02/ 2/8) | glucuronosyltransferase activity (2.8e-03/5.1e-02/ 3/12) | Pentose and glucuronate interconversions (3.5e-03/6.7e-02/ 3/13) | ||
| 397 | 3.2/2 | 39 | 9 | intermediate filament bundle assembly (5.6e-03/1.3e-02/ 2/ 3) | extracellular space (3.4e-04/1.1e+00/ 8/246) | calcium ion binding (4.8e-02/1.6e+00/ 7/402) | |||
| 398 | 3.2/2 | 32 | 7 | embryonic eye morphogenesis (2.5e-02/3.0e-02/ 2/ 8) | aldo-keto reductase activity (1.3e-03/3.7e-02/ 3/11) | ||||
| 399 | 3.2/2 | 103 | 4 | response to stimulus (4.9e-02/1.4e+01/ 26/1350) | MAP-kinase scaffold activity (1.4e-02/2.2e-02/ 2/2) | ||||
| 400 | 3.2/2 | 13 | 5 | ||||||
| 401 | 3.2/2 | 25 | 6 | response to wounding (7.8e-03/7.6e-01/ 6/ 231) | extracellular region part (2.8e-03/1.1e+00/ 7/387) | G-protein-coupled receptor binding (1.1e-02/8.9e-02/ 3/30) | |||
| 402 | 3.2/2 | 22 | 5 | osteoblast differentiation (3.9e-03/6.5e-02/ 3/ 28) | |||||
| 403 | 3.2/2 | 56 | 3 | multicellular organismal process (2.9e-02/1.0e+01/ 21/1648) | actomyosin (4.3e-03/2.0e-02/ 2/3) | ||||
| 404 | 3.2/2 | 43 | 5 | genetic imprinting (5.9e-03/1.3e-02/ 2/ 3) | extracellular region (2.2e-02/3.2e+00/ 10/700) | growth factor activity (9.9e-03/4.5e-01/ 5/94) | |||
| 405 | 3.2/2 | 27 | 6 | extracellular region (1.8e-04/2.2e+00/ 11/700) | |||||
| 406 | 3.2/2 | 14 | 5 | sterol metabolic process (3.7e-07/1.2e-01/ 6/ 65) | endoplasmic reticulum membrane (3.9e-02/5.5e-01/ 4/336) | Biosynthesis of steroids (9.7e-07/7.6e-02/ 5/23) | |||
| 407 | 3.2/2 | 15 | 9 | ||||||
| 408 | 3.2/2 | 15 | 7 | brush border (5.4e-03/2.0e-02/ 2/13) | |||||
| 409 | 3.2/2 | 19 | 4 | compact myelin (4.9e-02/2.3e-03/ 1/1) | |||||
| 410 | 3.2/2 | 60 | 5 | retinoic acid metabolic process (1.1e-02/2.0e-02/ 2/ 3) | extracellular region (5.8e-03/4.8e+00/ 14/700) | ||||
| 411 | 3.2/2 | 42 | 6 | genetic imprinting (5.9e-03/1.3e-02/ 2/ 3) | extracellular region (2.4e-03/3.4e+00/ 12/700) | MAP kinase tyrosine/serine/threonine phosphatase activity (4.1e-02/3.6e-02/ 2/8) | |||
| 412 | 3.2/2 | 37 | 7 | ||||||
| 413 | 3.2/2 | 90 | 3 | transcription termination (4.9e-02/5.0e-02/ 2/ 5) | extracellular region (1.9e-03/7.1e+00/ 19/700) | ||||
| 414 | 3.2/1.8 | 23 | 7 | peptide secretion (4.8e-02/4.7e-02/ 2/ 19) | brush border (1.1e-02/3.0e-02/ 2/13) | ||||
| 415 | 3.2/1.8 | 53 | 8 | extracellular region (2.5e-02/3.8e+00/ 11/700) | |||||
| 416 | 3.2/1.8 | 28 | 6 | osteoblast differentiation (6.6e-03/8.1e-02/ 3/ 28) | |||||
| 417 | 3.2/1.8 | 101 | 10 | membrane organization (7.2e-03/2.7e+00/ 11/ 235) | cytoplasmic vesicle (3.6e-03/3.8e+00/ 13/323) | miR-320/320abcd (0.02382/ 5.7879/19/377) | |||
| 418 | 3.2/1.8 | 38 | 9 | multicellular organismal process (1.1e-03/7.2e+00/ 19/1648) | extracellular region (3.8e-06/3.0e+00/ 15/700) | GABA receptor activity (4.3e-02/3.7e-02/ 2/11) | |||
| 419 | 3.2/1.8 | 22 | 7 | ||||||
| 420 | 3.2/1.8 | 48 | 10 | plasma membrane (2.7e-03/7.8e+00/ 19/1443) | transmembrane receptor activity (1.8e-02/1.6e+00/ 8/334) | B cell receptor signaling pathway (1.9e-02/3.3e-01/ 4/47) | |||
| 421 | 3.2/1.8 | 15 | 10 | brush border (7.1e-03/2.3e-02/ 2/13) | |||||
| 422 | 3.2/1.8 | 40 | 7 | extracellular region (5.9e-03/3.2e+00/ 11/700) | MAP kinase tyrosine/serine/threonine phosphatase activity (4.4e-02/3.8e-02/ 2/8) | ||||
| 423 | 3.2/1.8 | 23 | 8 | cell cycle phase (1.8e-07/7.5e-01/ 10/ 287) | chromosome (1.1e-06/7.2e-01/ 9/248) | ||||
| 424 | 3.2/1.8 | 11 | 9 | ||||||
| 425 | 3.2/1.8 | 24 | 7 | ||||||
| 426 | 3.2/1.8 | 26 | 7 | cell-cell signaling (4.3e-02/7.7e-01/ 5/ 267) | |||||
| 427 | 3.2/1.8 | 16 | 6 | cartilage development (1.9e-03/5.0e-02/ 3/ 26) | extracellular space (2.4e-02/4.7e-01/ 4/246) | cytokine activity (2.5e-02/1.3e-01/ 3/73) | |||
| 428 | 3.2/1.8 | 22 | 8 | brush border (1.1e-02/3.0e-02/ 2/13) | |||||
| 429 | 3.2/1.8 | 47 | 6 | plasma membrane part (1.6e-04/4.5e+00/ 16/875) | signal transducer activity (1.1e-02/4.0e+00/ 13/798) | B cell receptor signaling pathway (1.6e-02/3.1e-01/ 4/47) | |||
| 430 | 3.2/1.8 | 26 | 6 | ||||||
| 431 | 3.2/1.8 | 74 | 8 | immune response (2.8e-02/2.3e+00/ 9/ 295) | plasma membrane (7.8e-03/1.1e+01/ 23/1443) | signal transducer activity (2.2e-03/6.5e+00/ 19/798) | |||
| 432 | 3.2/1.6 | 18 | 5 | extracellular space (2.4e-02/4.7e-01/ 4/246) | cytokine activity (3.4e-02/1.5e-01/ 3/73) | ||||
| 433 | 3.2/1.6 | 27 | 14 | ||||||
| 434 | 3.2/1.6 | 36 | 11 | intermediate filament bundle assembly (5.3e-03/1.2e-02/ 2/ 3) | extracellular space (1.4e-03/9.6e-01/ 7/246) | calcium ion binding (1.3e-02/1.6e+00/ 8/402) | |||
| 435 | 3.2/1.6 | 33 | 6 | osteoblast development (1.1e-02/1.8e-02/ 2/ 5) | |||||
| 436 | 3.2/1.6 | 28 | 6 | ||||||
| 437 | 3.2/1.6 | 12 | 7 | insulin receptor complex (2.6e-02/1.0e-03/ 1/1) | |||||
| 438 | 3.2/1.6 | 30 | 9 | intermediate filament bundle assembly (3.6e-03/9.9e-03/ 2/ 3) | neurofilament (1.3e-03/9.8e-03/ 2/3) | ||||
| 439 | 3.2/1.6 | 33 | 10 | peptide hormone processing (2.7e-02/3.1e-02/ 2/ 9) | |||||
| 440 | 3.2/1.6 | 17 | 12 | ||||||
| 441 | 3.2/1.6 | 40 | 12 | intermediate filament bundle assembly (5.9e-03/1.3e-02/ 2/ 3) | extracellular space (5.1e-04/1.1e+00/ 8/246) | calcium ion binding (1.0e-03/1.7e+00/ 10/402) | Neuroactive ligand-receptor interaction (4.2e-03/4.3e-01/ 5/83) | ||
| 442 | 3.2/1.6 | 31 | 9 | eye photoreceptor cell differentiation (1.2e-02/1.9e-02/ 2/ 5) | |||||
| 443 | 3.2/1.6 | 14 | 13 | ||||||
| 444 | 3.2/1.6 | 16 | 12 | neurological system process (1.0e-02/5.4e-01/ 5/ 328) | platelet alpha granule membrane (1.4e-03/9.5e-03/ 2/5) | ||||
| 445 | 3.2/1.6 | 42 | 13 | integral to Golgi membrane (4.4e-03/1.0e-01/ 3/25) | |||||
| 446 | 3.2/1.6 | 16 | 9 | extrachromosomal circular DNA (3.8e-02/1.6e-03/ 1/1) | |||||
| 447 | 3.2/1.6 | 13 | 8 | insulin receptor complex (2.8e-02/1.1e-03/ 1/1) | |||||
| 448 | 3.2/1.6 | 37 | 11 | basal plasma membrane (1.8e-02/3.9e-02/ 2/11) | |||||
| 449 | 3.2/1.6 | 45 | 13 | immune response (7.3e-03/1.5e+00/ 8/ 295) | integral to Golgi membrane (6.5e-03/1.2e-01/ 3/25) | MAP-kinase scaffold activity (3.8e-03/9.6e-03/ 2/2) | |||
| 450 | 3.2/1.6 | 75 | 10 | cell cycle phase (3.0e-26/2.6e+00/ 33/ 287) | chromosomal part (6.1e-19/1.7e+00/ 24/198) | microtubule motor activity (9.4e-06/2.9e-01/ 7/37) | Cell cycle (2.1e-06/9.3e-01/10/98) | ||
| 451 | 3.2/1.6 | 18 | 11 | plasma membrane (3.1e-02/3.1e+00/ 9/1443) | alkali metal ion binding (4.3e-02/1.7e-01/ 3/77) | ||||
| 452 | 3.2/1.6 | 27 | 16 | endocytic vesicle (4.9e-02/7.2e-02/ 2/21) | |||||
| 453 | 3.2/1.6 | 24 | 7 | sterol metabolic process (2.4e-07/2.0e-01/ 7/ 65) | endoplasmic reticulum membrane (1.3e-03/9.7e-01/ 7/336) | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (4.1e-02/1.7e-01/ 3/58) | Biosynthesis of steroids (8.5e-06/1.1e-01/ 5/23) | ||
| 454 | 3.2/1.6 | 17 | 8 | ||||||
| 455 | 3.2/1.4 | 95 | 13 | cell cycle phase (9.9e-48/3.5e+00/ 52/ 287) | chromosome (2.2e-27/2.9e+00/ 36/248) | ATP binding (1.6e-06/8.5e+00/ 29/809) | DNA replication (1.4e-10/3.5e-01/10/33) | ||
| 456 | 3.2/1.4 | 18 | 12 | ||||||
| 457 | 3.2/1.4 | 93 | 14 | cell cycle phase (1.3e-47/3.3e+00/ 51/ 287) | chromosome (3.9e-28/2.8e+00/ 36/248) | ATP binding (2.7e-05/8.2e+00/ 26/809) | Cell cycle (2.0e-10/1.1e+00/14/98) | ||
| 458 | 3.2/1.4 | 21 | 14 | neurotransmitter transport (7.2e-03/8.4e-02/ 3/ 36) | myosin complex (3.7e-02/6.0e-02/ 2/25) | ||||
| 459 | 3.2/1.4 | 31 | 23 | ||||||
| 460 | 3.2/1.4 | 43 | 15 | regulation of multicellular organismal process (2.6e-02/1.4e+00/ 7/ 320) | |||||
| 461 | 3.2/1.4 | 38 | 15 | sensory perception (8.1e-03/7.5e-01/ 6/ 177) | basal plasma membrane (2.2e-02/4.4e-02/ 2/11) | MAP-kinase scaffold activity (2.9e-03/8.0e-03/ 2/2) | |||
| 462 | 3.2/1.4 | 33 | 19 | ||||||
| 463 | 3.2/1.4 | 29 | 17 | ||||||
| 464 | 3.2/1.4 | 40 | 6 | xenobiotic metabolic process (2.7e-03/5.7e-02/ 3/ 13) | glucuronosyltransferase activity (2.6e-03/5.0e-02/ 3/12) | Pentose and glucuronate interconversions (4.2e-03/7.2e-02/ 3/13) | |||
| 465 | 3.2/1.4 | 22 | 16 | ||||||
| 466 | 3.2/1.4 | 11 | 17 | platelet alpha granule (8.8e-03/2.6e-02/ 2/23) | sulfotransferase activity (2.3e-02/2.4e-02/ 2/23) | ||||
| 467 | 3.2/1.4 | 22 | 18 | Golgi apparatus (2.2e-02/1.2e+00/ 6/534) | |||||
| 468 | 3.2/1.4 | 13 | 17 | ||||||
| 469 | 3.2/1.4 | 13 | 18 | peptide transport (2.1e-02/2.6e-02/ 2/ 24) | D-Arginine and D-ornithine metabolism (4.3e-02/7.3e-04/ 1/1) | ||||
| 470 | 3.2/1.4 | 33 | 22 | ||||||
| 471 | 3.2/1.4 | 35 | 20 | artery morphogenesis (1.8e-02/2.4e-02/ 2/ 6) | MAPK signaling pathway (1.5e-02/9.6e-01/ 6/186) | ||||
| 472 | 3.2/1.4 | 26 | 13 | aromatic compound biosynthetic process (3.0e-02/3.3e-02/ 2/ 11) | extracellular region (2.8e-02/1.8e+00/ 7/700) | ||||
| 473 | 3.2/1.4 | 21 | 14 | system process (2.7e-02/1.1e+00/ 6/ 456) | extracellular region part (4.1e-02/9.3e-01/ 5/387) | ||||
| 474 | 3.2/1.2 | 32 | 24 | ||||||
| 475 | 3.2/1.2 | 29 | 19 | translational elongation (1.6e-07/3.2e-01/ 8/ 93) | cytosolic ribosome (2.4e-07/2.4e-01/ 7/71) | structural constituent of ribosome (4.7e-04/3.8e-01/ 6/123) | Ribosome (4.0e-04/2.6e-01/ 5/70) | ||
| 476 | 3.2/1.2 | 30 | 22 | extracellular region (2.0e-02/2.1e+00/ 8/700) | |||||
| 477 | 3.2/1.2 | 127 | 22 | cell cycle phase (6.0e-59/4.6e+00/ 66/ 287) | chromosome (3.1e-31/3.7e+00/ 43/248) | microtubule motor activity (1.4e-08/5.3e-01/ 11/37) | Cell cycle (1.2e-15/1.5e+00/20/98) | ||
| 478 | 3.2/1.2 | 20 | 18 | inward rectifier potassium channel activity (9.9e-03/1.4e-02/ 2/6) | |||||
| 479 | 3.2/1.2 | 42 | 17 | immune response (7.3e-03/1.5e+00/ 8/ 295) | |||||
| 480 | 3.2/1.2 | 73 | 14 | organ development (1.6e-06/7.0e+00/ 25/ 743) | extracellular space (1.7e-08/2.1e+00/ 16/246) | receptor binding (2.4e-07/3.5e+00/ 20/408) | Cytokine-cytokine receptor interaction (6.3e-05/1.7e+00/11/122) | ||
| 481 | 3.2/1.2 | 16 | 24 | eye photoreceptor cell differentiation (4.4e-03/1.0e-02/ 2/ 5) | |||||
| 482 | 3.2/1.2 | 10 | 24 | ||||||
| 483 | 3.2/1.2 | 32 | 29 | ||||||
| 484 | 3.2/1.2 | 20 | 24 | eye photoreceptor cell differentiation (6.0e-03/1.2e-02/ 2/ 5) | plasma membrane (3.0e-02/3.6e+00/ 10/1443) | ||||
| 485 | 3.2/1.2 | 17 | 23 | ||||||
| 486 | 3.2/1.2 | 11 | 21 | collagen type XI (4.9e-02/2.3e-03/ 1/2) | |||||
| 487 | 3.2/1.2 | 19 | 18 | ||||||
| 488 | 3.2/1.2 | 22 | 17 | ||||||
| 489 | 3.2/1.2 | 22 | 23 | brush border (1.1e-02/3.0e-02/ 2/13) | |||||
| 490 | 3.2/1.2 | 18 | 20 | ||||||
| 491 | 3.2/1.2 | 12 | 23 | ||||||
| 492 | 3.2/1.2 | 16 | 17 | ||||||
| 493 | 3.2/1.2 | 20 | 22 | plasma membrane (3.0e-02/3.6e+00/ 10/1443) | |||||
| 494 | 3.2/1.2 | 20 | 21 | ||||||
| 495 | 3.2/1.2 | 16 | 24 | ||||||
| 496 | 3.2/1 | 111 | 35 | M phase (2.5e-56/3.2e+00/ 57/ 231) | chromosome (2.2e-28/3.1e+00/ 38/248) | microtubule motor activity (2.8e-10/4.5e-01/ 12/37) | Cell cycle (3.2e-10/1.2e+00/14/98) | ||
| 497 | 3.2/1 | 31 | 33 | ||||||
| 498 | 3.2/1 | 78 | 23 | response to wounding (1.7e-10/2.2e+00/ 19/ 231) | extracellular space (7.6e-10/2.3e+00/ 18/246) | cytokine activity (1.2e-07/6.5e-01/ 11/73) | Cytokine-cytokine receptor interaction (6.6e-07/1.7e+00/13/122) | ||
| 499 | 3.2/1 | 13 | 33 | ||||||
| 500 | 3.2/1 | 41 | 20 | chondroitin sulfate proteoglycan biosynthetic process (3.2e-02/3.5e-02/ 2/ 8) | extracellular region (7.5e-03/3.3e+00/ 11/700) | ||||
| 501 | 3.2/1 | 18 | 27 | inward rectifier potassium channel activity (6.6e-03/1.1e-02/ 2/6) | |||||
| 502 | 3.2/1 | 25 | 39 | disaccharide metabolic process (3.1e-03/9.0e-03/ 2/ 3) | |||||
| 503 | 3.2/1 | 73 | 28 | inflammatory response (1.1e-08/1.3e+00/ 14/ 153) | extracellular region (1.7e-12/6.0e+00/ 30/700) | cytokine activity (3.1e-08/5.6e-01/ 11/73) | Cytokine-cytokine receptor interaction (1.3e-04/1.4e+00/10/122) | ||
| 504 | 3.2/1 | 31 | 36 | cell morphogenesis (4.6e-02/1.2e+00/ 6/ 317) | transcription regulator activity (4.7e-02/2.6e+00/ 9/816) | ||||
| 505 | 3.2/1 | 36 | 37 | ||||||
| 506 | 3.2/1 | 13 | 30 | ||||||
| 507 | 3/2 | 47 | 4 | cell morphogenesis (2.9e-02/1.4e+00/ 7/ 317) | |||||
| 508 | 3/2 | 66 | 5 | cholesterol catabolic process (1.2e-02/2.1e-02/ 2/ 3) | intrinsic to membrane (1.4e-03/1.5e+01/ 30/2051) | transmembrane receptor activity (3.2e-03/2.4e+00/ 11/334) | |||
| 509 | 3/2 | 61 | 5 | xenobiotic metabolic process (6.6e-03/8.2e-02/ 3/ 13) | extracellular matrix part (1.8e-02/4.0e-01/ 4/64) | glucuronosyltransferase activity (7.5e-03/7.8e-02/ 3/12) | Pentose and glucuronate interconversions (6.8e-03/8.6e-02/ 3/13) | ||
| 510 | 3/2 | 59 | 8 | intermediate filament bundle assembly (1.1e-02/2.0e-02/ 2/ 3) | neurofilament (4.2e-03/1.9e-02/ 2/3) | ||||
| 511 | 3/2 | 72 | 4 | multicellular organismal development (3.6e-03/9.9e+00/ 23/1284) | extracellular region (1.0e-04/5.7e+00/ 19/700) | sequence-specific DNA binding (1.3e-02/1.9e+00/ 9/261) | |||
| 512 | 3/2 | 44 | 5 | response to stress (3.3e-03/4.2e+00/ 14/ 858) | |||||
| 513 | 3/2 | 45 | 5 | osteoblast development (1.7e-02/2.4e-02/ 2/ 5) | |||||
| 514 | 3/2 | 65 | 3 | positive regulation of tumor necrosis factor biosynthetic process (2.2e-02/2.9e-02/ 2/ 4) | plasma membrane (3.2e-03/9.8e+00/ 22/1443) | sugar binding (1.1e-02/4.5e-01/ 5/65) | |||
| 515 | 3/2 | 30 | 6 | ||||||
| 516 | 3/2 | 26 | 3 | ||||||
| 517 | 3/2 | 48 | 7 | cellular aldehyde metabolic process (5.3e-03/7.5e-02/ 3/ 14) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (6.2e-05/1.5e-02/ 3/3) | Metabolism of xenobiotics by cytochrome P450 (1.7e-02/3.1e-01/ 4/37) | |||
| 518 | 3/2 | 51 | 3 | ||||||
| 519 | 3/2 | 41 | 4 | negative regulation of gliogenesis (6.8e-03/1.4e-02/ 2/ 3) | extracellular region part (1.0e-02/1.8e+00/ 8/387) | ||||
| 520 | 3/2 | 126 | 3 | response to reactive oxygen species (4.9e-03/4.1e-01/ 5/ 28) | extracellular region (3.2e-04/1.0e+01/ 26/700) | transmembrane receptor activity (2.3e-02/4.7e+00/ 14/334) | |||
| 521 | 3/2 | 51 | 4 | sterol metabolic process (2.8e-09/4.2e-01/ 10/ 65) | endoplasmic reticulum membrane (7.6e-04/1.9e+00/ 10/336) | Biosynthesis of steroids (2.7e-09/2.1e-01/ 8/23) | |||
| 522 | 3/2 | 118 | 6 | regulation of exocytosis (1.7e-02/1.2e-01/ 3/ 10) | plasma membrane (3.7e-04/1.8e+01/ 36/1443) | signal transducer activity (6.9e-03/1.0e+01/ 24/798) | 19 (4.5e-04/ 7.2393/23/580) | ||
| 523 | 3/2 | 37 | 5 | ||||||
| 524 | 3/2 | 32 | 6 | cell adhesion (7.4e-04/1.4e+00/ 9/ 376) | extracellular region (9.3e-05/2.5e+00/ 12/700) | receptor binding (2.7e-02/1.4e+00/ 7/408) | |||
| 525 | 3/2 | 47 | 4 | cell death (4.7e-03/3.2e+00/ 12/ 637) | miR-15/16/195/424/497 (0.02123/ 2.6504/12/633) | ||||
| 526 | 3/2 | 66 | 6 | response to wounding (1.2e-03/1.8e+00/ 10/ 231) | extracellular region part (4.8e-10/3.0e+00/ 20/387) | cytokine activity (5.0e-06/5.8e-01/ 9/73) | Cytokine-cytokine receptor interaction (1.2e-02/1.2e+00/ 7/122) | ||
| 527 | 3/2 | 40 | 6 | secretory granule (4.7e-02/2.6e-01/ 3/57) | |||||
| 528 | 3/2 | 54 | 4 | vascular endothelial growth factor receptor activity (2.7e-02/2.8e-02/ 2/5) | |||||
| 529 | 3/2 | 86 | 4 | multicellular organismal process (6.5e-03/1.5e+01/ 30/1648) | plasma membrane part (3.6e-03/8.2e+00/ 20/875) | ||||
| 530 | 3/2 | 37 | 6 | steroid biosynthetic process (1.0e-02/2.5e-01/ 4/ 56) | extracellular region (1.1e-02/2.9e+00/ 10/700) | Biosynthesis of steroids (2.6e-03/1.8e-01/ 4/23) | |||
| 531 | 3/2 | 81 | 5 | regulation of tumor necrosis factor production (4.8e-03/7.4e-02/ 3/ 9) | extracellular region (2.8e-02/6.3e+00/ 15/700) | ||||
| 532 | 3/1.8 | 29 | 9 | ||||||
| 533 | 3/1.8 | 88 | 7 | extracellular region (4.5e-03/6.4e+00/ 17/700) | |||||
| 534 | 3/1.8 | 90 | 7 | cell cycle phase (3.0e-20/3.2e+00/ 31/ 287) | chromosomal part (3.5e-19/2.1e+00/ 26/198) | microtubule motor activity (2.9e-05/3.5e-01/ 7/37) | DNA replication (1.3e-05/3.9e-01/ 7/33) | ||
| 535 | 3/1.8 | 107 | 6 | response to stimulus (5.1e-03/1.5e+01/ 30/1350) | plasma membrane (3.8e-04/1.6e+01/ 33/1443) | transmembrane receptor activity (1.2e-02/3.8e+00/ 13/334) | |||
| 536 | 3/1.8 | 39 | 5 | sterol biosynthetic process (2.2e-03/1.6e-01/ 4/ 34) | extracellular region part (2.7e-02/1.7e+00/ 7/387) | Biosynthesis of steroids (2.2e-03/1.7e-01/ 4/23) | |||
| 537 | 3/1.8 | 53 | 10 | tissue development (1.6e-02/8.7e-01/ 6/ 154) | extracellular space (4.4e-04/1.4e+00/ 9/246) | receptor binding (9.7e-03/2.3e+00/ 10/408) | |||
| 538 | 3/1.8 | 151 | 5 | ion transport (3.3e-02/4.5e+00/ 13/ 297) | plasma membrane (8.8e-03/2.2e+01/ 38/1443) | MAP-kinase scaffold activity (2.4e-02/3.2e-02/ 2/2) | |||
| 539 | 3/1.8 | 45 | 5 | osteoblast development (1.5e-02/2.2e-02/ 2/ 5) | |||||
| 540 | 3/1.8 | 35 | 7 | ||||||
| 541 | 3/1.8 | 46 | 10 | neurotransmitter transport (3.3e-02/1.6e-01/ 3/ 36) | plasma membrane part (9.4e-04/4.6e+00/ 15/875) | B cell receptor signaling pathway (1.1e-02/2.8e-01/ 4/47) | |||
| 542 | 3/1.8 | 114 | 8 | cell cycle phase (7.6e-28/3.9e+00/ 40/ 287) | chromosomal part (2.3e-23/2.7e+00/ 32/198) | microtubule motor activity (8.8e-06/4.5e-01/ 8/37) | Cell cycle (4.0e-08/1.6e+00/14/98) | ||
| 543 | 3/1.8 | 44 | 5 | sterol metabolic process (1.8e-11/3.7e-01/ 11/ 65) | endoplasmic reticulum membrane (1.4e-03/1.7e+00/ 9/336) | Biosynthesis of steroids (8.8e-10/1.9e-01/ 8/23) | |||
| 544 | 3/1.8 | 29 | 6 | gene silencing by RNA (3.7e-02/3.8e-02/ 2/ 14) | |||||
| 545 | 3/1.8 | 58 | 7 | activation of adenylate cyclase activity (6.8e-03/8.3e-02/ 3/ 14) | extracellular space (8.3e-04/1.6e+00/ 9/246) | ||||
| 546 | 3/1.8 | 44 | 9 | multicellular organismal process (3.7e-02/7.9e+00/ 17/1648) | extracellular region part (3.6e-02/1.8e+00/ 7/387) | ||||
| 547 | 3/1.6 | 102 | 9 | cell cycle phase (5.6e-51/3.6e+00/ 55/ 287) | chromosome (2.4e-31/3.0e+00/ 40/248) | microtubule motor activity (4.2e-07/4.1e-01/ 9/37) | DNA replication (8.1e-09/3.6e-01/ 9/33) | ||
| 548 | 3/1.6 | 35 | 13 | neurotransmitter transport (1.5e-03/1.4e-01/ 4/ 36) | myosin complex (4.4e-03/1.0e-01/ 3/25) | alkali metal ion binding (2.3e-03/3.1e-01/ 5/77) | |||
| 549 | 3/1.6 | 51 | 13 | neurological system process (4.8e-03/1.8e+00/ 9/ 328) | extracellular region (1.4e-02/3.5e+00/ 11/700) | neurotransmitter receptor activity (2.2e-02/1.2e-01/ 3/24) | |||
| 550 | 3/1.6 | 66 | 12 | ||||||
| 551 | 3/1.6 | 37 | 8 | nuclear division (6.7e-11/7.6e-01/ 13/ 174) | microtubule cytoskeleton (4.8e-05/1.4e+00/ 10/322) | ||||
| 552 | 3/1.6 | 62 | 6 | sterol metabolic process (4.8e-07/5.2e-01/ 9/ 65) | chromosomal part (9.2e-05/1.5e+00/ 10/198) | DNA primase activity (1.5e-02/2.0e-02/ 2/3) | Biosynthesis of steroids (6.1e-07/2.5e-01/ 7/23) | ||
| 553 | 3/1.6 | 54 | 11 | brush border (2.1e-03/7.7e-02/ 3/13) | transmembrane receptor activity (1.3e-02/1.9e+00/ 9/334) | ||||
| 554 | 3/1.6 | 26 | 11 | ||||||
| 555 | 3/1.6 | 36 | 12 | osteoblast development (1.2e-02/1.9e-02/ 2/ 5) | |||||
| 556 | 3/1.6 | 30 | 9 | hormone biosynthetic process (4.0e-02/4.0e-02/ 2/ 14) | |||||
| 557 | 3/1.6 | 43 | 11 | sensory perception (1.2e-02/8.2e-01/ 6/ 177) | brush border (3.6e-02/5.9e-02/ 2/13) | ||||
| 558 | 3/1.6 | 70 | 8 | cell cycle phase (2.4e-35/2.4e+00/ 38/ 287) | chromosome (1.3e-18/2.1e+00/ 25/248) | microtubule motor activity (8.6e-06/2.8e-01/ 7/37) | Cell cycle (1.4e-05/8.6e-01/ 9/98) | ||
| 559 | 3/1.6 | 31 | 12 | ||||||
| 560 | 3/1.6 | 47 | 14 | extracellular region part (3.0e-03/1.9e+00/ 9/387) | |||||
| 561 | 3/1.6 | 63 | 13 | immune response (1.1e-02/2.0e+00/ 9/ 295) | extracellular region (2.7e-06/4.6e+00/ 19/700) | MAP-kinase scaffold activity (6.1e-03/1.3e-02/ 2/2) | |||
| 562 | 3/1.6 | 43 | 11 | anion transport (1.9e-02/3.2e-01/ 4/ 59) | bile acid transmembrane transporter activity (9.3e-03/1.5e-02/ 2/3) | Olfactory transduction (2.2e-02/1.4e-01/ 3/27) | |||
| 563 | 3/1.6 | 25 | 10 | multicellular organismal process (1.4e-02/4.3e+00/ 12/1648) | fibrillar collagen (9.9e-03/2.8e-02/ 2/10) | platelet-derived growth factor binding (5.8e-03/1.0e-02/ 2/4) | |||
| 564 | 3/1.6 | 37 | 12 | system process (2.6e-02/1.9e+00/ 8/ 456) | brush border (3.0e-02/5.2e-02/ 2/13) | neuropeptide receptor activity (1.1e-02/1.6e-02/ 2/4) | |||
| 565 | 3/1.4 | 37 | 16 | ||||||
| 566 | 3/1.4 | 133 | 13 | cell cycle phase (4.7e-59/4.7e+00/ 67/ 287) | chromosome (2.4e-31/3.8e+00/ 44/248) | ATP binding (1.2e-08/1.2e+01/ 40/809) | Cell cycle (5.1e-17/1.7e+00/22/98) | ||
| 567 | 3/1.4 | 82 | 9 | response to wounding (2.0e-08/2.3e+00/ 17/ 231) | extracellular region part (4.9e-09/3.7e+00/ 21/387) | cytokine activity (1.0e-03/6.7e-01/ 7/73) | |||
| 568 | 3/1.4 | 30 | 14 | eye photoreceptor cell differentiation (1.1e-02/1.8e-02/ 2/ 5) | |||||
| 569 | 3/1.4 | 61 | 18 | activation of JUN kinase activity (8.8e-03/9.2e-02/ 3/ 14) | |||||
| 570 | 3/1.4 | 64 | 16 | endomembrane system (5.4e-03/4.8e+00/ 14/756) | |||||
| 571 | 3/1.4 | 48 | 21 | activation of JUN kinase activity (4.4e-03/6.9e-02/ 3/ 14) | |||||
| 572 | 3/1.4 | 25 | 18 | axoneme (3.1e-03/1.5e-02/ 2/5) | |||||
| 573 | 3/1.4 | 52 | 17 | endomembrane system (9.3e-03/3.9e+00/ 12/756) | |||||
| 574 | 3/1.4 | 32 | 17 | endoplasmic reticulum (1.2e-02/1.9e+00/ 8/562) | |||||
| 575 | 3/1.4 | 21 | 17 | sensory perception (3.7e-02/4.1e-01/ 4/ 177) | |||||
| 576 | 3/1.4 | 44 | 15 | osteoclast differentiation (5.0e-02/4.8e-02/ 2/ 11) | mitochondrial outer membrane (4.6e-02/2.6e-01/ 3/60) | long-chain-fatty-acid-CoA ligase activity (2.1e-02/2.3e-02/ 2/5) | PPAR signaling pathway (4.8e-02/2.0e-01/ 3/39) | ||
| 577 | 3/1.4 | 55 | 21 | ||||||
| 578 | 3/1.4 | 33 | 14 | extracellular region part (6.0e-03/1.3e+00/ 7/387) | scavenger receptor activity (4.6e-02/3.9e-02/ 2/12) | ||||
| 579 | 3/1.2 | 31 | 16 | ||||||
| 580 | 3/1.2 | 16 | 22 | membrane fraction (3.7e-02/5.5e-01/ 4/362) | Retinol metabolism (4.0e-02/4.2e-02/ 2/23) | ||||
| 581 | 3/1.2 | 31 | 17 | ||||||
| 582 | 3/1.2 | 40 | 24 | sensory perception (9.4e-03/7.8e-01/ 6/ 177) | brush border (3.1e-02/5.4e-02/ 2/13) | ||||
| 583 | 3/1.2 | 27 | 21 | osteoclast differentiation (2.4e-02/2.9e-02/ 2/ 11) | |||||
| 584 | 3/1.2 | 58 | 27 | 19 (6.6e-06/ 3.5583/18/580) | |||||
| 585 | 3/1.2 | 17 | 26 | ||||||
| 586 | 3/1.2 | 18 | 22 | membrane fraction (6.0e-03/5.9e-01/ 5/362) | |||||
| 587 | 3/1.2 | 31 | 23 | neurotransmitter transport (1.8e-02/1.2e-01/ 3/ 36) | |||||
| 588 | 3/1.2 | 37 | 22 | neurotransmitter transport (2.9e-02/1.5e-01/ 3/ 36) | alkali metal ion binding (2.5e-02/3.2e-01/ 4/77) | ||||
| 589 | 3/1.2 | 31 | 26 | artery morphogenesis (1.2e-02/1.9e-02/ 2/ 6) | dendrite (3.7e-03/9.5e-02/ 3/30) | Pancreatic cancer (4.1e-02/1.9e-01/ 3/66) | |||
| 590 | 3/1.2 | 28 | 22 | positive regulation of cell size (3.7e-02/3.8e-02/ 2/ 14) | |||||
| 591 | 3/1.2 | 26 | 22 | sensory perception (4.4e-03/4.1e-01/ 5/ 177) | brush border (1.1e-02/3.0e-02/ 2/13) | ||||
| 592 | 3/1 | 41 | 35 | ||||||
| 593 | 3/1 | 17 | 30 | ||||||
| 594 | 3/1 | 27 | 32 | ||||||
| 595 | 3/1 | 151 | 37 | cell cycle phase (2.5e-60/5.3e+00/ 71/ 287) | chromosome (3.7e-32/4.3e+00/ 47/248) | microtubule motor activity (5.5e-09/6.3e-01/ 12/37) | Cell cycle (3.7e-16/1.8e+00/22/98) | ||
| 596 | 3/1 | 30 | 31 | eye photoreceptor cell differentiation (1.1e-02/1.8e-02/ 2/ 5) | plasma membrane (4.7e-02/5.1e+00/ 12/1443) | ||||
| 597 | 3/1 | 32 | 30 | neurotransmitter transport (2.0e-02/1.3e-01/ 3/ 36) | plasma membrane (2.5e-02/4.7e+00/ 12/1443) | alkali metal ion binding (1.2e-02/2.5e-01/ 4/77) | |||
| 598 | 3/1 | 15 | 30 | membrane fraction (2.0e-02/4.6e-01/ 4/362) | Retinol metabolism (2.7e-02/3.4e-02/ 2/23) | ||||
| 599 | 3/1 | 17 | 29 | eye photoreceptor cell differentiation (4.4e-03/1.0e-02/ 2/ 5) | cell projection part (4.9e-02/7.2e-02/ 2/38) | ||||
| 600 | 3/1 | 48 | 31 | ||||||
| 601 | 3/1 | 22 | 29 | ||||||
| 602 | 3/1 | 49 | 34 | 19 (5.6e-04/ 3.0061/14/580) | |||||
| 603 | 3/1 | 51 | 36 | peptide hormone processing (4.6e-02/4.6e-02/ 2/ 9) | |||||
| 604 | 2.8/2 | 63 | 6 | ||||||
| 605 | 2.8/2 | 126 | 4 | defense response (6.2e-03/3.1e+00/ 12/ 263) | |||||
| 606 | 2.8/2 | 67 | 8 | multicellular organismal process (5.2e-05/1.2e+01/ 30/1648) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (1.4e-04/2.1e-02/ 3/3) | Metabolism of xenobiotics by cytochrome P450 (5.0e-03/4.2e-01/ 5/37) | |||
| 607 | 2.8/2 | 103 | 6 | retinoic acid metabolic process (2.4e-02/3.2e-02/ 2/ 3) | extracellular region (7.1e-03/7.9e+00/ 19/700) | TAP1 binding (1.4e-02/2.2e-02/ 2/2) | |||
| 608 | 2.8/2 | 74 | 6 | ribosomal large subunit biogenesis (3.8e-02/4.0e-02/ 2/ 6) | |||||
| 609 | 2.8/2 | 70 | 8 | Golgi membrane (1.6e-02/1.9e+00/ 8/243) | |||||
| 610 | 2.8/2 | 92 | 5 | cell cycle phase (1.4e-05/2.8e+00/ 15/ 287) | chromosome (3.8e-04/2.6e+00/ 12/248) | ||||
| 611 | 2.8/2 | 66 | 5 | ||||||
| 612 | 2.8/2 | 196 | 9 | post-translational protein modification (4.5e-03/1.6e+01/ 33/ 709) | cytoplasmic vesicle (1.8e-03/7.4e+00/ 20/323) | protein tyrosine phosphatase activity (3.5e-02/1.4e+00/ 7/62) | miR-320/320abcd (0.00153/11.1811/32/377) | ||
| 613 | 2.8/2 | 98 | 6 | multicellular organismal process (3.8e-04/1.7e+01/ 36/1648) | extracellular region (3.4e-05/7.9e+00/ 24/700) | organic acid transmembrane transporter activity (4.4e-02/3.9e-01/ 4/40) | |||
| 614 | 2.8/2 | 96 | 5 | sterol metabolic process (6.6e-12/7.6e-01/ 14/ 65) | endoplasmic reticulum membrane (2.5e-03/3.7e+00/ 13/336) | DNA primase activity (2.9e-02/3.2e-02/ 2/3) | Biosynthesis of steroids (5.6e-09/3.5e-01/ 9/23) | ||
| 615 | 2.8/2 | 126 | 4 | DNA replication (4.4e-09/2.7e+00/ 19/ 181) | chromosomal part (1.5e-11/2.9e+00/ 22/198) | DNA binding (1.4e-02/1.7e+01/ 33/1210) | DNA replication (1.5e-04/5.6e-01/ 7/33) | ||
| 616 | 2.8/2 | 114 | 6 | multicellular organismal process (1.8e-05/2.2e+01/ 46/1648) | neurofilament cytoskeleton (4.1e-04/5.2e-02/ 3/4) | calcium ion binding (6.5e-03/5.1e+00/ 16/402) | |||
| 617 | 2.8/2 | 99 | 4 | regulation of response to stimulus (1.6e-02/1.2e+00/ 7/ 123) | |||||
| 618 | 2.8/2 | 70 | 4 | cell morphogenesis (3.6e-02/2.0e+00/ 8/ 317) | |||||
| 619 | 2.8/2 | 96 | 5 | genetic imprinting (2.2e-02/3.0e-02/ 2/ 3) | extracellular region (9.3e-06/7.4e+00/ 24/700) | serine-type endopeptidase activity (3.1e-03/5.5e-01/ 6/55) | |||
| 620 | 2.8/2 | 113 | 4 | immune response (7.7e-03/3.2e+00/ 12/ 295) | extracellular region (3.1e-03/7.9e+00/ 20/700) | ||||
| 621 | 2.8/2 | 115 | 3 | regulation of macromolecule biosynthetic process (2.0e-03/1.8e+01/ 35/1463) | axoneme (3.6e-02/6.3e-02/ 2/5) | transcription factor activity (5.9e-03/6.2e+00/ 18/483) | |||
| 622 | 2.8/2 | 102 | 4 | multicellular organismal development (3.5e-03/1.4e+01/ 30/1284) | extracellular region (2.4e-04/8.3e+00/ 23/700) | transcription factor activity (1.4e-02/5.1e+00/ 15/483) | |||
| 623 | 2.8/2 | 50 | 3 | pyridine nucleotide biosynthetic process (4.1e-02/4.2e-02/ 2/ 8) | neurofilament cytoskeleton (6.4e-03/2.3e-02/ 2/4) | ||||
| 624 | 2.8/2 | 66 | 6 | sterol biosynthetic process (5.2e-05/2.7e-01/ 6/ 34) | extracellular region (4.5e-03/5.2e+00/ 15/700) | Biosynthesis of steroids (1.2e-06/2.8e-01/ 7/23) | |||
| 625 | 2.8/2 | 52 | 8 | system process (4.2e-03/2.6e+00/ 11/ 456) | platelet alpha granule membrane (1.0e-02/3.0e-02/ 2/5) | G-protein coupled receptor activity (1.6e-03/7.4e-01/ 7/137) | |||
| 626 | 2.8/2 | 126 | 3 | cell surface receptor linked signal transduction (2.7e-02/8.9e+00/ 20/ 698) | integral to plasma membrane (9.6e-03/7.3e+00/ 18/549) | transmembrane receptor activity (3.2e-02/4.4e+00/ 13/334) | |||
| 627 | 2.8/2 | 72 | 5 | platelet alpha granule membrane (1.7e-02/4.0e-02/ 2/5) | |||||
| 628 | 2.8/2 | 122 | 5 | cell cycle phase (4.3e-14/4.3e+00/ 29/ 287) | chromosomal part (7.8e-17/2.9e+00/ 27/198) | growth factor activity (7.0e-03/1.3e+00/ 8/94) | DNA replication (8.8e-08/6.5e-01/10/33) | ||
| 629 | 2.8/2 | 43 | 6 | sensory perception of chemical stimulus (1.4e-02/1.1e-01/ 3/ 24) | intrinsic to membrane (1.1e-02/9.8e+00/ 20/2051) | G-protein coupled receptor activity (4.1e-03/6.0e-01/ 6/137) | |||
| 630 | 2.8/1.8 | 100 | 6 | translational elongation (3.8e-03/9.2e-01/ 7/ 93) | cytosolic ribosome (3.7e-04/7.3e-01/ 7/71) | ||||
| 631 | 2.8/1.8 | 77 | 8 | cell cycle phase (1.4e-04/2.5e+00/ 13/ 287) | chromosomal part (1.7e-03/1.7e+00/ 9/198) | Biosynthesis of steroids (4.7e-02/1.9e-01/ 3/23) | |||
| 632 | 2.8/1.8 | 51 | 8 | intracellular mRNA localization (7.8e-03/1.6e-02/ 2/ 3) | |||||
| 633 | 2.8/1.8 | 55 | 10 | ||||||
| 634 | 2.8/1.8 | 82 | 9 | osteoclast differentiation (7.2e-03/8.6e-02/ 3/ 11) | intrinsic to membrane (2.1e-02/1.8e+01/ 30/2051) | transmembrane receptor activity (9.1e-03/2.7e+00/ 11/334) | Neuroactive ligand-receptor interaction (3.3e-02/7.0e-01/ 5/83) | ||
| 635 | 2.8/1.8 | 60 | 5 | cAMP-mediated signaling (3.2e-02/1.6e-01/ 3/ 25) | trans-Golgi network transport vesicle (3.6e-03/9.5e-02/ 3/15) | amine binding (1.4e-02/1.0e-01/ 3/15) | |||
| 636 | 2.8/1.8 | 103 | 6 | cell cycle phase (5.9e-33/3.5e+00/ 42/ 287) | chromosome (8.4e-19/3.0e+00/ 29/248) | microtubule motor activity (7.5e-05/4.2e-01/ 7/37) | Cell cycle (1.0e-05/1.4e+00/11/98) | ||
| 637 | 2.8/1.8 | 132 | 6 | cell cycle phase (6.5e-27/4.6e+00/ 42/ 287) | chromosomal part (4.3e-18/3.1e+00/ 29/198) | adenyl nucleotide binding (8.7e-07/1.3e+01/ 37/864) | Cell cycle (3.3e-09/1.9e+00/16/98) | ||
| 638 | 2.8/1.8 | 136 | 6 | fibrinolysis (1.1e-02/1.1e-01/ 3/ 8) | 19 (4.5e-04/ 8.3436/25/580) | ||||
| 639 | 2.8/1.8 | 61 | 7 | ||||||
| 640 | 2.8/1.8 | 102 | 7 | cell cycle phase (6.1e-38/3.6e+00/ 46/ 287) | chromosome (5.0e-22/3.0e+00/ 32/248) | microtubule motor activity (6.0e-06/4.2e-01/ 8/37) | DNA replication (1.6e-06/4.5e-01/ 8/33) | ||
| 641 | 2.8/1.8 | 66 | 6 | positive regulation of MAP kinase activity (1.3e-02/2.8e-01/ 4/ 47) | intrinsic to membrane (3.1e-02/1.4e+01/ 25/2051) | ||||
| 642 | 2.8/1.8 | 73 | 5 | intrinsic to membrane (1.7e-03/1.7e+01/ 32/2051) | 13 (5.2e-04/ 1.3358/10/173) | ||||
| 643 | 2.8/1.8 | 63 | 6 | ||||||
| 644 | 2.8/1.8 | 73 | 9 | ||||||
| 645 | 2.8/1.8 | 103 | 7 | regulation of protein kinase activity (8.1e-03/1.8e+00/ 9/ 170) | extracellular region (6.2e-05/8.2e+00/ 24/700) | serine-type endopeptidase activity (2.7e-02/6.0e-01/ 5/55) | |||
| 646 | 2.8/1.8 | 92 | 7 | immune response (3.6e-03/3.0e+00/ 12/ 295) | TAP complex (1.8e-02/4.2e-02/ 2/4) | cytokine binding (2.0e-03/5.1e-01/ 6/53) | 13 (4.0e-03/ 1.6835/10/173) | ||
| 647 | 2.8/1.8 | 109 | 5 | vein smooth muscle contraction (1.1e-02/2.3e-02/ 2/ 2) | growth factor activity (4.7e-02/1.1e+00/ 6/94) | ||||
| 648 | 2.8/1.8 | 52 | 8 | sensory perception (1.5e-04/1.1e+00/ 9/ 177) | intrinsic to membrane (1.7e-03/1.3e+01/ 26/2051) | transmembrane receptor activity (5.2e-04/1.9e+00/ 11/334) | |||
| 649 | 2.8/1.8 | 62 | 8 | extracellular region (2.6e-03/4.9e+00/ 15/700) | |||||
| 650 | 2.8/1.8 | 76 | 9 | system process (3.5e-03/3.5e+00/ 13/ 456) | intrinsic to membrane (2.5e-04/1.6e+01/ 32/2051) | G-protein coupled receptor activity (2.1e-04/1.0e+00/ 9/137) | Neuroactive ligand-receptor interaction (1.5e-02/8.8e-01/ 6/83) | ||
| 651 | 2.8/1.6 | 48 | 9 | PPAR signaling pathway (2.8e-02/1.6e-01/ 3/39) | |||||
| 652 | 2.8/1.6 | 144 | 9 | cell cycle phase (3.2e-57/5.2e+00/ 68/ 287) | chromosome (1.1e-29/4.2e+00/ 44/248) | microtubule motor activity (4.5e-08/6.0e-01/ 11/37) | Cell cycle (8.4e-14/1.9e+00/20/98) | ||
| 653 | 2.8/1.6 | 44 | 11 | embryonic pattern specification (1.2e-02/1.0e-01/ 3/ 23) | integral to plasma membrane (3.3e-02/2.8e+00/ 9/549) | ||||
| 654 | 2.8/1.6 | 47 | 9 | ||||||
| 655 | 2.8/1.6 | 91 | 10 | intermediate filament bundle assembly (2.1e-02/2.9e-02/ 2/ 3) | extracellular space (4.6e-03/2.4e+00/ 10/246) | ||||
| 656 | 2.8/1.6 | 172 | 11 | cell cycle phase (1.2e-59/6.0e+00/ 74/ 287) | chromosome (6.2e-32/4.9e+00/ 49/248) | ATP binding (1.7e-09/1.6e+01/ 49/809) | Cell cycle (4.3e-18/2.3e+00/26/98) | ||
| 657 | 2.8/1.6 | 94 | 10 | plasma membrane (4.0e-02/1.5e+01/ 26/1443) | |||||
| 658 | 2.8/1.6 | 51 | 10 | multicellular organismal process (2.8e-05/8.1e+00/ 23/1648) | intrinsic to plasma membrane (2.0e-02/3.1e+00/ 10/554) | platelet-derived growth factor binding (1.7e-02/2.1e-02/ 2/4) | |||
| 659 | 2.8/1.6 | 28 | 9 | anatomical structure development (2.4e-02/3.7e+00/ 11/1233) | brush border (2.2e-02/4.4e-02/ 2/13) | transmembrane receptor activity (4.2e-03/9.5e-01/ 7/334) | |||
| 660 | 2.8/1.6 | 84 | 11 | xenobiotic metabolic process (5.2e-04/1.1e-01/ 4/ 13) | proteinaceous extracellular matrix (1.2e-02/1.4e+00/ 7/156) | glucuronosyltransferase activity (1.5e-02/1.1e-01/ 3/12) | Pentose and glucuronate interconversions (1.7e-02/1.2e-01/ 3/13) | ||
| 661 | 2.8/1.6 | 34 | 11 | multicellular organismal process (2.1e-02/5.6e+00/ 14/1648) | basal plasma membrane (1.9e-02/4.0e-02/ 2/11) | ||||
| 662 | 2.8/1.6 | 43 | 10 | positive regulation of isotype switching to IgG isotypes (3.0e-03/1.0e-02/ 2/ 2) | brush border (4.4e-02/6.7e-02/ 2/13) | ||||
| 663 | 2.8/1.6 | 84 | 13 | system process (1.0e-02/3.9e+00/ 13/ 456) | extracellular region part (1.5e-03/3.5e+00/ 13/387) | MAP-kinase scaffold activity (9.2e-03/1.7e-02/ 2/2) | |||
| 664 | 2.8/1.6 | 34 | 11 | eye photoreceptor cell differentiation (1.2e-02/1.9e-02/ 2/ 5) | plasma membrane (2.7e-02/6.0e+00/ 14/1443) | transmembrane receptor activity (3.6e-04/1.2e+00/ 9/334) | |||
| 665 | 2.8/1.6 | 64 | 14 | eye photoreceptor cell differentiation (2.7e-02/3.2e-02/ 2/ 5) | structural constituent of myelin sheath (2.2e-02/2.5e-02/ 2/4) | Retinol metabolism (3.0e-02/1.6e-01/ 3/23) | |||
| 666 | 2.8/1.6 | 64 | 13 | endomembrane system (1.2e-02/5.1e+00/ 14/756) | heat shock protein binding (1.5e-02/2.7e-01/ 4/39) | ||||
| 667 | 2.8/1.6 | 61 | 12 | homophilic cell adhesion (7.5e-03/2.3e-01/ 4/ 40) | |||||
| 668 | 2.8/1.6 | 44 | 11 | multicellular organismal process (4.2e-03/7.2e+00/ 18/1648) | fibrillar collagen (2.5e-02/4.8e-02/ 2/10) | platelet-derived growth factor binding (1.4e-02/1.8e-02/ 2/4) | |||
| 669 | 2.8/1.6 | 71 | 10 | sensory perception (7.1e-03/1.4e+00/ 8/ 177) | intrinsic to membrane (1.2e-02/1.6e+01/ 28/2051) | neurotransmitter receptor activity (4.9e-03/1.9e-01/ 4/24) | Neuroactive ligand-receptor interaction (5.0e-02/7.9e-01/ 5/83) | ||
| 670 | 2.8/1.4 | 78 | 14 | ||||||
| 671 | 2.8/1.4 | 38 | 19 | eye photoreceptor cell differentiation (1.4e-02/2.1e-02/ 2/ 5) | plasma membrane (7.7e-03/6.6e+00/ 16/1443) | G-protein coupled receptor activity (1.5e-02/5.1e-01/ 5/137) | |||
| 672 | 2.8/1.4 | 51 | 14 | protein import into nucleus (4.3e-02/4.2e-01/ 4/ 77) | Chronic myeloid leukemia (3.5e-02/4.1e-01/ 4/65) | ||||
| 673 | 2.8/1.4 | 52 | 18 | activation of JUN kinase activity (6.8e-03/8.3e-02/ 3/ 14) | |||||
| 674 | 2.8/1.4 | 71 | 16 | endomembrane system (1.7e-03/5.3e+00/ 16/756) | miR-590/590-3p (0.04930/ 5.9068/18/513) | ||||
| 675 | 2.8/1.4 | 43 | 18 | sensory perception (1.6e-02/8.7e-01/ 6/ 177) | Leukocyte transendothelial migration (1.1e-02/2.9e-01/ 4/71) | ||||
| 676 | 2.8/1.4 | 102 | 16 | endomembrane system (1.6e-02/7.8e+00/ 18/756) | |||||
| 677 | 2.8/1.4 | 95 | 13 | intermediate filament bundle assembly (2.1e-02/3.0e-02/ 2/ 3) | extracellular space (3.2e-04/2.5e+00/ 12/246) | purinergic nucleotide receptor activity (9.9e-03/9.0e-02/ 3/9) | Neuroactive ligand-receptor interaction (2.2e-03/8.8e-01/ 7/83) | ||
| 678 | 2.8/1.4 | 103 | 14 | positive regulation of specific transcription from RNA polymerase II promoter (3.6e-02/1.7e-01/ 3/ 15) | anchored to membrane (2.5e-02/4.5e-01/ 4/39) | very-low-density lipoprotein receptor activity (1.4e-02/2.2e-02/ 2/2) | |||
| 679 | 2.8/1.4 | 107 | 15 | circulatory system process (3.5e-02/1.0e+00/ 6/ 91) | plasma membrane (1.2e-02/1.6e+01/ 30/1443) | very-low-density lipoprotein receptor activity (1.5e-02/2.3e-02/ 2/2) | |||
| 680 | 2.8/1.4 | 61 | 15 | positive regulation of specific transcription from RNA polymerase II promoter (1.1e-02/1.0e-01/ 3/ 15) | |||||
| 681 | 2.8/1.2 | 60 | 16 | ||||||
| 682 | 2.8/1.2 | 71 | 23 | ||||||
| 683 | 2.8/1.2 | 65 | 24 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (3.5e-02/3.3e-02/ 2/6) | Retinol metabolism (1.8e-02/1.3e-01/ 3/23) | ||||
| 684 | 2.8/1.2 | 103 | 18 | epidermis development (7.2e-04/6.8e-01/ 7/ 64) | extracellular region (5.2e-04/8.1e+00/ 22/700) | purinergic nucleotide receptor activity (1.1e-02/9.5e-02/ 3/9) | Neuroactive ligand-receptor interaction (1.4e-03/1.1e+00/ 8/83) | ||
| 685 | 2.8/1.2 | 71 | 9 | xenobiotic metabolic process (9.7e-03/9.6e-02/ 3/ 13) | proteinaceous extracellular matrix (4.9e-03/1.2e+00/ 7/156) | glucuronosyltransferase activity (1.0e-02/8.8e-02/ 3/12) | Starch and sucrose metabolism (2.1e-03/1.7e-01/ 4/24) | ||
| 686 | 2.8/1.2 | 54 | 18 | regulation of multicellular organismal process (3.8e-02/2.0e+00/ 8/ 320) | insoluble fraction (3.4e-02/2.2e+00/ 8/375) | ||||
| 687 | 2.8/1.2 | 81 | 28 | regulation of transcription by carbon catabolites (7.7e-03/1.8e-02/ 2/ 2) | transcription regulator activity (1.7e-02/6.5e+00/ 17/816) | 19 (1.3e-02/ 4.9693/16/580) | |||
| 688 | 2.8/1.2 | 58 | 25 | lipopolysaccharide-mediated signaling pathway (2.6e-02/3.2e-02/ 2/ 5) | |||||
| 689 | 2.8/1 | 56 | 30 | ||||||
| 690 | 2.8/1 | 48 | 24 | ||||||
| 691 | 2.8/1 | 25 | 30 | membrane fraction (3.2e-02/8.7e-01/ 5/362) | Limonene and pinene degradation (2.5e-02/3.1e-02/ 2/14) | ||||
| 692 | 2.8/1 | 79 | 33 | 19 (7.3e-06/ 4.8466/21/580) | |||||
| 693 | 2.8/1 | 55 | 31 | sodium ion transport (2.4e-02/3.4e-01/ 4/ 54) | integral to plasma membrane (1.2e-02/3.4e+00/ 11/549) | alkali metal ion binding (1.3e-02/4.8e-01/ 5/77) | |||
| 694 | 2.8/1 | 86 | 37 | homophilic cell adhesion (3.6e-02/3.9e-01/ 4/ 40) | 19 (1.1e-07/ 5.2761/25/580) | ||||
| 695 | 2.8/1 | 42 | 33 | integral to membrane (2.0e-02/8.2e+00/ 17/2022) | |||||
| 696 | 2.8/1 | 86 | 30 | activation of JUN kinase activity (1.5e-02/1.2e-01/ 3/ 14) | |||||
| 697 | 2.8/1 | 92 | 36 | adherens junction (4.7e-02/5.5e-01/ 4/53) | 19 (6.3e-06/ 5.6442/23/580) | ||||
| 698 | 2.8/1 | 34 | 34 | Limonene and pinene degradation (4.8e-02/4.6e-02/ 2/14) | |||||
| 699 | 2.6/2 | 234 | 4 | generation of a signal involved in cell-cell signaling (4.1e-02/1.1e+00/ 6/ 46) | intrinsic to membrane (4.4e-03/4.8e+01/ 71/2051) | hormone activity (1.1e-03/7.1e-01/ 7/29) | 19 (1.8e-02/14.3558/31/580) | ||
| 700 | 2.6/2 | 137 | 6 | nucleic acid binding (3.2e-03/2.2e+01/ 41/1801) | |||||
| 701 | 2.6/2 | 216 | 6 | cell cycle phase (2.2e-36/7.4e+00/ 60/ 287) | chromosomal part (6.2e-27/4.9e+00/ 44/198) | adenyl nucleotide binding (2.3e-06/2.1e+01/ 50/864) | DNA replication (1.3e-13/1.0e+00/16/33) | ||
| 702 | 2.6/2 | 163 | 5 | organ morphogenesis (1.6e-02/5.2e+00/ 15/ 312) | MHC class I peptide loading complex (7.2e-05/1.0e-01/ 4/6) | TAP1 binding (2.7e-02/3.4e-02/ 2/2) | Phenylalanine metabolism (3.9e-02/1.8e-01/ 3/10) | ||
| 703 | 2.6/2 | 128 | 5 | G-protein coupled receptor protein signaling pathway (2.7e-04/3.0e+00/ 14/ 237) | intrinsic to membrane (5.1e-07/2.8e+01/ 56/2051) | transmembrane receptor activity (2.1e-06/4.4e+00/ 21/334) | Neuroactive ligand-receptor interaction (2.0e-03/1.2e+00/ 8/83) | ||
| 704 | 2.6/2 | 104 | 6 | system process (1.7e-02/4.8e+00/ 14/ 456) | intrinsic to membrane (2.7e-04/2.3e+01/ 42/2051) | transmembrane receptor activity (1.5e-03/3.5e+00/ 14/334) | |||
| 705 | 2.6/2 | 142 | 5 | genetic imprinting (4.0e-02/4.6e-02/ 2/ 3) | extracellular region (3.5e-06/1.1e+01/ 32/700) | endopeptidase activity (1.2e-02/2.8e+00/ 11/181) | |||
| 706 | 2.6/2 | 126 | 6 | common-partner SMAD protein phosphorylation (3.1e-02/3.9e-02/ 2/ 3) | plasma membrane part (6.4e-03/1.1e+01/ 24/875) | ||||
| 707 | 2.6/2 | 114 | 4 | intrinsic to membrane (2.7e-02/2.4e+01/ 38/2051) | |||||
| 708 | 2.6/2 | 119 | 8 | calcium-dependent cell-cell adhesion (3.0e-03/6.6e-02/ 3/ 6) | |||||
| 709 | 2.6/2 | 99 | 6 | multicellular organismal process (1.9e-03/1.7e+01/ 34/1648) | extracellular region part (3.0e-04/4.4e+00/ 16/387) | monooxygenase activity (3.9e-03/3.5e-01/ 5/34) | |||
| 710 | 2.6/2 | 105 | 4 | intracellular mRNA localization (2.3e-02/3.2e-02/ 2/ 3) | |||||
| 711 | 2.6/2 | 155 | 6 | retinoic acid metabolic process (4.2e-02/4.9e-02/ 2/ 3) | extracellular region (1.2e-03/1.2e+01/ 27/700) | TAP1 binding (2.5e-02/3.3e-02/ 2/2) | |||
| 712 | 2.6/2 | 133 | 5 | xenobiotic metabolic process (3.7e-02/1.8e-01/ 3/ 13) | melanosome membrane (6.4e-03/2.8e-02/ 2/2) | glucuronosyltransferase activity (4.0e-02/1.7e-01/ 3/12) | Porphyrin and chlorophyll metabolism (1.1e-02/2.7e-01/ 4/24) | ||
| 713 | 2.6/2 | 94 | 5 | multicellular organismal process (1.0e-03/1.7e+01/ 34/1648) | intrinsic to membrane (1.7e-04/2.1e+01/ 41/2051) | neurotransmitter receptor activity (9.8e-03/2.3e-01/ 4/24) | |||
| 714 | 2.6/2 | 168 | 6 | cell cycle phase (2.4e-41/5.7e+00/ 58/ 287) | chromosome (2.6e-27/4.8e+00/ 44/248) | microtubule motor activity (1.6e-06/7.0e-01/ 10/37) | DNA replication (1.5e-07/6.9e-01/10/33) | ||
| 715 | 2.6/2 | 158 | 7 | positive regulation of B cell mediated immunity (5.7e-03/8.9e-02/ 3/ 5) | extracellular region (6.2e-08/1.2e+01/ 37/700) | transmembrane receptor activity (1.1e-02/6.0e+00/ 17/334) | |||
| 716 | 2.6/2 | 122 | 5 | common-partner SMAD protein phosphorylation (3.2e-02/3.9e-02/ 2/ 3) | plasma membrane part (1.2e-02/1.2e+01/ 24/875) | ||||
| 717 | 2.6/2 | 209 | 4 | cell cycle phase (2.3e-18/7.3e+00/ 42/ 287) | chromosomal part (3.1e-15/4.9e+00/ 32/198) | DNA binding (8.3e-05/2.8e+01/ 56/1210) | DNA replication (6.8e-07/1.1e+00/11/33) | ||
| 718 | 2.6/2 | 111 | 7 | multicellular organismal process (5.1e-05/2.0e+01/ 42/1648) | anchored to membrane (3.5e-02/5.0e-01/ 4/39) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (5.0e-04/3.6e-02/ 3/3) | Metabolism of xenobiotics by cytochrome P450 (1.5e-02/5.6e-01/ 5/37) | ||
| 719 | 2.6/2 | 129 | 3 | circadian sleep/wake cycle (1.3e-02/2.5e-02/ 2/ 2) | anchored to membrane (6.1e-04/5.4e-01/ 6/39) | scavenger receptor activity (3.2e-02/1.5e-01/ 3/12) | |||
| 720 | 2.6/2 | 148 | 3 | genetic imprinting (4.0e-02/4.6e-02/ 2/ 3) | extracellular region part (4.2e-04/6.1e+00/ 19/387) | ||||
| 721 | 2.6/2 | 108 | 8 | multicellular organismal process (5.1e-04/2.0e+01/ 39/1648) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (5.1e-04/3.6e-02/ 3/3) | Metabolism of xenobiotics by cytochrome P450 (1.3e-02/5.3e-01/ 5/37) | |||
| 722 | 2.6/2 | 180 | 4 | immune response (3.9e-02/5.2e+00/ 14/ 295) | integral to plasma membrane (2.0e-03/1.0e+01/ 24/549) | signal transducer activity (1.1e-03/1.4e+01/ 32/798) | |||
| 723 | 2.6/2 | 80 | 3 | neurofilament cytoskeleton (1.4e-02/3.6e-02/ 2/4) | |||||
| 724 | 2.6/2 | 257 | 4 | cell adhesion (6.2e-04/1.1e+01/ 28/ 376) | extracellular region (2.4e-04/2.0e+01/ 42/700) | transmembrane receptor activity (4.5e-04/9.8e+00/ 27/334) | Small cell lung cancer (1.6e-02/2.6e+00/10/73) | ||
| 725 | 2.6/2 | 112 | 6 | system process (4.3e-07/5.8e+00/ 24/ 456) | plasma membrane (7.8e-05/1.9e+01/ 39/1443) | G-protein coupled receptor activity (2.7e-04/1.7e+00/ 11/137) | Olfactory transduction (1.5e-02/3.0e-01/ 4/27) | ||
| 726 | 2.6/2 | 196 | 5 | cell cycle phase (8.3e-16/6.8e+00/ 38/ 287) | chromosome, centromeric region (4.1e-17/1.4e+00/ 21/63) | microtubule motor activity (2.1e-03/7.9e-01/ 7/37) | Biosynthesis of steroids (9.7e-07/6.3e-01/ 9/23) | ||
| 727 | 2.6/2 | 123 | 5 | intracellular mRNA localization (3.0e-02/3.8e-02/ 2/ 3) | platelet alpha granule membrane (3.6e-02/6.3e-02/ 2/5) | ||||
| 728 | 2.6/2 | 183 | 6 | multicellular organismal process (2.5e-08/3.5e+01/ 71/1648) | extracellular region part (1.8e-06/8.1e+00/ 27/387) | calcium ion binding (1.5e-03/8.3e+00/ 23/402) | |||
| 729 | 2.6/2 | 151 | 6 | genetic imprinting (4.3e-02/4.9e-02/ 2/ 3) | extracellular region (6.6e-07/1.2e+01/ 34/700) | endopeptidase activity (1.4e-03/2.9e+00/ 13/181) | |||
| 730 | 2.6/2 | 133 | 6 | regulation of protein kinase activity (1.4e-02/2.5e+00/ 10/ 170) | extracellular region (5.0e-04/1.1e+01/ 26/700) | prostaglandin-endoperoxide synthase activity (2.1e-02/2.9e-02/ 2/2) | |||
| 731 | 2.6/2 | 119 | 5 | gastrulation (3.9e-02/4.1e-01/ 4/ 37) | sodium:bicarbonate symporter activity (1.5e-02/2.3e-02/ 2/2) | ||||
| 732 | 2.6/1.8 | 218 | 5 | cell cycle phase (2.3e-33/7.6e+00/ 58/ 287) | chromosomal part (2.7e-22/5.1e+00/ 40/198) | DNA binding (1.5e-05/3.0e+01/ 60/1210) | DNA replication (5.0e-08/1.1e+00/12/33) | ||
| 733 | 2.6/1.8 | 105 | 8 | G-protein coupled receptor protein signaling pathway (1.7e-04/2.5e+00/ 13/ 237) | intrinsic to membrane (5.6e-07/2.3e+01/ 49/2051) | transmembrane receptor activity (2.3e-06/3.6e+00/ 19/334) | Neuroactive ligand-receptor interaction (5.3e-04/9.7e-01/ 8/83) | ||
| 734 | 2.6/1.8 | 219 | 6 | response to stimulus (3.4e-03/2.9e+01/ 50/1350) | extracellular region (3.2e-03/1.5e+01/ 31/700) | transferase activity, transferring amino-acyl groups (1.3e-02/1.1e-01/ 3/5) | 19 (3.0e-02/13.4356/29/580) | ||
| 735 | 2.6/1.8 | 121 | 8 | nucleic acid binding (2.6e-02/2.1e+01/ 36/1801) | |||||
| 736 | 2.6/1.8 | 204 | 7 | cell-cell signaling (4.8e-03/5.6e+00/ 17/ 267) | neuron projection (1.9e-03/1.3e+00/ 8/66) | hormone activity (4.2e-03/6.1e-01/ 6/29) | 19 (2.3e-05/12.5153/35/580) | ||
| 737 | 2.6/1.8 | 106 | 10 | regulation of transcription factor import into nucleus (2.0e-02/1.3e-01/ 3/ 13) | neurofilament (1.0e-02/3.2e-02/ 2/3) | calcium ion binding (2.2e-02/4.2e+00/ 13/402) | |||
| 738 | 2.6/1.8 | 110 | 7 | gastrulation (4.1e-02/4.2e-01/ 4/ 37) | |||||
| 739 | 2.6/1.8 | 182 | 6 | fibrinolysis (2.3e-02/1.5e-01/ 3/ 8) | extracellular region (2.2e-02/1.3e+01/ 25/700) | 19 (4.5e-04/11.1656/30/580) | |||
| 740 | 2.6/1.8 | 108 | 8 | multicellular organismal process (2.8e-04/1.9e+01/ 38/1648) | intrinsic to membrane (3.2e-06/2.4e+01/ 49/2051) | transmembrane receptor activity (2.0e-04/3.7e+00/ 16/334) | |||
| 741 | 2.6/1.8 | 159 | 8 | multicellular organismal development (1.7e-03/2.1e+01/ 41/1284) | extracellular region (1.6e-04/1.2e+01/ 30/700) | TAP1 binding (2.5e-02/3.3e-02/ 2/2) | |||
| 742 | 2.6/1.8 | 126 | 7 | neuropeptide signaling pathway (4.3e-02/4.3e-01/ 4/ 33) | extracellular region (3.2e-02/9.0e+00/ 19/700) | ||||
| 743 | 2.6/1.8 | 96 | 8 | multicellular organismal process (2.1e-05/1.8e+01/ 39/1648) | plasma membrane (3.3e-06/1.6e+01/ 38/1443) | transmembrane receptor activity (1.9e-05/3.4e+00/ 17/334) | |||
| 744 | 2.6/1.8 | 105 | 6 | positive regulation of JUN kinase activity (2.7e-03/1.8e-01/ 4/ 16) | cell-cell adherens junction (5.5e-03/1.1e-01/ 3/10) | ||||
| 745 | 2.6/1.6 | 98 | 15 | cell morphogenesis (1.3e-02/3.5e+00/ 12/ 317) | sequence-specific DNA binding (1.2e-02/2.8e+00/ 11/261) | ||||
| 746 | 2.6/1.6 | 207 | 8 | cell cycle phase (2.5e-58/7.2e+00/ 78/ 287) | chromosome (2.4e-31/5.9e+00/ 52/248) | ATP binding (1.8e-09/1.9e+01/ 55/809) | Cell cycle (4.3e-18/2.8e+00/28/98) | ||
| 747 | 2.6/1.6 | 243 | 10 | cell cycle phase (7.6e-54/8.2e+00/ 78/ 287) | chromosome (1.1e-28/6.8e+00/ 52/248) | ATP binding (1.8e-08/2.2e+01/ 57/809) | DNA replication (8.9e-16/1.1e+00/18/33) | ||
| 748 | 2.6/1.6 | 165 | 13 | response to dsRNA (2.5e-03/1.8e-01/ 4/ 10) | plasma membrane (3.4e-03/2.5e+01/ 44/1443) | very-low-density lipoprotein receptor activity (2.7e-02/3.4e-02/ 2/2) | Neuroactive ligand-receptor interaction (4.3e-02/1.6e+00/ 7/83) | ||
| 749 | 2.6/1.6 | 175 | 7 | cell cycle phase (8.9e-46/6.1e+00/ 63/ 287) | chromosome (7.4e-28/5.0e+00/ 45/248) | ATP binding (4.8e-06/1.6e+01/ 41/809) | DNA replication (4.8e-10/7.3e-01/12/33) | ||
| 750 | 2.6/1.6 | 146 | 11 | cell cycle phase (6.8e-39/5.0e+00/ 53/ 287) | chromosome (2.6e-20/4.2e+00/ 35/248) | microtubule motor activity (4.6e-06/5.8e-01/ 9/37) | Cell cycle (1.7e-05/1.8e+00/12/98) | ||
| 751 | 2.6/1.6 | 114 | 14 | regulation of multicellular organismal process (2.2e-03/3.7e+00/ 14/ 320) | neurofilament (1.3e-02/3.7e-02/ 2/3) | ||||
| 752 | 2.6/1.6 | 100 | 11 | system process (1.4e-05/5.0e+00/ 20/ 456) | integral to plasma membrane (3.8e-04/6.2e+00/ 19/549) | transmembrane receptor activity (3.0e-04/3.4e+00/ 15/334) | |||
| 753 | 2.6/1.6 | 125 | 10 | xenobiotic metabolic process (2.5e-03/1.7e-01/ 4/ 13) | proteinaceous extracellular matrix (8.6e-03/2.1e+00/ 9/156) | glucuronosyltransferase activity (3.7e-02/1.6e-01/ 3/12) | Androgen and estrogen metabolism (1.3e-02/2.9e-01/ 4/21) | ||
| 754 | 2.6/1.6 | 95 | 10 | regulation of translation in response to stress (1.6e-02/2.5e-02/ 2/ 3) | organelle outer membrane (1.4e-02/6.5e-01/ 5/72) | ||||
| 755 | 2.6/1.6 | 81 | 13 | sensory perception (2.6e-03/1.6e+00/ 9/ 177) | membrane part (5.5e-05/2.2e+01/ 42/2426) | transmembrane receptor activity (5.2e-04/2.7e+00/ 13/334) | Leukocyte transendothelial migration (2.2e-02/6.3e-01/ 5/71) | ||
| 756 | 2.6/1.6 | 85 | 12 | sensory perception (5.0e-04/1.6e+00/ 10/ 177) | plasma membrane (6.0e-05/1.4e+01/ 32/1443) | transmembrane receptor activity (3.7e-05/2.8e+00/ 15/334) | Leukocyte transendothelial migration (2.2e-02/6.3e-01/ 5/71) | ||
| 757 | 2.6/1.6 | 91 | 10 | multicellular organismal process (4.0e-05/1.6e+01/ 36/1648) | plasma membrane (2.7e-03/1.4e+01/ 29/1443) | G-protein coupled receptor activity (3.3e-05/1.3e+00/ 11/137) | |||
| 758 | 2.6/1.6 | 105 | 11 | regulation of transcription factor import into nucleus (2.1e-02/1.4e-01/ 3/ 13) | neurofilament (1.0e-02/3.3e-02/ 2/3) | ||||
| 759 | 2.6/1.6 | 137 | 10 | regulation of multicellular organismal process (9.8e-03/4.4e+00/ 14/ 320) | intrinsic to membrane (9.0e-03/2.9e+01/ 46/2051) | transmembrane receptor activity (1.8e-02/4.6e+00/ 14/334) | |||
| 760 | 2.6/1.4 | 158 | 15 | multicellular organismal process (3.2e-03/2.8e+01/ 48/1648) | plasma membrane (5.9e-03/2.4e+01/ 41/1443) | very-low-density lipoprotein receptor activity (2.5e-02/3.3e-02/ 2/2) | |||
| 761 | 2.6/1.4 | 139 | 17 | regulation of translation in response to stress (3.5e-02/4.2e-02/ 2/ 3) | endomembrane system (1.4e-03/1.1e+01/ 25/756) | miR-590/590-3p (0.04930/10.5607/26/513) | |||
| 762 | 2.6/1.4 | 130 | 8 | axon transport of mitochondrion (3.4e-02/4.2e-02/ 2/ 3) | proteinaceous extracellular matrix (2.6e-03/2.2e+00/ 10/156) | RNA-dependent ATPase activity (7.3e-03/2.2e-01/ 4/16) | Drug metabolism - other enzymes (2.4e-02/3.5e-01/ 4/29) | ||
| 763 | 2.6/1.4 | 82 | 16 | multicellular organismal process (4.8e-04/1.4e+01/ 31/1648) | integral to plasma membrane (1.4e-03/5.1e+00/ 16/549) | transmembrane receptor activity (8.0e-03/2.7e+00/ 11/334) | Leukocyte transendothelial migration (1.8e-03/5.7e-01/ 6/71) | ||
| 764 | 2.6/1.4 | 161 | 14 | cell communication (3.1e-03/3.4e+01/ 56/1947) | membrane (5.6e-04/5.5e+01/ 80/3167) | transmembrane receptor activity (5.1e-03/5.5e+00/ 17/334) | Neuroactive ligand-receptor interaction (2.2e-02/1.8e+00/ 8/83) | ||
| 765 | 2.6/1.4 | 80 | 19 | protein kinase C activity (4.9e-03/6.7e-02/ 3/8) | 19 (1.0e-02/ 4.8466/16/580) | ||||
| 766 | 2.6/1.4 | 118 | 16 | myeloid leukocyte differentiation (1.4e-02/5.3e-01/ 5/ 46) | |||||
| 767 | 2.6/1.4 | 103 | 18 | regulation of transcription factor import into nucleus (2.4e-02/1.4e-01/ 3/ 13) | |||||
| 768 | 2.6/1.4 | 106 | 16 | regulation of transcription factor import into nucleus (2.3e-02/1.4e-01/ 3/ 13) | neurofilament (1.1e-02/3.3e-02/ 2/3) | ||||
| 769 | 2.6/1.4 | 81 | 14 | osteoblast development (3.3e-02/3.8e-02/ 2/ 5) | long-chain-fatty-acid-CoA ligase activity (4.5e-02/4.0e-02/ 2/5) | ||||
| 770 | 2.6/1.4 | 149 | 9 | organ morphogenesis (2.9e-02/5.0e+00/ 14/ 312) | intrinsic to membrane (2.2e-04/3.3e+01/ 57/2051) | TAP1 binding (2.3e-02/3.1e-02/ 2/2) | |||
| 771 | 2.6/1.4 | 113 | 18 | calcium-dependent cell-cell adhesion (3.1e-03/6.7e-02/ 3/ 6) | |||||
| 772 | 2.6/1.4 | 101 | 18 | multicellular organismal process (1.9e-04/1.7e+01/ 36/1648) | integral to plasma membrane (1.3e-03/6.2e+00/ 18/549) | structural constituent of myelin sheath (4.6e-02/4.2e-02/ 2/4) | Leukocyte transendothelial migration (3.9e-02/7.3e-01/ 5/71) | ||
| 773 | 2.6/1.4 | 78 | 20 | activation of JUN kinase activity (1.7e-02/1.2e-01/ 3/ 14) | protein kinase C activity (4.5e-03/6.5e-02/ 3/8) | ||||
| 774 | 2.6/1.4 | 84 | 10 | nervous system development (1.6e-03/3.7e+00/ 14/ 411) | anchored to membrane (1.4e-02/3.7e-01/ 4/39) | platelet-derived growth factor binding (3.9e-02/3.7e-02/ 2/4) | |||
| 775 | 2.6/1.2 | 116 | 27 | activation of JUN kinase activity (3.6e-02/1.7e-01/ 3/ 14) | 19 (6.6e-06/ 7.1166/26/580) | ||||
| 776 | 2.6/1.2 | 71 | 21 | outer membrane (3.1e-02/4.8e-01/ 4/74) | folic acid transporter activity (1.8e-02/2.3e-02/ 2/3) | ||||
| 777 | 2.6/1.2 | 108 | 16 | neurite morphogenesis (1.7e-02/8.7e-01/ 6/ 81) | |||||
| 778 | 2.6/1.2 | 104 | 9 | response to hormone stimulus (2.2e-02/9.2e-01/ 6/ 82) | extracellular region (1.2e-02/7.6e+00/ 18/700) | glucuronosyltransferase activity (2.5e-02/1.3e-01/ 3/12) | Starch and sucrose metabolism (9.0e-03/2.6e-01/ 4/24) | ||
| 779 | 2.6/1.2 | 98 | 18 | spermatogenesis (1.3e-02/8.2e-01/ 6/ 97) | acrosome (6.9e-03/1.2e-01/ 3/14) | Retinol metabolism (3.4e-02/1.7e-01/ 3/23) | |||
| 780 | 2.6/1.2 | 99 | 11 | xenobiotic metabolic process (2.1e-02/1.4e-01/ 3/ 13) | melanosome membrane (3.6e-03/2.0e-02/ 2/2) | glucuronosyltransferase activity (1.0e-03/1.2e-01/ 4/12) | Starch and sucrose metabolism (9.1e-04/2.8e-01/ 5/24) | ||
| 781 | 2.6/1.2 | 128 | 24 | regulation of transcription by carbon catabolites (1.5e-02/2.7e-02/ 2/ 2) | Dentatorubropallidoluysian atrophy (DRPLA) (3.4e-02/1.7e-01/ 3/14) | ||||
| 782 | 2.6/1 | 96 | 29 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.9e-03/4.7e-02/ 3/6) | Retinol metabolism (3.0e-03/1.9e-01/ 4/23) | ||||
| 783 | 2.6/1 | 97 | 27 | adenosine receptor activity, G-protein coupled (1.8e-02/2.3e-02/ 2/3) | Retinol metabolism (2.6e-03/1.8e-01/ 4/23) | ||||
| 784 | 2.6/1 | 100 | 27 | spermatogenesis (1.4e-02/8.4e-01/ 6/ 97) | secretory granule (4.6e-03/5.0e-01/ 5/57) | cation transmembrane transporter activity (1.1e-02/1.9e+00/ 9/221) | Retinol metabolism (3.0e-03/1.9e-01/ 4/23) | ||
| 785 | 2.6/1 | 90 | 30 | adenosine receptor activity, G-protein coupled (1.6e-02/2.1e-02/ 2/3) | Retinol metabolism (2.3e-02/1.4e-01/ 3/23) | ||||
| 786 | 2.6/1 | 87 | 32 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (4.7e-02/4.1e-02/ 2/6) | Retinol metabolism (2.7e-02/1.5e-01/ 3/23) | ||||
| 787 | 2.6/1 | 102 | 36 | 19 (3.5e-05/ 6.2577/23/580) | |||||
| 788 | 2.6/1 | 83 | 27 | folic acid transporter activity (2.2e-02/2.6e-02/ 2/3) | miR-17-5p/20/93.mr/106/519.d (0.04930/ 8.3610/22/639) | ||||
| 789 | 2.6/1 | 132 | 34 | regulation of transcription by carbon catabolites (1.6e-02/2.8e-02/ 2/ 2) | 19 (8.9e-03/ 8.0982/22/580) | ||||
| 790 | 2.6/1 | 143 | 36 | homophilic cell adhesion (2.5e-02/6.2e-01/ 5/ 40) | 19 (6.5e-09/ 8.7730/35/580) | ||||
| 791 | 2.6/1 | 85 | 35 | receptor metabolic process (3.1e-02/1.6e-01/ 3/ 17) | |||||
| 792 | 2.6/1 | 128 | 34 | regulation of transcription by carbon catabolites (1.4e-02/2.6e-02/ 2/ 2) | 19 (1.2e-05/ 7.8528/27/580) | ||||
| 793 | 2.4/2 | 201 | 5 | positive regulation of defense response to virus by host (2.9e-02/4.2e-02/ 2/ 2) | proteinaceous extracellular matrix (4.7e-03/3.4e+00/ 12/156) | RNA-dependent ATPase activity (2.9e-02/3.5e-01/ 4/16) | Starch and sucrose metabolism (4.8e-02/4.5e-01/ 4/24) | ||
| 794 | 2.4/2 | 327 | 4 | cell cycle phase (1.2e-37/1.1e+01/ 72/ 287) | chromosome (4.4e-21/9.1e+00/ 50/248) | DNA binding (1.2e-05/4.4e+01/ 80/1210) | DNA replication (1.1e-08/1.5e+00/14/33) | ||
| 795 | 2.4/2 | 134 | 3 | sodium ion transport (3.5e-02/6.9e-01/ 5/ 54) | neurofilament cytoskeleton (3.2e-02/6.0e-02/ 2/4) | ||||
| 796 | 2.4/2 | 195 | 7 | multicellular organismal process (1.2e-03/3.5e+01/ 59/1648) | anchored to membrane (5.7e-03/8.5e-01/ 6/39) | aldo-keto reductase activity (5.2e-04/2.3e-01/ 5/11) | |||
| 797 | 2.4/2 | 228 | 5 | gene expression (2.5e-02/4.2e+01/ 62/2093) | nucleic acid binding (7.6e-04/3.9e+01/ 65/1801) | ||||
| 798 | 2.4/2 | 299 | 5 | cell cycle phase (1.9e-30/1.0e+01/ 63/ 287) | chromosomal part (2.6e-20/6.8e+00/ 43/198) | ATP binding (6.6e-05/2.7e+01/ 55/809) | DNA replication (1.2e-11/1.4e+00/16/33) | ||
| 799 | 2.4/2 | 269 | 6 | multicellular organismal process (4.3e-08/4.9e+01/ 91/1648) | extracellular region part (8.6e-09/1.2e+01/ 38/387) | calcium ion binding (1.7e-03/1.2e+01/ 29/402) | |||
| 800 | 2.4/2 | 314 | 5 | cell cycle phase (6.6e-38/1.0e+01/ 71/ 287) | chromosome (1.3e-23/8.7e+00/ 52/248) | microtubule motor activity (2.2e-05/1.3e+00/ 11/37) | DNA replication (5.4e-08/1.4e+00/13/33) | ||
| 801 | 2.4/2 | 198 | 6 | multicellular organismal process (1.9e-02/3.2e+01/ 50/1648) | intrinsic to membrane (1.6e-02/4.1e+01/ 60/2051) | calcium ion binding (2.2e-03/7.9e+00/ 22/402) | |||
| 802 | 2.4/2 | 199 | 5 | response to dsRNA (4.3e-02/1.9e-01/ 3/ 10) | intrinsic to membrane (2.7e-02/4.1e+01/ 59/2051) | sodium:bicarbonate symporter activity (3.2e-02/3.9e-02/ 2/2) | |||
| 803 | 2.4/2 | 311 | 4 | cell cycle phase (1.7e-33/1.1e+01/ 67/ 287) | chromosomal part (8.4e-19/7.1e+00/ 42/198) | DNA binding (3.9e-05/4.2e+01/ 76/1210) | Cell cycle (4.3e-10/4.3e+00/24/98) | ||
| 804 | 2.4/2 | 197 | 6 | system process (1.4e-08/9.5e+00/ 34/ 456) | intrinsic to membrane (6.2e-08/4.5e+01/ 82/2051) | transmembrane receptor activity (5.1e-07/7.0e+00/ 28/334) | Neuroactive ligand-receptor interaction (8.7e-03/1.9e+00/ 9/83) | ||
| 805 | 2.4/2 | 316 | 5 | cell cycle phase (4.0e-38/1.1e+01/ 72/ 287) | chromosomal part (1.0e-19/7.1e+00/ 43/198) | DNA binding (1.6e-05/4.3e+01/ 79/1210) | Cell cycle (3.0e-10/4.2e+00/24/98) | ||
| 806 | 2.4/2 | 239 | 5 | antigen processing and presentation of peptide antigen (1.2e-02/5.2e-01/ 5/ 21) | intrinsic to membrane (2.6e-06/5.3e+01/ 89/2051) | transmembrane receptor activity (2.2e-02/8.3e+00/ 20/334) | |||
| 807 | 2.4/2 | 127 | 5 | ||||||
| 808 | 2.4/2 | 189 | 8 | immune system process (3.6e-11/1.1e+01/ 41/ 475) | extracellular region (5.3e-17/1.6e+01/ 58/700) | cytokine activity (1.4e-07/1.6e+00/ 15/73) | Cytokine-cytokine receptor interaction (5.7e-04/3.4e+00/14/122) | ||
| 809 | 2.4/2 | 191 | 5 | antigen processing and presentation of peptide antigen (5.2e-03/4.2e-01/ 5/ 21) | extracellular region (3.1e-05/1.5e+01/ 36/700) | oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor (1.4e-02/2.8e-01/ 4/14) | Ascorbate and aldarate metabolism (3.7e-02/1.8e-01/ 3/8) | ||
| 810 | 2.4/2 | 261 | 4 | synaptic transmission (2.7e-02/3.3e+00/ 11/ 123) | ion channel complex (7.9e-04/1.2e+00/ 8/42) | signal transducer activity (2.4e-02/2.1e+01/ 38/798) | Olfactory transduction (4.3e-02/7.5e-01/ 5/27) | ||
| 811 | 2.4/2 | 285 | 4 | visual perception (2.5e-02/2.2e+00/ 9/ 78) | plasma membrane (3.6e-03/4.1e+01/ 64/1443) | transmembrane receptor activity (7.1e-04/1.0e+01/ 27/334) | 19 (1.3e-02/17.4847/36/580) | ||
| 812 | 2.4/1.8 | 325 | 6 | cell cycle phase (1.5e-41/1.1e+01/ 76/ 287) | chromosomal part (2.1e-25/7.3e+00/ 50/198) | microtubule motor activity (4.1e-06/1.3e+00/ 12/37) | Cell cycle (3.0e-12/4.5e+00/27/98) | ||
| 813 | 2.4/1.8 | 183 | 6 | response to dsRNA (3.3e-02/1.7e-01/ 3/ 10) | intrinsic to membrane (9.0e-03/3.8e+01/ 57/2051) | ||||
| 814 | 2.4/1.8 | 193 | 10 | positive regulation of gene expression, epigenetic (1.4e-02/1.2e-01/ 3/ 6) | 19 (1.8e-04/11.8405/32/580) | ||||
| 815 | 2.4/1.8 | 193 | 7 | positive regulation of cyclase activity (1.3e-02/2.9e-01/ 4/ 15) | outer kinetochore of condensed chromosome (2.8e-02/5.8e-02/ 2/3) | sodium:bicarbonate symporter activity (3.3e-02/4.0e-02/ 2/2) | |||
| 816 | 2.4/1.8 | 156 | 11 | neurological system process (5.5e-07/5.3e+00/ 23/ 328) | plasma membrane (9.2e-07/2.5e+01/ 53/1443) | G-protein coupled receptor activity (1.3e-04/2.3e+00/ 13/137) | Leukocyte transendothelial migration (1.9e-02/1.3e+00/ 7/71) | ||
| 817 | 2.4/1.8 | 201 | 8 | proteinaceous extracellular matrix (4.1e-04/3.5e+00/ 14/156) | |||||
| 818 | 2.4/1.8 | 191 | 7 | nucleic acid binding (4.4e-03/3.2e+01/ 53/1801) | Retinol metabolism (2.4e-02/3.5e-01/ 4/23) | ||||
| 819 | 2.4/1.8 | 212 | 7 | extracellular matrix organization (2.3e-02/9.5e-01/ 6/ 43) | neurofilament (3.3e-02/6.5e-02/ 2/3) | ||||
| 820 | 2.4/1.8 | 232 | 4 | ear development (5.8e-03/7.0e-01/ 6/ 29) | plasma membrane part (6.0e-04/2.2e+01/ 42/875) | nicotinic acetylcholine-activated cation-selective channel activity (4.5e-04/1.2e-01/ 4/5) | |||
| 821 | 2.4/1.8 | 170 | 8 | neurological system process (2.2e-06/5.7e+00/ 23/ 328) | intrinsic to membrane (3.7e-07/3.8e+01/ 70/2051) | transmembrane receptor activity (3.3e-06/5.8e+00/ 24/334) | |||
| 822 | 2.4/1.8 | 246 | 6 | cell cycle phase (4.2e-47/8.1e+00/ 72/ 287) | chromosome (1.6e-26/6.9e+00/ 50/248) | microtubule motor activity (3.0e-07/1.0e+00/ 12/37) | Cell cycle (5.7e-11/2.9e+00/21/98) | ||
| 823 | 2.4/1.8 | 230 | 5 | immune response (2.3e-02/6.6e+00/ 17/ 295) | extracellular region (2.2e-03/1.6e+01/ 33/700) | signal transducer activity (1.2e-02/1.8e+01/ 35/798) | |||
| 824 | 2.4/1.8 | 213 | 11 | activation of JUN kinase activity (1.6e-02/3.1e-01/ 4/ 14) | neurofilament (3.5e-02/6.7e-02/ 2/3) | gamma-glutamyltransferase activity (3.9e-02/4.5e-02/ 2/2) | |||
| 825 | 2.4/1.8 | 301 | 6 | cell cycle phase (3.2e-31/1.0e+01/ 64/ 287) | chromosomal part (1.7e-17/6.9e+00/ 40/198) | growth factor activity (3.9e-05/3.1e+00/ 16/94) | DNA replication (1.4e-07/1.5e+00/13/33) | ||
| 826 | 2.4/1.8 | 151 | 7 | multicellular organismal process (1.7e-06/2.7e+01/ 55/1648) | intrinsic to membrane (7.6e-07/3.5e+01/ 66/2051) | transmembrane receptor activity (3.5e-06/5.4e+00/ 23/334) | Neuroactive ligand-receptor interaction (4.3e-02/1.6e+00/ 7/83) | ||
| 827 | 2.4/1.8 | 226 | 7 | MHC class I peptide loading complex (2.6e-04/1.5e-01/ 4/6) | TAP1 binding (4.1e-02/4.7e-02/ 2/2) | ||||
| 828 | 2.4/1.8 | 207 | 4 | translational elongation (3.5e-02/1.9e+00/ 8/ 93) | cytosolic ribosome (2.2e-02/1.5e+00/ 7/71) | prostaglandin-endoperoxide synthase activity (3.6e-02/4.3e-02/ 2/2) | |||
| 829 | 2.4/1.8 | 230 | 9 | plasma membrane part (1.2e-03/2.1e+01/ 40/875) | gamma-glutamyltransferase activity (4.1e-02/4.7e-02/ 2/2) | ||||
| 830 | 2.4/1.8 | 270 | 4 | monovalent inorganic cation transport (1.8e-02/3.6e+00/ 12/ 132) | plasma membrane (4.7e-05/4.1e+01/ 71/1443) | alkali metal ion binding (7.4e-03/2.2e+00/ 10/77) | |||
| 831 | 2.4/1.8 | 188 | 10 | system process (1.5e-05/9.1e+00/ 28/ 456) | extracellular region (3.1e-07/1.5e+01/ 40/700) | transmembrane receptor activity (6.9e-06/6.6e+00/ 25/334) | Neuroactive ligand-receptor interaction (2.8e-04/1.9e+00/11/83) | ||
| 832 | 2.4/1.8 | 175 | 8 | neurological system process (7.0e-07/6.3e+00/ 25/ 328) | intrinsic to membrane (1.6e-06/4.0e+01/ 72/2051) | transmembrane receptor activity (1.9e-07/6.2e+00/ 27/334) | Neuroactive ligand-receptor interaction (5.0e-03/1.8e+00/ 9/83) | ||
| 833 | 2.4/1.8 | 175 | 8 | multicellular organismal process (8.1e-07/3.2e+01/ 63/1648) | plasma membrane (2.2e-06/2.9e+01/ 58/1443) | transmembrane receptor activity (1.2e-05/6.3e+00/ 24/334) | Neuroactive ligand-receptor interaction (1.8e-02/1.7e+00/ 8/83) | ||
| 834 | 2.4/1.6 | 208 | 7 | peripheral nervous system neuron differentiation (3.0e-02/4.4e-02/ 2/ 2) | extracellular region (1.2e-04/1.6e+01/ 36/700) | endopeptidase activity (4.7e-03/3.9e+00/ 14/181) | |||
| 835 | 2.4/1.6 | 251 | 7 | cell cycle phase (3.7e-51/8.6e+00/ 77/ 287) | chromosome (5.7e-26/7.1e+00/ 50/248) | microtubule motor activity (4.4e-07/1.0e+00/ 12/37) | DNA replication (1.1e-11/1.1e+00/15/33) | ||
| 836 | 2.4/1.6 | 263 | 8 | cell cycle phase (2.7e-55/8.9e+00/ 82/ 287) | chromosome (1.4e-28/7.5e+00/ 54/248) | ATP binding (2.5e-08/2.4e+01/ 60/809) | Cell cycle (2.3e-16/3.6e+00/29/98) | ||
| 837 | 2.4/1.6 | 194 | 14 | system process (5.5e-07/9.3e+00/ 31/ 456) | extracellular region (5.4e-06/1.5e+01/ 38/700) | monooxygenase activity (1.4e-05/6.9e-01/ 9/34) | Neuroactive ligand-receptor interaction (7.9e-03/1.9e+00/ 9/83) | ||
| 838 | 2.4/1.6 | 160 | 14 | ||||||
| 839 | 2.4/1.6 | 188 | 8 | catecholamine metabolic process (8.3e-03/2.5e-01/ 4/ 12) | anchored to membrane (3.0e-02/8.2e-01/ 5/39) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (1.8e-03/6.2e-02/ 3/3) | Metabolism of xenobiotics by cytochrome P450 (1.6e-02/8.8e-01/ 6/37) | ||
| 840 | 2.4/1.6 | 153 | 11 | multicellular organismal process (4.4e-04/2.7e+01/ 50/1648) | vascular endothelial growth factor receptor activity (6.4e-03/8.3e-02/ 3/5) | ||||
| 841 | 2.4/1.6 | 255 | 10 | cell cycle phase (1.0e-41/9.0e+00/ 70/ 287) | chromosome (2.2e-22/7.4e+00/ 47/248) | ATP binding (5.0e-06/2.3e+01/ 53/809) | DNA replication (3.2e-11/1.2e+00/15/33) | ||
| 842 | 2.4/1.6 | 313 | 9 | cell cycle phase (4.7e-56/1.0e+01/ 88/ 287) | chromosome (1.1e-28/8.8e+00/ 58/248) | microtubule motor activity (3.4e-07/1.3e+00/ 13/37) | Cell cycle (3.4e-16/4.0e+00/30/98) | ||
| 843 | 2.4/1.6 | 186 | 13 | regulation of transcription factor import into nucleus (7.1e-03/2.4e-01/ 4/ 13) | neurofilament (2.6e-02/5.6e-02/ 2/3) | calcium ion binding (4.3e-02/7.6e+00/ 18/402) | |||
| 844 | 2.4/1.6 | 163 | 13 | system process (1.0e-04/7.8e+00/ 24/ 456) | plasma membrane (1.1e-05/2.6e+01/ 52/1443) | transmembrane receptor activity (8.7e-05/5.7e+00/ 21/334) | Neuroactive ligand-receptor interaction (2.0e-03/1.6e+00/ 9/83) | ||
| 845 | 2.4/1.6 | 177 | 8 | axon transport of mitochondrion (5.0e-02/5.6e-02/ 2/ 3) | Starch and sucrose metabolism (2.1e-02/3.3e-01/ 4/24) | ||||
| 846 | 2.4/1.6 | 187 | 12 | endoplasmic reticulum (1.4e-02/1.1e+01/ 23/562) | collagen binding (3.9e-02/3.9e-01/ 4/21) | ||||
| 847 | 2.4/1.6 | 224 | 10 | positive regulation of JUN kinase activity (2.9e-03/3.8e-01/ 5/ 16) | plasma membrane part (4.9e-04/2.1e+01/ 41/875) | ||||
| 848 | 2.4/1.6 | 229 | 10 | extracellular region (1.7e-03/1.7e+01/ 34/700) | signal transducer activity (3.1e-02/1.9e+01/ 35/798) | ||||
| 849 | 2.4/1.6 | 183 | 14 | regulation of multicellular organismal process (1.7e-02/5.8e+00/ 16/ 320) | neurofilament (2.7e-02/5.8e-02/ 2/3) | calcium ion binding (1.7e-02/7.5e+00/ 19/402) | |||
| 850 | 2.4/1.6 | 235 | 10 | positive regulation of JUN kinase activity (3.6e-03/4.0e-01/ 5/ 16) | |||||
| 851 | 2.4/1.6 | 163 | 12 | multicellular organismal process (1.4e-07/2.8e+01/ 60/1648) | plasma membrane (1.4e-07/2.6e+01/ 57/1443) | transmembrane receptor activity (3.4e-05/5.8e+00/ 22/334) | Neuroactive ligand-receptor interaction (5.0e-02/1.6e+00/ 7/83) | ||
| 852 | 2.4/1.6 | 165 | 11 | activation of plasma proteins during acute inflammatory response (1.3e-02/2.8e-01/ 4/ 17) | |||||
| 853 | 2.4/1.4 | 235 | 12 | cell cycle phase (5.4e-50/8.0e+00/ 74/ 287) | chromosome (1.6e-25/6.6e+00/ 48/248) | ATP binding (1.2e-07/2.1e+01/ 54/809) | Cell cycle (2.3e-08/3.1e+00/19/98) | ||
| 854 | 2.4/1.4 | 191 | 14 | axonemal dynein complex (1.0e-02/3.7e-02/ 2/2) | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.3e-02/1.1e-01/ 3/6) | Retinol metabolism (3.4e-03/3.9e-01/ 5/23) | |||
| 855 | 2.4/1.4 | 243 | 11 | cell cycle phase (8.6e-45/8.1e+00/ 70/ 287) | chromosome (3.5e-25/6.7e+00/ 48/248) | microtubule motor activity (2.8e-07/9.9e-01/ 12/37) | DNA replication (7.6e-06/1.0e+00/10/33) | ||
| 856 | 2.4/1.4 | 269 | 13 | cell cycle phase (5.0e-52/9.2e+00/ 80/ 287) | chromosome (7.3e-27/7.8e+00/ 53/248) | ATP binding (1.4e-08/2.4e+01/ 62/809) | Cell cycle (2.1e-15/3.7e+00/28/98) | ||
| 857 | 2.4/1.4 | 179 | 12 | response to xenobiotic stimulus (1.5e-03/3.2e-01/ 5/ 16) | proteinaceous extracellular matrix (6.9e-03/3.0e+00/ 11/156) | Androgen and estrogen metabolism (4.2e-03/4.1e-01/ 5/21) | |||
| 858 | 2.4/1.4 | 168 | 17 | calcium-dependent cell-cell adhesion (8.5e-03/1.0e-01/ 3/ 6) | Dentatorubropallidoluysian atrophy (DRPLA) (6.5e-03/2.4e-01/ 4/14) | ||||
| 859 | 2.4/1.4 | 169 | 14 | multicellular organismal process (5.0e-09/3.0e+01/ 65/1648) | plasma membrane (1.2e-05/2.7e+01/ 54/1443) | transmembrane receptor activity (1.7e-04/6.0e+00/ 21/334) | |||
| 860 | 2.4/1.4 | 194 | 17 | nervous system development (8.1e-03/9.0e+00/ 22/ 411) | extracellular region (2.7e-03/1.6e+01/ 32/700) | endopeptidase inhibitor activity (6.8e-04/1.2e+00/ 9/58) | |||
| 861 | 2.4/1.4 | 278 | 14 | cell cycle phase (2.1e-57/8.9e+00/ 84/ 287) | chromosome (1.1e-28/7.8e+00/ 55/248) | ATP binding (3.2e-09/2.5e+01/ 64/809) | Cell cycle (3.4e-17/3.3e+00/29/98) | ||
| 862 | 2.4/1.4 | 237 | 14 | digestion (4.5e-03/6.7e-01/ 6/ 27) | plasma membrane (3.1e-03/3.7e+01/ 59/1443) | purinergic nucleotide receptor activity (5.9e-03/2.2e-01/ 4/9) | Neuroactive ligand-receptor interaction (6.1e-04/2.5e+00/12/83) | ||
| 863 | 2.4/1.4 | 212 | 22 | positive regulation of gene expression, epigenetic (5.2e-04/1.3e-01/ 4/ 6) | 19 (8.4e-03/13.0061/30/580) | ||||
| 864 | 2.4/1.2 | 151 | 22 | negative regulation of transcription factor import into nucleus (6.7e-03/9.0e-02/ 3/ 6) | calcium ion binding (3.6e-02/6.2e+00/ 16/402) | ||||
| 865 | 2.4/1.2 | 176 | 31 | ||||||
| 866 | 2.4/1.2 | 152 | 22 | lipid catabolic process (4.6e-02/1.1e+00/ 6/ 70) | lipase activity (4.3e-03/6.1e-01/ 6/37) | ||||
| 867 | 2.4/1.2 | 115 | 27 | antigen processing and presentation of peptide antigen via MHC class I (3.0e-04/2.2e-01/ 5/ 17) | cell surface (7.3e-04/1.5e+00/ 9/130) | MHC class I receptor activity (1.6e-02/1.1e-01/ 3/9) | |||
| 868 | 2.4/1 | 206 | 33 | activation of JUN kinase activity (1.5e-02/3.1e-01/ 4/ 14) | cytoskeletal protein binding (4.3e-02/5.7e+00/ 15/268) | 19 (1.2e-06/12.6380/38/580) | |||
| 869 | 2.4/1 | 160 | 27 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process (8.6e-03/2.3e+01/ 40/1419) | miR-200bc/429 (0.04930/13.7669/31/576) | ||||
| 870 | 2.4/1 | 179 | 35 | regulation of synaptic transmission (2.8e-02/6.5e-01/ 5/ 35) | intercalated disc (2.7e-02/5.7e-02/ 2/3) | cytoskeletal protein binding (3.8e-02/5.0e+00/ 14/268) | 19 (1.1e-07/10.9816/37/580) | ||
| 871 | 2.4/1 | 190 | 35 | activation of JUN kinase activity (1.2e-02/2.8e-01/ 4/ 14) | 19 (7.8e-08/11.6564/39/580) | ||||
| 872 | 2.2/2 | 429 | 3 | cell adhesion (1.1e-03/1.8e+01/ 38/ 376) | extracellular region (1.2e-04/3.4e+01/ 62/700) | cytokine binding (6.6e-05/2.6e+00/ 14/53) | Cytokine-cytokine receptor interaction (4.8e-02/6.8e+00/16/122) | 21 (3.9e-02/ 4.8554/15/107) | |
| 873 | 2.2/2 | 300 | 3 | antigen processing and presentation (3.8e-03/1.3e+00/ 8/ 40) | MHC class I peptide loading complex (7.4e-04/2.0e-01/ 4/6) | MHC class I protein binding (1.8e-02/3.2e-01/ 4/10) | Antigen processing and presentation (5.0e-02/1.6e+00/ 7/45) | 13 (4.9e-02/ 5.4897/16/173) | |
| 874 | 2.2/2 | 329 | 5 | negative regulation of transport (1.1e-02/1.5e+00/ 8/ 47) | caveola (3.8e-02/5.4e-01/ 4/16) | ||||
| 875 | 2.2/2 | 352 | 5 | transcription (6.6e-06/4.7e+01/ 83/1435) | nucleus (8.4e-04/1.0e+02/135/3091) | nucleic acid binding (2.9e-06/6.1e+01/104/1801) | |||
| 876 | 2.2/2 | 314 | 6 | neurological system process (2.1e-10/1.0e+01/ 39/ 328) | plasma membrane (2.8e-08/4.9e+01/ 91/1443) | transmembrane receptor activity (1.8e-09/1.1e+01/ 41/334) | Neuroactive ligand-receptor interaction (9.7e-03/2.9e+00/11/83) | ||
| 877 | 2.2/2 | 339 | 6 | antigen processing and presentation of peptide antigen (4.2e-02/7.6e-01/ 5/ 21) | MHC class I peptide loading complex (1.0e-03/2.2e-01/ 4/6) | ||||
| 878 | 2.2/2 | 297 | 4 | transmembrane receptor protein tyrosine kinase signaling pathway (4.3e-02/4.7e+00/ 13/ 150) | proteinaceous extracellular matrix (1.4e-03/5.0e+00/ 16/156) | RNA-dependent ATPase activity (1.2e-02/5.1e-01/ 5/16) | |||
| 879 | 2.2/2 | 265 | 5 | immune system process (3.2e-10/1.5e+01/ 48/ 475) | extracellular region (3.4e-14/2.2e+01/ 65/700) | growth factor activity (6.4e-05/2.9e+00/ 15/94) | Glycan structures - degradation (2.8e-04/9.2e-01/ 8/23) | ||
| 880 | 2.2/2 | 214 | 6 | immune system process (8.4e-09/1.2e+01/ 40/ 475) | extracellular region (1.1e-12/1.8e+01/ 55/700) | cytokine activity (7.9e-05/1.8e+00/ 12/73) | Cytokine-cytokine receptor interaction (4.7e-04/3.8e+00/15/122) | ||
| 881 | 2.2/2 | 429 | 4 | cell cycle phase (4.3e-37/1.5e+01/ 81/ 287) | chromosomal part (4.7e-18/9.5e+00/ 47/198) | DNA binding (1.4e-05/5.9e+01/100/1210) | Cell cycle (1.2e-10/5.7e+00/28/98) | ||
| 882 | 2.2/2 | 370 | 6 | multicellular organismal process (2.2e-08/6.6e+01/115/1648) | extracellular region part (4.7e-09/1.6e+01/ 46/387) | calcium ion binding (3.2e-03/1.7e+01/ 35/402) | |||
| 883 | 2.2/2 | 450 | 4 | cell cycle phase (1.8e-41/1.5e+01/ 86/ 287) | chromosome (5.0e-26/1.2e+01/ 64/248) | DNA binding (3.7e-06/6.0e+01/104/1210) | Cell cycle (8.8e-11/5.6e+00/28/98) | ||
| 884 | 2.2/2 | 426 | 5 | cell cycle phase (3.3e-40/1.4e+01/ 84/ 287) | chromosomal part (6.4e-19/9.5e+00/ 48/198) | microtubule motor activity (3.6e-05/1.7e+00/ 12/37) | Cell cycle (1.9e-12/5.6e+00/30/98) | ||
| 885 | 2.2/2 | 302 | 6 | nuclear division (7.3e-03/5.3e+00/ 16/ 174) | intrinsic to membrane (1.3e-02/6.3e+01/ 87/2051) | ||||
| 886 | 2.2/2 | 359 | 6 | MAPKKK cascade (1.9e-03/4.7e+00/ 16/ 113) | cell surface (7.5e-04/5.2e+00/ 17/130) | protein binding (2.3e-04/1.9e+02/227/4565) | miR-320/320abcd (0.02028/19.0736/41/377) | ||
| 887 | 2.2/2 | 262 | 8 | response to wounding (6.7e-11/7.3e+00/ 33/ 231) | extracellular region (1.8e-18/2.1e+01/ 71/700) | cytokine activity (6.4e-07/2.2e+00/ 16/73) | Cytokine-cytokine receptor interaction (2.8e-04/4.6e+00/17/122) | ||
| 888 | 2.2/2 | 239 | 3 | antigen processing and presentation of peptide antigen via MHC class I (3.9e-03/4.0e-01/ 5/ 17) | MHC class I protein complex (1.1e-03/3.8e-01/ 5/15) | MHC class I receptor activity (6.1e-03/2.2e-01/ 4/9) | Type I diabetes mellitus (2.3e-02/6.3e-01/ 5/26) | ||
| 889 | 2.2/2 | 370 | 5 | cell cycle phase (2.3e-49/1.2e+01/ 86/ 287) | chromosome (2.3e-26/1.0e+01/ 59/248) | DNA binding (6.4e-07/4.8e+01/ 91/1210) | Cell cycle (3.2e-14/4.5e+00/29/98) | ||
| 890 | 2.2/2 | 266 | 7 | immune system process (1.2e-08/1.5e+01/ 44/ 475) | extracellular region (2.3e-18/2.1e+01/ 71/700) | cytokine activity (8.3e-05/2.2e+00/ 13/73) | Complement and coagulation cascades (2.6e-03/1.2e+00/ 8/34) | ||
| 891 | 2.2/2 | 341 | 6 | multicellular organismal process (9.4e-03/5.8e+01/ 84/1648) | plasma membrane (3.3e-04/5.2e+01/ 82/1443) | transmembrane receptor activity (3.1e-02/1.2e+01/ 25/334) | Neuroactive ligand-receptor interaction (6.4e-03/3.2e+00/12/83) | ||
| 892 | 2.2/2 | 289 | 5 | melanosome membrane (2.4e-02/6.1e-02/ 2/2) | |||||
| 893 | 2.2/2 | 417 | 9 | cell cycle phase (1.1e-29/1.3e+01/ 70/ 287) | chromosomal part (1.9e-19/9.2e+00/ 48/198) | microtubule motor activity (1.6e-04/1.7e+00/ 11/37) | DNA replication (2.8e-14/1.6e+00/19/33) | ||
| 894 | 2.2/2 | 272 | 7 | plasma membrane part (4.9e-02/2.5e+01/ 40/875) | |||||
| 895 | 2.2/2 | 297 | 4 | plasma membrane (1.4e-03/4.5e+01/ 71/1443) | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NADH or NADPH as one donor, and incorporation of one atom of oxygen (2.9e-02/3.6e-01/ 4/12) | ||||
| 896 | 2.2/1.8 | 313 | 7 | negative regulation of transcription factor import into nucleus (1.8e-03/1.9e-01/ 4/ 6) | caveola (3.2e-02/5.0e-01/ 4/16) | ||||
| 897 | 2.2/1.8 | 359 | 7 | cell cycle phase (4.1e-50/1.2e+01/ 86/ 287) | chromosome (2.2e-25/9.9e+00/ 57/248) | ATP binding (1.0e-06/3.2e+01/ 68/809) | Cell cycle (8.4e-14/4.7e+00/29/98) | ||
| 898 | 2.2/1.8 | 367 | 8 | cell cycle phase (1.4e-16/1.2e+01/ 52/ 287) | chromosomal part (3.5e-07/8.4e+00/ 29/198) | cytokine activity (1.8e-05/2.9e+00/ 16/73) | DNA replication (1.6e-07/1.8e+00/14/33) | ||
| 899 | 2.2/1.8 | 266 | 8 | positive regulation of transcription from RNA polymerase II promoter (1.7e-02/4.1e+00/ 13/ 145) | vascular endothelial growth factor receptor activity (2.2e-02/1.4e-01/ 3/5) | ||||
| 900 | 2.2/1.8 | 425 | 8 | cell cycle phase (1.3e-51/1.4e+01/ 94/ 287) | chromosome (5.7e-27/1.2e+01/ 64/248) | microtubule motor activity (5.2e-06/1.7e+00/ 13/37) | Cell cycle (2.7e-14/5.2e+00/31/98) | ||
| 901 | 2.2/1.8 | 297 | 8 | multicellular organismal process (2.6e-07/5.2e+01/ 92/1648) | extracellular region (6.2e-06/2.2e+01/ 49/700) | calcium ion binding (1.9e-05/1.3e+01/ 35/402) | |||
| 902 | 2.2/1.8 | 442 | 8 | cell cycle phase (3.3e-36/1.5e+01/ 81/ 287) | chromosomal part (1.5e-19/1.0e+01/ 50/198) | microtubule motor activity (5.2e-05/1.8e+00/ 12/37) | DNA replication (9.0e-13/2.0e+00/19/33) | ||
| 903 | 2.2/1.8 | 297 | 10 | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (5.5e-03/9.9e-02/ 3/3) | |||||
| 904 | 2.2/1.8 | 260 | 6 | segmentation (4.2e-02/4.4e-01/ 4/ 16) | vascular endothelial growth factor receptor activity (1.8e-02/1.3e-01/ 3/5) | ||||
| 905 | 2.2/1.8 | 244 | 5 | antigen processing and presentation of peptide antigen (1.2e-02/5.2e-01/ 5/ 21) | intrinsic to membrane (1.4e-02/5.5e+01/ 77/2051) | MHC class I receptor activity (6.1e-03/2.2e-01/ 4/9) | Cell adhesion molecules (CAMs) (1.6e-02/1.7e+00/ 8/70) | ||
| 906 | 2.2/1.8 | 271 | 5 | response to biotic stimulus (4.6e-02/4.7e+00/ 13/ 170) | intrinsic to membrane (3.9e-02/6.0e+01/ 80/2051) | glutathione transferase activity (6.3e-03/4.3e-01/ 5/15) | Drug metabolism - cytochrome P450 (6.8e-03/1.1e+00/ 7/36) | ||
| 907 | 2.2/1.8 | 361 | 9 | inositol metabolic process (6.0e-03/2.6e-01/ 4/ 7) | extracellular region (6.6e-03/2.6e+01/ 45/700) | receptor binding (2.7e-02/1.5e+01/ 30/408) | |||
| 908 | 2.2/1.8 | 308 | 7 | transcription (3.0e-02/4.1e+01/ 61/1435) | nucleic acid binding (9.8e-03/5.2e+01/ 77/1801) | ||||
| 909 | 2.2/1.8 | 304 | 12 | regulation of transcription factor import into nucleus (3.3e-02/4.1e-01/ 4/ 13) | calcium ion binding (7.8e-03/1.3e+01/ 28/402) | ||||
| 910 | 2.2/1.8 | 248 | 8 | immune system process (7.7e-12/1.4e+01/ 48/ 475) | extracellular region (3.3e-18/2.0e+01/ 68/700) | signal transducer activity (6.9e-06/2.2e+01/ 51/798) | Complement and coagulation cascades (2.7e-05/1.2e+00/10/34) | ||
| 911 | 2.2/1.6 | 283 | 10 | pattern specification process (1.6e-02/3.0e+00/ 11/ 101) | vascular endothelial growth factor receptor activity (2.4e-02/1.5e-01/ 3/5) | ||||
| 912 | 2.2/1.6 | 291 | 13 | positive regulation of MAP kinase activity (6.1e-03/1.4e+00/ 8/ 47) | intrinsic to membrane (3.5e-02/6.2e+01/ 83/2051) | calcium ion binding (8.7e-03/1.2e+01/ 27/402) | Dentatorubropallidoluysian atrophy (DRPLA) (4.7e-02/4.6e-01/ 4/14) | ||
| 913 | 2.2/1.6 | 292 | 13 | system process (7.6e-09/1.4e+01/ 43/ 456) | extracellular region (1.6e-07/2.2e+01/ 53/700) | transmembrane receptor activity (1.3e-08/1.0e+01/ 38/334) | Neuroactive ligand-receptor interaction (2.3e-03/2.9e+00/12/83) | ||
| 914 | 2.2/1.6 | 288 | 12 | RNA localization (1.8e-02/2.1e+00/ 9/ 73) | calcium ion binding (1.3e-02/1.2e+01/ 26/402) | Dentatorubropallidoluysian atrophy (DRPLA) (3.9e-02/4.3e-01/ 4/14) | |||
| 915 | 2.2/1.6 | 302 | 7 | positive regulation of defense response to virus by host (5.0e-02/6.4e-02/ 2/ 2) | extracellular matrix (8.7e-03/5.3e+00/ 15/166) | Starch and sucrose metabolism (2.9e-02/6.8e-01/ 5/24) | |||
| 916 | 2.2/1.6 | 368 | 9 | cell cycle phase (1.6e-42/1.2e+01/ 81/ 287) | chromosome (1.1e-22/1.0e+01/ 55/248) | ATP binding (5.7e-06/3.3e+01/ 67/809) | DNA replication (1.5e-11/1.7e+00/17/33) | ||
| 917 | 2.2/1.6 | 292 | 9 | stress-activated MAPK cascade (4.4e-02/5.7e-02/ 2/ 2) | integral to plasma membrane (2.0e-02/1.6e+01/ 29/549) | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (3.2e-02/1.6e-01/ 3/6) | Retinol metabolism (1.5e-02/5.6e-01/ 5/23) | ||
| 918 | 2.2/1.6 | 287 | 10 | positive regulation of defense response to virus by host (4.9e-02/6.2e-02/ 2/ 2) | RNA-dependent ATPase activity (9.7e-03/4.8e-01/ 5/16) | ||||
| 919 | 2.2/1.6 | 271 | 10 | extracellular region (3.0e-05/2.1e+01/ 45/700) | UDP-glycosyltransferase activity (1.7e-03/1.8e+00/ 10/61) | Starch and sucrose metabolism (6.8e-03/7.5e-01/ 6/24) | |||
| 920 | 2.2/1.6 | 368 | 9 | cell cycle phase (1.0e-52/1.2e+01/ 89/ 287) | chromosome (2.1e-25/1.0e+01/ 58/248) | ATP binding (6.2e-08/3.3e+01/ 73/809) | Cell cycle (9.7e-16/4.6e+00/31/98) | ||
| 921 | 2.2/1.6 | 339 | 11 | positive regulation of JUN kinase activity (1.3e-02/5.5e-01/ 5/ 16) | plasma membrane part (2.3e-03/3.0e+01/ 52/875) | ||||
| 922 | 2.2/1.6 | 280 | 9 | response to xenobiotic stimulus (7.1e-03/4.7e-01/ 5/ 16) | proteinaceous extracellular matrix (2.6e-03/4.7e+00/ 15/156) | serine-type endopeptidase inhibitor activity (4.1e-02/1.1e+00/ 6/36) | Androgen and estrogen metabolism (1.6e-02/5.8e-01/ 5/21) | ||
| 923 | 2.2/1.4 | 366 | 14 | cell cycle phase (8.6e-44/1.2e+01/ 80/ 287) | chromosome (1.3e-25/9.8e+00/ 57/248) | microtubule motor activity (1.2e-06/1.5e+00/ 13/37) | DNA replication (7.6e-10/1.5e+00/15/33) | ||
| 924 | 2.2/1.4 | 375 | 12 | cell cycle phase (6.8e-44/1.2e+01/ 81/ 287) | chromosome (5.9e-25/1.0e+01/ 57/248) | microtubule motor activity (1.6e-06/1.5e+00/ 13/37) | DNA replication (8.5e-10/1.5e+00/15/33) | ||
| 925 | 2.2/1.4 | 285 | 16 | multicellular organismal process (3.9e-03/4.7e+01/ 72/1648) | integral to plasma membrane (1.3e-03/1.6e+01/ 33/549) | G-protein coupled receptor activity (3.7e-03/3.8e+00/ 14/137) | Neuroactive ligand-receptor interaction (8.1e-03/2.3e+00/10/83) | ||
| 926 | 2.2/1.4 | 301 | 18 | positive regulation of JUN kinase activity (8.8e-03/5.0e-01/ 5/ 16) | 19 (1.6e-03/18.4049/40/580) | ||||
| 927 | 2.2/1.4 | 287 | 13 | cAMP metabolic process (1.2e-02/1.2e+00/ 7/ 38) | cadmium ion binding (3.8e-02/1.8e-01/ 3/6) | ||||
| 928 | 2.2/1.4 | 402 | 14 | cell cycle phase (2.0e-55/1.3e+01/ 95/ 287) | chromosome (5.4e-29/1.1e+01/ 65/248) | ATP binding (6.4e-07/3.5e+01/ 74/809) | Cell cycle (3.1e-17/4.9e+00/34/98) | ||
| 929 | 2.2/1.4 | 308 | 11 | multicellular organismal process (1.1e-02/5.6e+01/ 81/1648) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (5.4e-03/9.9e-02/ 3/3) | ||||
| 930 | 2.2/1.4 | 297 | 20 | regulation of specific transcription from RNA polymerase II promoter (2.2e-02/6.2e-01/ 5/ 20) | 19 (1.3e-02/18.1595/37/580) | ||||
| 931 | 2.2/1.4 | 321 | 13 | cell cycle phase (8.7e-37/1.1e+01/ 71/ 287) | chromosome (2.8e-20/9.1e+00/ 49/248) | ATP binding (1.4e-05/2.9e+01/ 60/809) | DNA replication (2.1e-10/1.4e+00/15/33) | ||
| 932 | 2.2/1.4 | 281 | 16 | RNA localization (1.6e-02/2.1e+00/ 9/ 73) | Dentatorubropallidoluysian atrophy (DRPLA) (2.8e-02/3.9e-01/ 4/14) | ||||
| 933 | 2.2/1.4 | 295 | 17 | homophilic cell adhesion (1.3e-02/1.2e+00/ 7/ 40) | |||||
| 934 | 2.2/1.2 | 345 | 20 | response to dsRNA (1.9e-03/3.7e-01/ 5/ 10) | small conjugating protein binding (3.6e-02/6.9e-01/ 5/19) | Neuroactive ligand-receptor interaction (8.6e-03/3.3e+00/12/83) | |||
| 935 | 2.2/1.2 | 308 | 12 | melanosome membrane (2.7e-02/6.6e-02/ 2/2) | copper ion binding (2.5e-02/1.3e+00/ 7/40) | Porphyrin and chlorophyll metabolism (3.7e-02/7.2e-01/ 5/24) | |||
| 936 | 2.2/1.2 | 349 | 20 | cell cycle phase (4.8e-55/1.1e+01/ 90/ 287) | chromosome (6.8e-27/9.9e+00/ 59/248) | ATP binding (2.4e-07/3.1e+01/ 69/809) | Cell cycle (6.5e-17/4.4e+00/32/98) | ||
| 937 | 2.2/1.2 | 288 | 31 | activation of JUN kinase activity (4.7e-03/4.3e-01/ 5/ 14) | |||||
| 938 | 2.2/1.2 | 303 | 22 | ||||||
| 939 | 2.2/1.2 | 292 | 18 | positive regulation of JUN kinase activity (8.0e-03/4.8e-01/ 5/ 16) | plasma membrane part (3.2e-02/2.6e+01/ 42/875) | calcium ion binding (2.0e-02/1.2e+01/ 26/402) | |||
| 940 | 2.2/1.2 | 291 | 18 | regulation of multicellular organismal process (1.7e-02/9.6e+00/ 22/ 320) | plasma membrane part (5.6e-03/2.6e+01/ 45/875) | calcium ion binding (1.2e-02/1.2e+01/ 27/402) | |||
| 941 | 2.2/1 | 294 | 31 | multicellular organismal process (2.6e-05/4.8e+01/ 81/1648) | integral to plasma membrane (2.2e-04/1.6e+01/ 36/549) | G-protein coupled receptor activity (4.4e-04/3.9e+00/ 16/137) | Neuroactive ligand-receptor interaction (2.3e-03/2.4e+00/11/83) | ||
| 942 | 2.2/1 | 298 | 20 | response to external stimulus (1.6e-12/1.3e+01/ 48/ 370) | extracellular region (1.3e-12/2.5e+01/ 67/700) | cytokine activity (4.0e-07/2.4e+00/ 17/73) | Cytokine-cytokine receptor interaction (2.2e-04/5.5e+00/19/122) | ||
| 943 | 2.2/1 | 305 | 32 | embryonic heart tube development (1.1e-02/1.3e-01/ 3/ 4) | neuron projection (2.4e-02/2.0e+00/ 8/66) | ||||
| 944 | 2.2/1 | 333 | 23 | defense response (6.2e-04/9.1e+00/ 25/ 263) | plasma membrane (1.4e-03/5.1e+01/ 78/1443) | transmembrane receptor activity (3.0e-03/1.2e+01/ 28/334) | |||
| 945 | 2.2/1 | 303 | 36 | positive regulation of gene expression, epigenetic (3.8e-05/1.9e-01/ 5/ 6) | 19 (5.9e-05/18.5890/44/580) | ||||
| 946 | 2.2/1 | 285 | 36 | receptor metabolic process (9.0e-03/5.0e-01/ 5/ 17) | A band (2.3e-02/5.9e-02/ 2/2) | cytoskeletal protein binding (3.6e-02/8.1e+00/ 19/268) | 19 (5.2e-06/17.4847/45/580) | ||
| 947 | 2/2 | 595 | 5 | cell cycle phase (3.1e-37/2.0e+01/ 93/ 287) | chromosomal part (2.8e-20/1.3e+01/ 58/198) | microtubule motor activity (1.2e-04/2.4e+00/ 13/37) | DNA replication (2.6e-12/2.5e+00/20/33) | ||
| 948 | 2/2 | 546 | 6 | sterol metabolic process (1.7e-04/3.9e+00/ 16/ 65) | Biosynthesis of steroids (1.2e-04/1.5e+00/10/23) | ||||
| 949 | 2/2 | 503 | 5 | transcription (1.9e-05/6.8e+01/108/1435) | nucleus (1.3e-02/1.5e+02/179/3091) | nucleic acid binding (3.3e-04/8.9e+01/129/1801) | |||
| 950 | 2/2 | 480 | 6 | regulation of translation in response to stress (1.1e-02/1.5e-01/ 3/ 3) | |||||
| 951 | 2/2 | 446 | 4 | morphogenesis of an epithelium (1.2e-02/2.0e+00/ 9/ 42) | extracellular region (6.4e-05/3.4e+01/ 62/700) | RNA-dependent ATPase activity (4.6e-02/7.6e-01/ 5/16) | |||
| 952 | 2/2 | 338 | 6 | response to wounding (4.6e-09/9.5e+00/ 35/ 231) | extracellular region (3.1e-12/2.7e+01/ 71/700) | MHC class I receptor activity (1.1e-04/3.5e-01/ 6/9) | Complement and coagulation cascades (5.6e-04/1.7e+00/10/34) | ||
| 953 | 2/2 | 384 | 9 | immune system process (7.6e-11/2.1e+01/ 59/ 475) | extracellular region (8.0e-17/3.0e+01/ 85/700) | signal transducer activity (2.2e-07/3.4e+01/ 73/798) | Complement and coagulation cascades (1.4e-04/1.8e+00/11/34) | ||
| 954 | 2/2 | 467 | 3 | serine family amino acid biosynthetic process (8.2e-03/3.0e-01/ 4/ 6) | MHC class I peptide loading complex (3.4e-03/3.1e-01/ 4/6) | Gap junction (2.1e-02/3.8e+00/12/70) | |||
| 955 | 2/2 | 467 | 6 | system process (4.0e-11/2.2e+01/ 61/ 456) | extracellular region (4.6e-11/3.5e+01/ 81/700) | transmembrane receptor activity (7.8e-11/1.6e+01/ 54/334) | Neuroactive ligand-receptor interaction (3.9e-06/4.3e+00/19/83) | ||
| 956 | 2/2 | 394 | 8 | response to external stimulus (1.1e-11/1.7e+01/ 54/ 370) | extracellular region (2.2e-18/3.2e+01/ 90/700) | cytokine activity (8.0e-10/3.2e+00/ 23/73) | Cytokine-cytokine receptor interaction (2.0e-07/6.7e+00/26/122) | ||
| 957 | 2/2 | 505 | 6 | protein kinase cascade (5.1e-03/1.7e+01/ 34/ 290) | cytoplasm (1.2e-04/2.5e+02/295/4480) | protein binding (2.2e-05/2.6e+02/311/4565) | miR-320/320abcd (0.01494/26.1111/52/377) | ||
| 958 | 2/2 | 481 | 7 | nuclear division (1.3e-05/8.4e+00/ 27/ 174) | microtubule cytoskeleton (4.6e-03/1.6e+01/ 32/322) | ||||
| 959 | 2/2 | 457 | 5 | enzyme linked receptor protein signaling pathway (1.1e-02/1.2e+01/ 26/ 232) | |||||
| 960 | 2/2 | 500 | 5 | nuclear division (1.3e-04/8.9e+00/ 26/ 174) | calcium ion transmembrane transporter activity (4.9e-02/4.6e-01/ 4/9) | ||||
| 961 | 2/2 | 452 | 5 | melanosome membrane (5.0e-02/9.6e-02/ 2/2) | phospholipase C activity (4.1e-02/7.3e-01/ 5/16) | ||||
| 962 | 2/2 | 378 | 8 | immune system process (5.1e-11/2.1e+01/ 59/ 475) | extracellular region (3.1e-20/3.0e+01/ 90/700) | signal transducer activity (1.3e-07/3.3e+01/ 73/798) | Complement and coagulation cascades (1.0e-05/1.7e+00/12/34) | ||
| 963 | 2/2 | 487 | 6 | regulation of nucleocytoplasmic transport (6.4e-03/1.5e+00/ 8/ 29) | microtubule cytoskeleton (1.4e-02/1.7e+01/ 31/322) | calcium ion binding (2.5e-02/2.0e+01/ 37/402) | |||
| 964 | 2/2 | 394 | 6 | immune system process (5.4e-10/2.2e+01/ 59/ 475) | extracellular region (1.4e-11/3.1e+01/ 76/700) | signal transducer activity (2.9e-06/3.6e+01/ 72/798) | Complement and coagulation cascades (1.9e-04/1.9e+00/11/34) | ||
| 965 | 2/2 | 500 | 6 | epidermal growth factor receptor signaling pathway (1.5e-02/1.3e+00/ 7/ 25) | late endosome membrane (1.2e-02/1.4e+00/ 7/28) | ||||
| 966 | 2/2 | 489 | 7 | multicellular organismal process (3.7e-03/8.3e+01/116/1648) | intrinsic to membrane (1.9e-02/1.0e+02/133/2051) | calcium ion binding (2.9e-02/2.1e+01/ 37/402) | |||
| 967 | 2/2 | 506 | 7 | proteasomal protein catabolic process (6.9e-03/4.2e+00/ 14/ 80) | |||||
| 968 | 2/2 | 467 | 7 | enzyme linked receptor protein signaling pathway (4.8e-03/1.2e+01/ 28/ 232) | plasma membrane (4.5e-05/7.6e+01/115/1443) | receptor activity (4.9e-04/2.8e+01/ 54/533) | Type I diabetes mellitus (3.0e-02/1.5e+00/ 7/26) | miR-320/320abcd (0.04930/24.0722/46/377) | |
| 969 | 2/2 | 603 | 6 | cell cycle phase (2.7e-42/2.0e+01/ 99/ 287) | chromosome (6.8e-23/1.7e+01/ 70/248) | DNA-dependent ATPase activity (4.7e-05/2.6e+00/ 14/39) | Cell cycle (6.2e-12/7.8e+00/34/98) | ||
| 970 | 2/2 | 379 | 5 | immune system process (3.9e-11/2.1e+01/ 60/ 475) | extracellular region (1.1e-15/3.0e+01/ 83/700) | signal transducer activity (4.1e-06/3.4e+01/ 70/798) | Complement and coagulation cascades (1.3e-04/1.8e+00/11/34) | ||
| 971 | 2/1.8 | 495 | 9 | cell cycle phase (5.2e-14/1.7e+01/ 57/ 287) | chromosomal part (3.8e-08/1.1e+01/ 36/198) | cytokine activity (8.6e-06/4.1e+00/ 19/73) | DNA replication (4.5e-07/2.4e+00/15/33) | ||
| 972 | 2/1.8 | 463 | 9 | neurological system process (6.2e-09/1.6e+01/ 46/ 328) | intrinsic to membrane (3.5e-10/1.0e+02/163/2051) | transmembrane receptor activity (1.7e-11/1.6e+01/ 55/334) | Neuroactive ligand-receptor interaction (9.0e-06/4.0e+00/18/83) | ||
| 973 | 2/1.8 | 473 | 11 | receptor metabolic process (9.5e-03/8.3e-01/ 6/ 17) | intrinsic to membrane (8.9e-03/1.0e+02/132/2051) | calcium ion binding (3.2e-03/2.0e+01/ 40/402) | |||
| 974 | 2/1.8 | 425 | 5 | organ morphogenesis (4.2e-02/1.3e+01/ 26/ 312) | extracellular region (1.4e-03/3.2e+01/ 55/700) | MHC class I receptor activity (3.1e-02/3.9e-01/ 4/9) | |||
| 975 | 2/1.8 | 493 | 9 | cell cycle phase (2.6e-22/1.6e+01/ 68/ 287) | chromosomal part (2.7e-10/1.1e+01/ 39/198) | DNA binding (1.0e-06/6.5e+01/113/1210) | DNA replication (9.2e-10/2.2e+00/17/33) | ||
| 976 | 2/1.8 | 500 | 7 | cell cycle phase (6.1e-44/1.6e+01/ 91/ 287) | chromosome (2.9e-23/1.3e+01/ 63/248) | microtubule motor activity (2.4e-05/2.0e+00/ 13/37) | Cell cycle (4.2e-10/5.6e+00/27/98) | ||
| 977 | 2/1.8 | 445 | 7 | signal transduction (3.9e-03/8.2e+01/114/1800) | plasma membrane part (1.3e-03/4.0e+01/ 66/875) | ||||
| 978 | 2/1.8 | 460 | 7 | ectoderm development (1.6e-02/3.6e+00/ 12/ 73) | extracellular matrix (1.7e-02/8.3e+00/ 19/166) | ||||
| 979 | 2/1.8 | 436 | 5 | MHC class I receptor activity (3.3e-02/4.0e-01/ 4/9) | |||||
| 980 | 2/1.8 | 458 | 6 | ||||||
| 981 | 2/1.8 | 497 | 8 | positive regulation of cell adhesion mediated by integrin (1.3e-02/1.6e-01/ 3/ 3) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (1.6e-02/1.6e-01/ 3/3) | ||||
| 982 | 2/1.8 | 466 | 7 | bile acid metabolic process (4.8e-02/2.3e-01/ 3/ 5) | phospholipase C activity (4.3e-02/7.4e-01/ 5/16) | ||||
| 983 | 2/1.8 | 503 | 6 | intermediate filament organization (3.8e-03/2.6e-01/ 4/ 5) | extracellular region (2.6e-03/3.7e+01/ 61/700) | serine-type endopeptidase activity (3.5e-02/2.8e+00/ 10/55) | |||
| 984 | 2/1.8 | 476 | 10 | centromere complex assembly (1.1e-02/1.5e-01/ 3/ 3) | intrinsic to membrane (2.0e-02/1.0e+02/128/2051) | calcium ion binding (2.2e-02/1.9e+01/ 36/402) | |||
| 985 | 2/1.8 | 576 | 7 | cell cycle phase (1.4e-39/1.9e+01/ 94/ 287) | chromosome (4.9e-20/1.6e+01/ 64/248) | DNA binding (2.5e-06/7.7e+01/126/1210) | DNA replication (3.0e-12/2.5e+00/20/33) | ||
| 986 | 2/1.8 | 468 | 5 | morphogenesis of a polarized epithelium (3.0e-02/2.0e-01/ 3/ 4) | extracellular region (1.4e-02/3.5e+01/ 55/700) | ||||
| 987 | 2/1.8 | 481 | 10 | activation of MAPK activity (1.1e-02/2.0e+00/ 9/ 37) | cell surface (6.7e-05/6.9e+00/ 22/130) | protein binding (2.9e-04/2.5e+02/292/4565) | miR-320/320abcd (0.02028/24.6642/49/377) | ||
| 988 | 2/1.8 | 482 | 12 | receptor metabolic process (9.3e-03/8.2e-01/ 6/ 17) | membrane part (5.5e-03/1.2e+02/153/2426) | calcium ion binding (9.9e-03/2.0e+01/ 38/402) | |||
| 989 | 2/1.8 | 497 | 9 | epithelial to mesenchymal transition (8.7e-03/8.3e-01/ 6/ 15) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (1.7e-02/1.6e-01/ 3/3) | ||||
| 990 | 2/1.6 | 501 | 7 | cell cycle phase (6.9e-45/1.6e+01/ 92/ 287) | chromosome (1.9e-23/1.3e+01/ 63/248) | ATP binding (5.1e-06/4.4e+01/ 83/809) | Cell cycle (6.1e-11/6.0e+00/29/98) | ||
| 991 | 2/1.6 | 373 | 12 | immune response (2.2e-04/1.2e+01/ 30/ 295) | extracellular region (1.3e-13/2.7e+01/ 73/700) | interleukin-1 receptor activity (5.7e-04/1.5e-01/ 4/4) | Cytokine-cytokine receptor interaction (3.3e-02/5.2e+00/14/122) | ||
| 992 | 2/1.6 | 529 | 11 | cell cycle phase (3.2e-40/1.6e+01/ 89/ 287) | chromosome (4.3e-22/1.4e+01/ 63/248) | ATP binding (7.7e-06/4.6e+01/ 85/809) | Cell cycle (2.5e-08/6.1e+00/26/98) | ||
| 993 | 2/1.6 | 519 | 4 | synaptic transmission (3.1e-02/6.3e+00/ 16/ 123) | plasma membrane (5.3e-05/7.5e+01/114/1443) | transmembrane receptor activity (3.7e-03/1.7e+01/ 36/334) | |||
| 994 | 2/1.6 | 438 | 14 | multicellular organismal process (5.1e-07/7.0e+01/115/1648) | integral to plasma membrane (5.4e-06/2.4e+01/ 52/549) | transmembrane receptor activity (1.1e-06/1.4e+01/ 41/334) | Neuroactive ligand-receptor interaction (1.0e-04/3.8e+00/16/83) | ||
| 995 | 2/1.6 | 492 | 11 | digestion (4.1e-03/1.4e+00/ 8/ 27) | membrane part (4.0e-04/1.3e+02/167/2426) | calcium ion binding (1.7e-03/2.1e+01/ 42/402) | |||
| 996 | 2/1.6 | 491 | 11 | cell cycle phase (2.5e-39/1.6e+01/ 87/ 287) | chromosome (4.9e-19/1.4e+01/ 58/248) | DNA binding (1.2e-05/6.5e+01/108/1210) | DNA replication (3.5e-11/2.1e+00/18/33) | ||
| 997 | 2/1.6 | 456 | 13 | MAPKKK cascade (1.5e-02/5.2e+00/ 15/ 113) | |||||
| 998 | 2/1.6 | 484 | 12 | MAPKKK cascade (9.4e-03/5.5e+00/ 16/ 113) | extracellular region (4.8e-04/3.4e+01/ 60/700) | Rap GTPase activator activity (1.4e-02/1.5e-01/ 3/3) | |||
| 999 | 2/1.6 | 466 | 12 | response to external stimulus (6.8e-11/2.0e+01/ 58/ 370) | chromosomal part (2.4e-08/1.1e+01/ 35/198) | cytokine activity (9.0e-07/3.8e+00/ 20/73) | DNA replication (8.8e-09/2.1e+00/16/33) | ||
| 1000 | 2/1.6 | 329 | 13 | multicellular organismal process (3.0e-05/5.8e+01/ 94/1648) | plasma membrane (1.8e-08/5.4e+01/ 98/1443) | transmembrane receptor activity (2.8e-05/1.2e+01/ 33/334) | Graft-versus-host disease (4.9e-02/8.0e-01/ 5/21) | ||
| 1001 | 2/1.6 | 498 | 8 | negative regulation of transcription factor import into nucleus (8.8e-03/3.1e-01/ 4/ 6) | protein kinase C activity (3.4e-02/4.1e-01/ 4/8) | ||||
| 1002 | 2/1.6 | 504 | 8 | negative regulation of catalytic activity (2.3e-02/7.9e+00/ 19/ 143) | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity (1.7e-02/1.6e-01/ 3/3) | ||||
| 1003 | 2/1.6 | 445 | 9 | response to xenobiotic stimulus (3.9e-02/7.6e-01/ 5/ 16) | extracellular matrix part (6.3e-03/3.1e+00/ 11/64) | RNA helicase activity (4.3e-02/1.1e+00/ 6/23) | Androgen and estrogen metabolism (3.0e-03/9.6e-01/ 7/21) | ||
| 1004 | 2/1.6 | 450 | 8 | alveolus development (5.0e-02/2.4e-01/ 3/ 5) | |||||
| 1005 | 2/1.4 | 533 | 16 | cell cycle phase (3.9e-50/1.7e+01/101/ 287) | chromosome (1.1e-28/1.5e+01/ 73/248) | ATP binding (7.9e-08/4.7e+01/ 93/809) | Cell cycle (1.8e-15/6.7e+00/36/98) | ||
| 1006 | 2/1.4 | 562 | 14 | cell cycle phase (7.3e-48/1.8e+01/101/ 287) | chromosome (1.4e-28/1.6e+01/ 75/248) | ATP binding (1.2e-05/4.9e+01/ 89/809) | Cell cycle (1.2e-15/6.6e+00/36/98) | ||
| 1007 | 2/1.4 | 522 | 18 | cell cycle phase (7.3e-50/1.7e+01/100/ 287) | chromosome (5.1e-28/1.5e+01/ 72/248) | DNA-dependent ATPase activity (1.1e-05/2.2e+00/ 14/39) | Cell cycle (3.2e-16/6.2e+00/36/98) | ||
| 1008 | 2/1.4 | 556 | 15 | cell cycle phase (1.2e-45/1.8e+01/ 98/ 287) | chromosome (1.3e-25/1.5e+01/ 70/248) | ATP binding (5.9e-06/4.9e+01/ 89/809) | Cell cycle (4.4e-14/7.0e+00/35/98) | ||
| 1009 | 2/1.4 | 414 | 20 | regulation of multicellular organismal process (4.5e-03/1.4e+01/ 30/ 320) | MAPK signaling pathway (3.0e-03/8.0e+00/21/186) | 19 (4.2e-07/25.3374/60/580) | |||
| 1010 | 2/1.4 | 465 | 16 | activation of MAPK activity (5.0e-03/1.8e+00/ 9/ 37) | neurofilament (3.8e-03/1.4e-01/ 3/3) | calcium ion binding (1.1e-02/1.9e+01/ 37/402) | MAPK signaling pathway (4.0e-02/9.3e+00/20/186) | ||
| 1011 | 2/1.4 | 452 | 11 | melanosome membrane (5.0e-02/9.6e-02/ 2/2) | |||||
| 1012 | 2/1.4 | 477 | 14 | negative regulation of foam cell differentiation (1.4e-02/3.4e-01/ 4/ 7) | neuron projection (3.0e-02/3.2e+00/ 10/66) | calcium ion binding (1.3e-02/1.9e+01/ 37/402) | |||
| 1013 | 2/1.4 | 534 | 14 | cell cycle phase (1.4e-42/1.7e+01/ 92/ 287) | chromosome (4.5e-21/1.4e+01/ 62/248) | microtubule motor activity (3.9e-05/2.1e+00/ 13/37) | Cell cycle (1.5e-09/5.9e+00/27/98) | ||
| 1014 | 2/1.4 | 464 | 16 | membrane organization (1.4e-02/1.2e+01/ 26/ 235) | cytoskeleton (4.7e-05/3.5e+01/ 65/699) | protein binding (2.2e-03/2.3e+02/271/4565) | miR-320/320abcd (0.01590/24.2038/49/377) | ||
| 1015 | 2/1.4 | 460 | 22 | receptor metabolic process (8.1e-03/8.0e-01/ 6/ 17) | anaphase-promoting complex (3.0e-02/5.2e-01/ 4/11) | protein binding (4.4e-02/2.2e+02/251/4565) | MAPK signaling pathway (4.0e-02/7.9e+00/18/186) | 19 (1.1e-07/28.2209/66/580) | |
| 1016 | 2/1.4 | 495 | 16 | cell cycle phase (4.1e-54/1.5e+01/101/ 287) | chromosome (4.2e-31/1.4e+01/ 74/248) | ATP binding (2.8e-07/4.3e+01/ 86/809) | Cell cycle (2.1e-15/5.9e+00/34/98) | ||
| 1017 | 2/1.4 | 531 | 14 | cell cycle phase (9.0e-50/1.7e+01/100/ 287) | chromosome (3.2e-27/1.5e+01/ 71/248) | DNA-dependent ATPase activity (1.1e-05/2.2e+00/ 14/39) | DNA replication (1.1e-14/2.2e+00/21/33) | ||
| 1018 | 2/1.4 | 479 | 16 | MAPKKK cascade (4.8e-03/5.7e+00/ 17/ 113) | intrinsic to membrane (1.5e-03/1.0e+02/139/2051) | calcium ion binding (5.1e-04/2.0e+01/ 43/402) | MAPK signaling pathway (4.8e-02/1.0e+01/21/186) | ||
| 1019 | 2/1.4 | 510 | 14 | cell cycle phase (1.4e-43/1.6e+01/ 91/ 287) | chromosome (6.0e-22/1.4e+01/ 62/248) | ATP binding (2.1e-05/4.4e+01/ 81/809) | DNA replication (1.4e-12/2.0e+00/19/33) | ||
| 1020 | 2/1.4 | 581 | 15 | cell cycle phase (3.5e-44/1.9e+01/ 99/ 287) | chromosome (2.8e-23/1.6e+01/ 69/248) | DNA-dependent ATPase activity (3.4e-05/2.5e+00/ 14/39) | Cell cycle (1.1e-14/7.1e+00/36/98) | ||
| 1021 | 2/1.4 | 409 | 11 | epidermis development (2.9e-02/2.8e+00/ 10/ 64) | extracellular region (4.1e-07/3.2e+01/ 66/700) | UDP-glycosyltransferase activity (7.9e-03/2.7e+00/ 11/61) | Starch and sucrose metabolism (4.1e-02/1.1e+00/ 6/24) | ||
| 1022 | 2/1.2 | 502 | 21 | cell cycle phase (5.1e-52/1.6e+01/100/ 287) | chromosome (1.5e-27/1.4e+01/ 70/248) | ATP binding (1.9e-06/4.4e+01/ 84/809) | DNA replication (5.5e-15/2.1e+00/21/33) | ||
| 1023 | 2/1.2 | 482 | 17 | cell cycle phase (9.3e-42/1.6e+01/ 89/ 287) | chromosome (7.9e-21/1.4e+01/ 60/248) | ATP binding (4.4e-05/4.3e+01/ 78/809) | DNA replication (6.8e-14/2.0e+00/20/33) | ||
| 1024 | 2/1.2 | 477 | 20 | activation of MAPK activity (2.1e-02/1.8e+00/ 8/ 37) | plasma membrane (2.7e-02/7.0e+01/ 94/1443) | calcium ion binding (1.4e-02/2.0e+01/ 37/402) | |||
| 1025 | 2/1.2 | 372 | 15 | response to external stimulus (8.6e-14/1.6e+01/ 55/ 370) | extracellular region (2.1e-20/3.0e+01/ 90/700) | cytokine activity (2.4e-10/3.0e+00/ 23/73) | Cytokine-cytokine receptor interaction (1.1e-08/6.4e+00/27/122) | ||
| 1026 | 2/1.2 | 555 | 24 | cell cycle phase (7.9e-48/1.8e+01/100/ 287) | chromosome (2.4e-26/1.5e+01/ 71/248) | ATP binding (3.3e-06/4.8e+01/ 89/809) | DNA replication (2.8e-14/2.3e+00/21/33) | ||
| 1027 | 2/1.2 | 470 | 28 | protein kinase cascade (1.2e-03/1.4e+01/ 32/ 290) | A band (5.0e-02/9.6e-02/ 2/2) | MAPK signaling pathway (3.0e-03/8.0e+00/21/186) | 19 (1.1e-07/28.8344/67/580) | ||
| 1028 | 2/1.2 | 491 | 21 | intracellular signaling cascade (5.7e-03/4.4e+01/ 69/ 905) | neuron projection (1.0e-02/3.3e+00/ 11/66) | protein kinase activity (4.8e-02/1.8e+01/ 32/358) | |||
| 1029 | 2/1.2 | 440 | 14 | multicellular organismal process (2.0e-02/7.7e+01/105/1648) | peptide binding (2.0e-02/3.6e+00/ 12/77) | Androgen and estrogen metabolism (5.5e-03/1.1e+00/ 7/21) | |||
| 1030 | 2/1.2 | 518 | 23 | cell cycle phase (1.3e-51/1.6e+01/101/ 287) | chromosome (6.3e-30/1.4e+01/ 74/248) | ATP binding (1.0e-06/4.5e+01/ 87/809) | DNA replication (8.0e-15/2.1e+00/21/33) | ||
| 1031 | 2/1 | 475 | 29 | multicellular organismal process (2.0e-08/7.8e+01/130/1648) | integral to plasma membrane (1.3e-08/2.6e+01/ 62/549) | transmembrane receptor activity (5.2e-09/1.6e+01/ 49/334) | Neuroactive ligand-receptor interaction (2.7e-06/4.2e+00/19/83) | ||
| 1032 | 2/1 | 452 | 35 | positive regulation of gene expression, epigenetic (6.7e-03/2.8e-01/ 4/ 6) | MAPK signaling pathway (1.5e-02/8.4e+00/20/186) | 19 (1.2e-07/27.7301/65/580) | |||
| 1033 | 2/1 | 453 | 17 | regulation of cyclic nucleotide metabolic process (3.3e-02/1.5e+00/ 7/ 31) | cadmium ion binding (9.6e-03/2.9e-01/ 4/6) | ||||
| 1034 | 2/1 | 489 | 26 | regulation of cell proliferation (5.6e-04/1.9e+01/ 41/ 381) | plasma membrane (1.2e-03/7.5e+01/108/1443) | small conjugating protein binding (2.5e-02/9.7e-01/ 6/19) | Neuroactive ligand-receptor interaction (1.8e-02/4.8e+00/14/83) | ||
| 1035 | 2/1 | 479 | 36 | positive regulation of gene expression, epigenetic (2.6e-04/2.9e-01/ 5/ 6) | MAPK signaling pathway (4.7e-02/8.7e+00/19/186) | 19 (2.6e-09/29.3252/73/580) |
